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ABSTRACT 
 
Background: Particularly important to the mechanical performance of native 
arterial blood vessels is elastin, an extracellular matrix (ECM) protein deposited 
by VSMCs in the form of elastic fibers, arranged in concentric lamellae in the 
media of the vessel wall. In addition to serving as major structural elements of 
arterial walls, providing extensibility and elastic recoil, elastic fibers also influence 
vascular cell behaviors. For these reasons tissue engineers are attempting to 
exploit elastic fiber biology to enhance vascular graft design and patency. 
Therefore, developing a greater understanding of the molecular mechanisms of 
elastogenesis may offer opportunities to control elastogenesis in tissue 
biofabrication.  
 
Approach: To discover genes critical for elastogenesis we performed analysis of 
gene expression profiles associated with elastogenesis occurring 1) during lung 
and aorta development, 2) in the lung and skin in response to injury, and 3) in 
vascular smooth muscle cells (VSMCs) stimulated to produce elastic fibers.  
On the resulting convergent gene set we employed Promoter Analysis and 
Interaction Network Toolset (PAINT) to identify transcription factor binding 
regions. We also mapped binding sites for microRNA (miRNA) within the 
convergent gene set. Subsequent screening for potential regulators of 
elastogenesis were performed using pharmacological agonists and antagonists 
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along with plasmid vector transfection to augment expression. Differences in 
elastin transcription were measured by quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR) and by anti-elastin immunostaining in the 
development of a novel elastin ELISA. A 3D proof of concept tissue culture 
model containing fibroblasts and macroporous gelatin microcarrier beads was 
also established and immunostained for elastin. 
 
Results: Our transcriptomic studies revealed a set of genes differentially 
regulated in all five models of elastogenesis tested. Aside from genes that have 
previously been established to act in the elastogenesis process there are >50 
genes that have not been implicated in elastogenesis. Moreover, promoter 
analysis of clusters of genes from the 63-gene set having a similar pattern of 
regulation during developmental elastogenesis revealed two potential 
elastogenesis regulatory network of TFs. We hypothesize that these sets of 
genes contain novel positive and negative effectors of elastogenesis. Effects of 
agonists, antagonists, and expression vectors of these genes on elastin 
expression were quantified in cultured fibroblasts to identify agents that can be 
employed to accelerate elastogenesis during tissue biofabrication.  
 
Conclusions: The findings highlight a group of genes whose expression is 
differentially expressed in multiple models of elastin formation and many not 
previously associated with elastogenesis and thus may represent novel 
 iv 
components of elastogenesis. Transcriptional regulatory network analysis 
revealed potential transcription factor regulators of elastogenesis. Candidate 
genes and transcription factors were regulated through agonist and antagonist 
treatment and transfection of plasmid expression vectors in order to augment 
elastogenesis in vascular tissue biofabrication. 
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CHAPTER ONE 
 
INTRODUCTION TO VASCULAR TISSUE ENGINEERING 
 
1.1 Role of elastin fibers in tissue 
Particularly important to the mechanical performance of tissues is elastin, an 
extracellular matrix (ECM) protein deposited by vascular smooth muscle cells 
(VSMCs) in the form of elastic fibers. Within blood vessels, especially large 
elastic vessels, elastic fibers constitute a major part of the ECM (30-57% w/w in 
the aorta) arranged in concentric lamellae in the media of the vessel wall (3). In 
addition to serving as major structural elements of arterial walls, providing 
extensibility and elastic recoil, elastic fibers also influence vascular cell behaviors 
such as biochemical signaling pathways. Disruption of elastic fibers can initiate 
and progressively lead to the pathology of life threatening complications such as 
atherosclerosis, aneurysm and vasospasms (4, 5). 
The mechanism of elastogenesis encompasses the transcription of the elastin 
gene, the translation of the elastic fiber precursor monomer tropoelastin, 
migration to the plasma membrane, binding to the elastin receptor, self-assembly 
and cross-linking of tropoelastin by lysyl oxidase, deposition onto a microfibrillar 
scaffold, and finally, elongation into a mature elastic fiber (6, 7). A deficiency in 
any step may result in impaired, inhibited, or completely disrupted elastogenesis. 
Some (ECM) proteins are critical to the formation of functional elastic fibers as 
evidenced in genetically deficient mouse models. For example, fibulin-5 deficient 
mice are characterized by disorganized elastic fibers, a tortuous aorta with loss 
of compliance, severe emphysema, and loose skin (cutis laxa) (8, 9). 
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Tropoelastin in these mice is synthesized but not assembled properly as 
evidenced by accumulation of fragmented elastin without an increase of elastase 
activity (8, 9). 
Because elastin is crucial to maintaining the native structural configuration (10, 
11) and regulating signaling pathways (12), failure to regenerate a healthy elastin 
matrix in response to damage during disease (e.g., inflammation-mediated 
elastin degradation in atherosclerosis) can severely compromise elastic tissue 
homeostasis (13, 14). A major concern in the construction of tissue engineered 
elastin-rich tissue is the ability to regulate cell behavior and encourage the 
regeneration of elastin fibers. 
Tissue engineers are attempting to exploit elastic fiber biology to enhance 
vascular graft design and patency, however overcoming the deficient quality of 
elastic fibers synthesized in vitro poses a challenge due to the ill-defined 
mechanism and insufficient knowledge of regulatory genes. Therefore, the goal 
of the study is to identify gene regulators of elastogenesis that may offer 
opportunities to control elastogenesis in tissue biofabrication.  
 
1.2  Clinical problems related to elastin and significance 
Human disease and elastin. DNA deletions and mutations in the elastin gene 
are associated with heritable diseases of the connective tissue (14-20). 
Supravalvular aortic stenosis (SVAS) and Williams-Beuren Syndrome are 
characterized by an elastin gene mutation and narrowing of the arterial tree and 
increased elastinolytic activity (14-16). Another mutation of the elastin gene 
 18 
results in cutis laxa with clinical effects of inelastic skin associated with severe 
aortic disease and pulmonary emphysema(17, 18). Deletions in genes 
comprising the microfibrillar scaffold, such as fibrillin-1 result in Marfan's 
Syndrome with a phenotype of vascular disease, including aortic aneurysms and 
dissections (19, 20). 
 
Biomechanical significance of defective elastin formation. The biological process 
of aging and certain diseases is characterized by a loss of tissue elasticity 
increasing the investigative efforts of biomaterials based on elastin for their 
application in tissue engineering. Challenges to elastin tissue engineering revolve 
around adequately controlling the process of elastin assembly into elastic fibers 
or organized layers of elastic lamellae. An organized ECM containing elastic 
fibers has superior mechanical structure and cellular signaling advantages over 
amorphous deposits of elastin typically synthesized in vitro. To address this 
impediment, we have employed DNA microarray transcriptomic profiling identify 
genes that are similarly regulated in a number of systems displaying increased 
expression of tropoelastin and increased formation of elastic fibers. The 
proposed research will contribute to a greater understanding of the molecular 
mechanisms of elastogenesis through identification and characterization of 
genes regulated in multiple experimental models of elastogenesis, which have 
not been previously identified. This understanding is expected to reveal new 
opportunities to induce cells to produce a functional elastin architecture in 
engineered vascular constructs. Ultimately, we expect this project to help 
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elucidate the mechanisms necessary for adequate control of elastogenesis in 
human vascular cells with clinical applications for repair and salvage of human 
vasculature. 
 
1.3  Project rationale and objectives 
The underlying mechanisms of elastogenesis remain largely ill-defined. 
Elastogenesis encompasses the biosynthesis of tropoelastin (TE), the elastic 
fiber precursor monomer, translocation of TE to the plasma membrane, TE 
binding to the elastin receptor, self-assembly and cross-linking of TE by lysyl 
oxidase, deposition of crosslinked TE onto a microfibrillar scaffold, and through 
iteration of this process, elongation into a mature elastic fiber (6, 7). A deficiency 
in any step may result in impaired or disorganized elastogenesis. Given that the 
mechanical structure and cellular signaling in elastin-containing tissues are 
dependent on elastic fibers, fabricated elastic constructs must be engineered to 
either have synthetic elastin-like components or elastin components produced by 
cellular constituents of the constructs. 
 
1.4  Specific aims and hypotheses 
Elastic fibers are critical for the function of multiple tissues including blood 
vessels, skin, lung, and auricular cartilage, periodontal ligaments and other 
connective tissue (21-24). An elastic fiber’s structure is comprised of a core of 
amorphous tropoelastin surrounded by a microfibrillar scaffold, which contains 
numerous proteins such as fibrillin, microfibrillar-associated glycoproteins, 
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fibulins, and others (25). The elastic core imparts the ability for a tissue to expand 
in response to a force with minimal resistance and then recoil, or return to its 
original shape (26, 27). Many applications of tissue engineering require the 
property of elastic recoil to repair or replace damaged and diseased tissues (i.e., 
arterial grafts, skin grafts). 
The overarching goal of this application was met by identifying regulators of 
elastogenesis, which will advance an approach to regenerative medicine 
involving accelerated production of elastic fibers. A number of studies point to the 
severe quantitative and qualitative deficiencies in the process of elastogenesis 
exhibited by cultured cells (28, 29). These deficiencies create an impediment to 
the engineering of tissues requiring functional elastin architecture. Through 
analysis of gene expression profiles associated with normal elastogenesis 
occurring during 1) mouse lung and aorta development, 2) elastogenesis in lung 
and skin in response to injury, and 3) in vascular smooth muscle cells (VSMCs) 
stimulated to produce elastin fibers, we will identify genes that appear to 
represent new players in the process of elastogenesis. We will also work toward 
development of a novel in vitro assay to quantify incorporation of elastin into the 
ECM of fibroblast monolayers, which we intend to use to further screen agents 
that modulate the activities of the putative elastogenic genes identified by our 
transcriptomic analysis. As a result of these studies, we expect that new 
elastogenesis related genes will be defined that offer new opportunities to 
regulate elastogenesis in elastic tissue biofabrication. 
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Based on these findings we hypothesize that expression profiling analysis 
can be used to identify modulatory genes of tropoelastin synthesis and elastic 
fiber assembly (elastogenesis) that have not been previously associated with the 
process. Experimentation outlined in this proposal will test this hypothesis by 
determining whether candidate genes regulate tropoelastin expression and 
elastic fiber assembly. These objectives will be reached through the following two 
interrelated specific aims: 
 
Aim 1: Use DNA microarray based transcriptomic profiling to identify genes that 
are similarly regulated in processes in which elastogenesis is a key component. 
 
Rationale and hypothesis:  
A number of studies point to severe quantitative and qualitative 
deficiencies in the process of elastogenesis mediated by cultured cells(28). 
These deficiencies are an impediment to cell-based bioengineering of blood 
vessels requiring functional elastin architecture. DNA microarray expression data 
has been performed on in vivo developing elastin-rich tissues including the lung 
(W Scott Argraves, MUSC, Charleston, SC) and aorta (Robert Mecham, 
Washington University School of Medicine, St. Louis, MO) and additionally 
unpublished in vitro DNA microarray expression data of vascular smooth muscle 
cells (VSMCs) induced to synthesize elastin (WS Argraves and TN Wight, 
Benaroya Institute at Virginia Mason, Seattle, WA). Other expression profiling 
studies of in vivo wound healing occurring in elastin-rich tissues have already 
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been performed and the data uploaded to the NCBI Data GeoSets(30, 31). In 
light of the current caveats in synthesizing elastic fibers in vitro, a convergent 
analysis of DNA microarray expression profiling data in processes in which 
elastogenic is a key component (in vivo studies of nascent elastic fiber formation, 
in vivo regeneration of injured elastic fibers, and in vitro VSMCs induced to 
synthesize elastin) will elucidate genes regulated during elastogenesis that can 
be employed in elastic tissue engineering. The set of significantly regulated 
genes should include genes reported to be directly or indirectly involved with 
elastogenesis in addition to other genes not yet reported to be involved. 
 
Approach: To discover genes critical for elastogenesis we will define a range of 
processes in which elastogenesis is a key component. We will conduct 
experiments to collect microarray data and gather publicly available microarray 
data to encompass multiple types of elastogenesis in different elastin-containing 
tissues: 1) development of native elastic fibers in lung and aorta, 2) regeneration 
of elastin in the wound healing response in the lung and skin, and 3) in cultured 
vascular smooth muscle cells stimulated to produce elastic fibers. We will 
analyze each data set individually to determine differentially expressed genes 
specific to each process and then converge individual datasets to discover 
regulated genes common to all elastogenic processes. From this study we will 
identify a set of consistently regulated genes common to five different microarray 
datasets in which elastogenesis is a key component which we will define as the 
“elastogenic gene set.” 
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Aim 2: Determine if candidate genes are modulators of tropoelastin expression 
in an in vitro culture model. 
 
Rationale and hypothesis: Previous transcriptomic studies have revealed 
genes critical to elastic fiber formation that we anticipate to be consistently 
regulated in multiple elastogenic processes. Aside from genes previously 
established to act in elastogenesis, we expect to discover genes that have not 
been implicated in elastogenesis. We hypothesize that this convergent set of 
genes will contain positive and negative effectors of elastogenesis. Genes 
regulated during the formation of elastic fibers may play a critical role in 
elastogenesis, however it is possible that a regulated gene may not be essential 
to the process. It is also possible that even with a low false discovery rate of 
comparative transcriptomic analysis, a gene may be identified incorrectly as 
being regulated during elastogenesis. It is necessary to determine whether 
tropoelastin expression and elastic fiber assembly processes will be disrupted in 
the case a gene is not expressed. Through the use of transcription factor 
agonists/antagonists and plasmid expression vectors we will selectively 
augment/inhibit expression of upregulated genes and assess the resulting effects 
of elastin expression. 
 
Approach: To discover genes critical for elastogenesis we will categorize genes 
into groups through coordinately regulated functional analysis and transcription 
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factor analysis as well as identify individual genes for experimental testing. 
Characterization of elastic fibers from multiple processes reveals higher 
organization and mechanical strength in the developmental process compared to 
wound healing and in vitro formation of elastic fibers (32-34). We will refer to the 
native development of elastic fibers as the gold standard and place emphasis the 
expression patterns of the “elastogenic gene set.” We will categorize genes into 
groups of potential enhancers and potential inhibitors of elastogenesis based on 
expression patterns similar or inverse to the expression pattern of the elastin 
gene in processes containing native development of elastic fibers. Enhancers of 
elastogenesis will be defined following the assumption of a similar expression 
pattern as elastin: at highest levels during periods of peak elastin expression 
(i.e., 4-21 days postnatal (d) in the developing aorta and 10-14 d in the 
developing lung) and expressed at lowest levels during minimum elastin 
expression. Conversely, it is reasonable to speculate that inhibitors of 
elastogenesis might display an inverse relationship to elastin: relatively low 
expression during peak periods of elastin expression (i.e., 4-21 d in the aorta and 
10-14 d in the developing lung) and high levels of expression during the period in 
which elastogenesis subsides (i.e., >60 d postnatal in the aorta). Within the 
dataset there are 20 potential enhancers of elastogenesis and 39 potential 
inhibitors of elastogenesis. 
Another consideration in the prioritization of genes for testing is the 
availability of agonists and antagonists for each gene. Cursory evaluations reveal 
that for most of the genes there are commercially available agonists and 
 25 
antagonists and purified gene products. Furthermore, siRNAs can readily be 
employed to suppress the expression of candidate genes. 
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CHAPTER TWO 
AN OVERVIEW OF ELASTOGENESIS 
The term elastogenesis is first used in a 1964 study using electron light 
microscopy to compare the aortae from fetuses, newborns, and adult. Haust et 
al. clearly described a low density elastic matrix surrounded by a higher density 
elastic membrane, surrounded further by arranged filaments. These “elastic 
units” originated at the basement 
membrane of SMCs where they 
aggregate and fuse to form larger 
elements of elastic tissue, a process 
defined as elastogenesis. 
It is now known that an elastic 
fiber is composed of a crosslinked 
tropoelastin core surrounded by a 
sheath of microfibrils that are based on 
the glycoprotein fibrillin. There are also 
a multitude of elastic fiber associated 
molecules shown to be essential to 
elastic fiber formation through knock-out animal studies such as lysyl oxidase 
(LOX) (35, 36) and fibulin-4 (37) and -5 (8, 9). This chapter will provide a 
background on the formation of elastic fibers, elastogenesis, and demonstrate 
the need to better understand elastogenesis for tissue engineering applications. 
 
 
Figure 2.1. Elastin occurrence the body. 
Elastic fibers are found predominantly in 
connective tissues such as skin, lungs, and 
blood vessels (Kielty 2002). 
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2.1 Elastin Fiber Structural Arrangement and Function 
2.1.1 Chemical Composition of Elastic Fiber  
 Elastin is an extracellular matrix protein encoded by a single gene on the 
human chromosome 7q11.23 codes for elastin (38). Elastin contains a highly 
conserved amino acid sequence (VGVAPG), rich in a high concentration of non-
polar amino acids proline (10%) and glycine (33%) resulting in a hydrophobic 
protein. Elastin contains additional amino acids such as OH-proline (1%), alanine, 
valine, and leucine (40-50%) (39) as shown in Table 2.1. The polypeptide chains 
in elastin are cross-linked by unique polyfunctional heterocyclic acids called 
desmosine and isodesmosine, as opposed to typical disulfide bridges. These 
distinctive internal linkages and inherent hydrophobicity make elastin a stable 
protein, resistant to the normal breakdown characteristic of most proteins. 
 Elastin is secreted as a soluble monomer, tropoelastin, which has a 
secondary structure characterized by alternating 
hydrophobic (β-sheet) and hydrophilic (α-chain) 
regions encoded by separate exons (40). The 
secondary structure of elastin consists of 10% α-
helices, 40% β-sheets, and 50% undefined 
conformations (41). The hydrophilic regions are 
alanine- and lysine-rich, while the hydrophobic 
domains are rich in proline, valine, and glycine 
(42). Lysyl oxidase (LOX), a copper-dependent 
enzyme (39), crosslinks targeting domains (43) of 
Table 2.1. Amino acid 
composition of elastin 
derived from bovine aorta. 
Values are expressed as a 
percentage of the total amino 
acid residues. Desmosine and 
Isodesmosine are expressed as 
lysine equivalents (Balazs 
1970). 
Amino Acid Percent 
Proline 11.27 
Glycine 33.24 
Alanine 22.39 
Valine 13.13 
Leucine 5.82 
Phenylalanine 2.97 
Desmosine 0.96 
Isodesmosine 0.55 
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the α-helical regions, via desmosine and isodesmosine linkages (41), to yield a 
crosslinked insoluble, yet flexible matrix protein. 
 
2.1.2 Elastin ultrastructure 
 Elastin may be ultrastructurally organized into individual and networked 
fibers (e.g., loose fibers and loose or compact meshes) or inter-woven, non-
fibrillar matrix structures (e.g., continuous sheets, fenestrated sheets) (Scott 
1996). The fibrillar structures contribute to the elasticity of the tissues that contain 
them, allowing them to characteristically recoil, when distending forces are 
removed. 
 
 
 Elastic fibers (~200-900 nm diameter) are major insoluble ECM 
assemblies deposited during early development in elastic connective tissues. 
They are composed of a central core of cross linked, amorphous elastin 
surrounded by microfibrils (Kielty 2002). The microfibrils are composed of a 
number of different glycoproteins, predominately fibrillin, which are essential both 
to maintain the integrity of the fibers and the ability of cells to interact and 
 
Figure.2.2 Elastin organization can vary depending upon its mechanical and functional 
role within different tissues. These differences in ultrastructure can be visualized with 
scanning electron microscopy (SEM) (Scott 1996). 
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respond to them. Microfibrils are typically 10 nm in diameter with an average 
periodicity of 57 nm (Lu 2006). They form linear bundles and are deposited as 
pre- scaffolds onto which soluble tropoelastin monomers then coalesce and are 
crosslinked. During the elastin deposition process, the microfibrils are displaced 
to the periphery of the growing elastin fibers, and typically appear electron-dense, 
as opposed to the electron lucent amorphous elastin. 
 
2.1.3 Biochemical Roles of Elastin 
 In addition to rendering tissues elastic, vascular matrix elastin also 
regulates vascular cell behavior (44, 45). Correlative studies have demonstrated 
large changes in the composition and distribution of extracellular matrix (ECM) 
components during tissue development, cell differentiation, and in response to 
growth factor, hormone, and cytokines (46). Modulation of a variety of cellular 
functions, including secretory activities and gene transcription, occurs via 
interaction with the ECM. The ECM also serves as a reservoir for growth factors 
and cytokines (44). Therefore, ECM proteins, such as elastin, may influence cell 
development, survival (anchorage-dependent), proliferation, phenotype, 
migration, differentiation, and function (47). 
 Elastin affects cell-fate. Some cell types are dependent upon anchorage to 
the surrounding ECM for survival. Anchoring junctions, such as adherens 
junctions and hemidesmosomes formed by integrin transmembrane proteins, 
mechanically attach cells and their cytoskeletons to the ECM (48). Therefore, the 
presence or absence of elastin may influence cell viability. The phenotype (the 
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appearance and behavior of 
cells) also depends upon the 
ECM. For example, in pathologic 
conditions, elastin may be 
fragmented and the fragments 
may encourage SMCs to change 
from a contractile to a synthetic 
phenotype. Additionally, cell 
locomotion is affected by ECM 
components, including elastin, and requires an initial polarization of the cell to 
promote migration in a particular direction. Cell movement is in response to 
chemical and physical cues in the cell environment. Therefore, the physical 
properties of elastin influence cell movement, specifically inflammatory cells in 
scenarios of disease. 
 Tropoelastin, the soluble elastin precursor, influences chemotaxis (Indik 
1990), stimulates vasodilation53, regulates intracellular Ca2+ (Faury 1998), and 
promotes cell adhesion (Grosso 1991). Mature elastin also has numerous effects 
on vascular SMCs including inducing actin stress fiber orientation, inhibiting SMC 
proliferation, and regulating cell migration (Rodgers 2005). 
 
2.2 Elastic Fiber Assembly 
2.2.1. Formation of an Elastic Fiber 
 Mature elastic fibers are composed of a central core of elastin surrounded 
 
Figure 2.3. Elastin Fiber Structure. An individual 
elastic fiber is composed of a core of aggregated 
tropoelastin monomers surrounded by an outer 
sheath of microfibrils. The microfibrillar scaffold is 
primarily composed of the fibrillin proteins. 
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by glycoprotein microfibrils (10-12 nm in diameter) (49). During the early stages 
of elastogenesis, these microfibrils are formed first in the extracellular matrix 
(ECM) space and play a major role in organizing elastin into elastic fibers. The 
major microfibrillar components are fibrillin -1 and -2 that polymerize in a head-to-
tail manner to yield the microfibrils. Calcium binding stabilizes the linear and rigid 
structure of fibrillin monomers, their interactions, the lateral packing of microfibrils, 
and thus the three-dimensional organization of their macroaggregates. While the 
ECM is organizing the microfibrillar scaffold for elastin deposition, the elastin 
monomers are synthesized within the cell. 
 
Figure 2.4 Elastogenesis involves the secretion of tropoelastin monomers to the 
extracellular space. Within the cell, the elastin binding protein (EBP), a splace variant of 
Beta galactosidase, binds to tropoelastin monomers to provide stability and prevent self-
aggregation of elastin. EBP chaperones elastin where it is secreted through the plasma 
membrane and binds to transmembrane proteins cathepsin A (PPCA) and neuraminidase 1 
(NEU1) forming the elastin receptor. Betagalactosidase sugars can bind to the EBP causing 
a conformational change and release of elastin into the extracellular matrix. 
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 The soluble elastin precursor, tropoelastin, is first synthesized within the 
cell and is chaperoned to the plasma membrane for secretion by the elastin 
binding protein (EBP) which also prevents premature self-aggregating. EBP and 
tropoelastin are secreted and EBP binds to two integral membrane proteins, 
neuraminidase 1 and cathepsin A, on the cell surface that form a transmembrane 
link between the extracellular compartment and the cytoskeleton (50) (Figure 
2.4). The complex of EBP, neuraminidase 1, and cathepsin A is known as the 
elastin receptor (51, 52) that tethers tropoelastin to the cell surface in the 
extracellular space where it interacts with the microfibrils and becomes oriented 
within a growing elastic fiber for eventual crosslinking (53) (Figure 2.5). EBP is 
bifunctional in that it also has galactolectin properties. It binds the hydrophobic 
VGVAPG sequence in elastin, the cell membrane, and galactosugars via three 
separate sites. The binding of galactosugars lowers its affinity for both 
tropoelastin and for the cell-binding site, resulting in the release of bound elastin 
 
Figure 2.5 Fibulins facilitate the formation of elastic fibers through binding of elastin 
monomers and transportation to the microfibrillar scaffold. Tropoelastin monomers are 
crosslinked by lysyl oxidase (LOX) and aggregated forming the elastin-rich dense core of an 
elastic fiber. Fibulins assist the transportation of tropoelastin as it is assembled on the fibrillin 
rich scaffold that will form the outer sheath of the elastic fiber. 
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and the dissociation of the 67 
kDa subunit from the cell 
membrane. Galactosugar-
containing microfibrillar 
glycoproteins may therefore be 
involved in the coordinated 
release of tropoelastin by the 
cell (54) (Figure 2.4).  
 The tropoelastin 
deposited onto the microfibril matrix is then crosslinked into mature elastin. 
Crosslinking of elastin is initiated by the action of lysyl oxidase (LOX), a Cu2+ 
dependent endogenously produced enzyme that catalyzes the oxidative 
deamination of lysine residues into allysine (55). This is the only enzymatic step 
involved in elastin crosslinking. Subsequent formation of crosslinks between 
tropoelastin molecules by desmosine and isodesmosine occurs as a series of 
spontaneous condensation reactions, resulting in the production of a complete 
elastic fiber. The relative proportion of microfibrils to elastin declines with 
increasing age of the animal, adult elastic fibers having only a very sparse 
peripheral mantle of microfibrillar material (56). 
 Elastin fibers form random coiled structural networks that allow them to be 
stretched and then to recoil to their original state upon load-release (Figure 2.6). 
Elastic fibers formed by such aggregation vary in thickness, length and three-
dimensional architecture depending on the direction and magnitude of the forces 
 
Figure 2.6. Elastin conformational shift from 
relaxation to stretch (2). 
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exerted upon the tissue. This morphological diversification can be seen in 
different organ systems. In the aortic wall, elastic fibers form thick concentric 
lamellae in the tunica media with interlaminar connecting fibers scattered radially. 
Additionally, microfibrils are present as a complex meshwork throughout the 
aortic wall. It can be generalized that the elastic fibers are responsible for dilation 
and recoil, with the microfibrils acting as flexible links that make the aortic wall a 
working unit (55). 
 
2.2.2 Dynamics and Mechanical Properties of Elastin 
 The mechanical properties of blood vessels influence a broad spectrum of 
physiologic phenomena, including blood pressure, flow rates, wall shear stress, 
biomolecules, and mass cell transport that, in turn, critically impact 
cardiovascular 
homeostasis. As 
mentioned 
previously, the 
mechanical 
properties of 
blood vessels 
stem from 
microstructural 
wall components, 
such as collagen 
 
Figure 2.7. Stress-strain curve for a blood vessel demonstrates 
the mechanical role of elastin in response to initial strain. The 
blood vessel initially distends in response to strain as contributed by 
elastin. At a certain strain the mechanical stress load is distributed to 
the collagen fibers within the blood vessel and the blood vessel 
becomes stiffer as evidenced by the sharp slope increase of stress to 
strain (http://biochemistry.utoronto.ca/keeley/bch.html). 
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and elastin fibers, smooth muscle cells, and fibroblasts (49). Since these 
individual components take up loads at different stress levels, their source and 
location-specific differences, content and distribution within blood vessels, and 
their alteration in diseased states can render the mechanical properties of blood 
vessels complex and difficult to predict. Collagen and elastin affect the 
mechanical behavior of vessels in different ways (Figure 2.7). Strain is initially 
accommodated by elastin allowing the vessel to expand with minimal resistance, 
and, eventually strain is strongly resisted by collagen preventing overexpansion. 
While collagen provides rigidity, elastin allows the connective tissues in blood 
vessels to stretch and then recoil to their original positions. A study by Gundiah 
et al. (57) has shown that axial elastin fibers in intimal and adventitial layers, and 
circumferential medial fibers help distribute tensile stresses during vessel 
inflation and relaxation, conclusively providing evidence that emphasizes 
mechanical importance and indispensability of elastin fibers in the aortal anatomy. 
 
2.3 Role of Extracellular Matrix Proteins in Elastogenesis 
2.3.1 Fibulins as Regulators of Elastogenesis 
Several members of the fibulin protein family also play important roles in 
elastogenesis.  For example, fibulin-5 (Fbln5) is essential to the incorporation of 
elastin into the core of elastic fibers; Fbln5 knockout mice have been shown to 
produce abnormal elastic fibers with elastin situated in globules on the surface of 
the microfibril scaffold (58).  Although fibulin-2 (Fbln2) knockout mice do not 
show an obvious phenotype, double knockouts of Fbln2 and Fbln5 exhibit a more 
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severe phenotype than Fbln5 knockouts; the aortas of double knockout mice 
have thin, disorganized internal elastic laminae and show abnormal repair after 
injury (59). 
 
2.3.2 Proteoglycans as Regulators of 
Elastogenesis 
 A number of studies point to an 
inhibitory role for certain proteoglycans 
(PGs) in the assembly of elastic fibers 
(60-62). Mechanistically, this is thought 
to involve β-galactosugars PGs acting to 
displace tropoelastin from the elastin 
binding protein (EBP) (63). Indeed, 
addition of either chondroitin sulfate (CS) 
chains, or the CS PG, versican, 
decreases elastic fiber formation (60). Furthermore, impaired elastic fiber 
assembly is observed in Hurler disease and Costello syndrome in which there is 
an accumulation of glycosaminoglycans (GAGs) (64). Similarly, increased elastin 
accumulation has been achieved in the rat carotid artery by seeding of VSMCs 
transduced to express a GAG-deficient form of the PG, biglycan (61).  
 
 
 
 
Figure 2.8. Alternate splicing of 
versican mRNA produces 4 distinct 
isoforms. Versican V3 is the smallest 
variant at 73 kDa and contains no GAG 
attachment sites. 
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2.3.3 Versican V3 as a Regulator of Elastogenesis 
Other extracellular matrix proteins have also been found to associate with 
elastic fibers and affect the process of elastogenesis. One such molecule is 
versican, a large chondroitin sulfate proteoglycan found in a variety of soft 
tissues. Versican contains four main domains as shown in Figure 2.8. The N-
terminal region binds to the glycosaminoglycan hyaluronan; aggregates of 
versican and hyaluronan associate with the cell surface and influence cell shape, 
cell division, and other processes. The C-terminal region serves a variety of 
regulatory functions and binds to integrins and extracellular matrix components.  
The remainder of the molecule is composed of two large regions containing 
binding sites for chondroitin sulfate (65). 
 Four versican splice variants of varying length have been identified. The 
full-length V0 isoform contains all four of the major domains, including both 
chondroitin sulfate-binding regions. The V1 and V2 variants are missing the β 
and α chondroitin sulfate-binding regions, respectively, and the V3 isoform 
consists of only the N-terminal and C-terminal regions with no chondroitin sulfate 
binding sites as shown in Figure 2.5. 
 Previous studies have shown that the chondroitin sulfate side chains of 
proteoglycans such as versican can disrupt the process of elastogenesis, leading 
to decreased elastin deposition in the extracellular matrix and abnormal elastic 
fiber assembly (66). The V3 form of versican, however, lacks these inhibitory side 
chains. In fact, the overexpression of V3 in arterial smooth muscle cells has been 
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shown to lead to increased elastic fiber formation in rat arterial smooth muscle 
cells both in vitro and in vivo (67, 68). 
 Furthermore, V3 has been shown to promote elastogenesis and improve 
the structural and functional properties of engineered vascular constructs (69). 
The positive effects of V3 on elastogenesis have been attributed to its ability to 
displace GAG containing variants of versican from binding sites in the vicinity of 
elastic fiber assembly complexes (i.e., EBP-tropoelastin complexes). 
Consequently, the suppressive effects of GAG moieties would be relieved and 
elastic fiber assembly would proceed. 
 
2.4 Elastic Fibers in Vascular Disease 
 A common pathologic feature of vascular disease is the disruption of 
elastic fibers and the accumulation of SMCs within the intima between the 
endothelium and medial layer of the vessel wall resulting in the progressive 
occlusion of blood flow. Under normal conditions, vascular SMCs in the tunica 
media of blood vessels are quiescent and embedded in a network of elastin-rich 
ECM that acts as a barrier to SMC migration and proliferation (70). During 
atherosclerosis, different cell types, including ECs, platelets, and inflammatory 
cells release mediators, such as growth factors and cytokines that induce 
phenotype change of vascular SMC from the quiescent "contractile" phenotype 
state to the active "synthetic" state, causing them to release matrix proteases 
degrading the ECM (including elastin) allowing them to aggressively migrate into 
the subendothelial space and contribute to neointima formation (71). The 
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degradation of vascular elastin exposes other medial components (i.e. collagen, 
SMCs) to very high tensile stresses (57). The high plasticity of SMCs makes 
these cells susceptible to mechanically induced phenotypic changes that may 
result in continued aggravated protease secretion and ECM degradation. 
 Since vascular SMCs modulate their phenotype readily, external factors in 
the arterial wall must instruct them to maintain a quiescent, contractile state if 
homeostasis is to be achieved. This regulation of vascular SMC activity occurs 
through defined receptor interactions and signaling pathways. In contrast to other 
matrix proteins, both in vitro and in vivo studies implicate elastin matrix as a 
negative regulator of SMC activity within the arterial wall (72). Thus elastin 
regulates vascular homeostasis by signaling SMCs through defined pathways to 
localize around the elastic fibers in organized lamellar units and remain in a 
quiescent, contractile state. The disruption of elastin by vascular disease, or 
direct mechanical injury can interrupt cell-matrix signaling and directly up-
regulate SMC hyper-proliferation (70). The disruption of elastin is not simply an 
end product of vascular disease, but an important contributor to the pathogenesis 
of occlusive vascular disease. Preventing elastin matrix degradation following 
vascular injury or restoring the lost/ degraded vascular elastin matrix is 
imperative for vascular homeostasis restoration (72). 
 In disease states, wherein elastin has been broken down, the binding of 
elastin peptides (the soluble products of elastin degradation) via the elastin 
receptor (EBP and two other integral membrane proteins), G protein-coupled 
receptors (GPCR), or other integrins results in activation of G proteins and 
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opening of calcium channels (73). The Rho signaling cascade can be stimulated 
by elastin and is mediated by GPCRs, the largest family of transmembrane 
receptors (74, 75). A study by Karnik proposed a molecular mechanism for 
vascular SMCs in which elastin activates a G-protein-coupled pathway (75), 
inhibits adenylate cyclase, reduces cAMP levels (76), and stimulates Rho 
induced actin polymerization (75). 
 Under pathologic conditions, such as in atherosclerosis and within 
abdominal aortic aneurysms (AAAs), elastin breaks down to generate elastin 
peptides at an accelerated rate. These elastin degradation products up-regulate 
SMC proliferation and activate phagocytic cells (73). Elastin peptides are 
released and through their interaction with receptors present on the surface of 
fibroblasts, phagocytes, lymphocytes, SMCs, and endothelial cells (ECs) elicit a 
variety of biologic effects such as matrix-metalloproteinase (MMP) over-
expression, greater Ca2+ influx, enhanced vasorelaxation and chemotactic activity. 
In atherosclerotic and neointimal lesions, SMCs migrate from the tunica media 
through the internal elastin lamina to the intima. Protease release by these SMCs 
is responsible for further elastin destruction in the arterial wall. Elastin is similarly 
enzymatically degraded by MMPs in aneurismal vessels, specifically MMP-2 and 
MMP-9 released by activated SMCs and infiltrated leukocytes, which leads to 
formation of floppy, de-elastized vascular segments, susceptible to rupture (77). 
The degradation of elastin is the result of a proteolytic cascade that involves the 
cooperation of several degradative enzyme types such as serine proteases, 
matrix metalloproteinases, and cysteine proteases (71). These may be present in 
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latent forms under healthy physiologic conditions, yet become activated following 
vessel wall injury. 
 
2.5 Engineering Strategies to Promote Elastin Regeneration 
 Elastin is crucial to maintaining the native structural configuration (11, 78-
80) and regulating the cell-signaling pathways (12, 81-83) of blood vessels. Thus, 
the failure to reinstate a healthy elastin matrix, when damaged by disease (e.g., 
inflammation-mediated elastin degradation in atherosclerosis) can severely 
compromise vessel homeostasis (13). In addition to achieving functional and 
complete endothelialization, a major concern in the development of tissue-
engineered vascular constructs is the ability of scaffolding materials to modulate 
SMC behavior and encourage the regeneration of elastin-rich matrix. 
 
2.5.1 Synthetic Scaffolds 
 The most widely used synthetic scaffolds are poly-lactic (PLA), poly-
glycolic acid (PGA), and poly-L-lactic acid (PLLA). Although these scaffolds are 
not ideal from the standpoint of eliciting poor cell attachment, PLLA has been 
shown to favor elastogenesis (84). SMCs seeded onto polyhydroxyalkanoates 
synthesize uniformly aligned elastin and collagen fibers in the direction of blood 
flow. Previous attempts by Stock et al. (85) to regenerate elastin on lamina-
coated PGA scaffolds in vitro, did not replicate the amounts and ultrastructure of 
elastin, synthesized by the same scaffolds when implanted in vivo (85). This 
underlies the absence of cell signals controlling elastin mRNA expression in vitro 
and also leads to the conclusion that biosynthesis and crosslinking of elastin 
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appears to be one of the most complex and tightly regulated processes during 
blood vessel maturation. Application of mechanical stimuli (e.g., dynamic 
stimulation), growth factors (e.g., TGF-β), and of stem cells (e.g., endothelial 
progenitor cells) can upregulate amounts of elastin biosynthesis within synthetic 
scaffolds but not to the extent of mimicking native arterial elastin (84). Thus, 
biological scaffolds, and more importantly ECM scaffolds, which theoretically 
would be expected to elicit more closely native cell responses have gained much 
attention in the context of elastic tissue regeneration (84). 
 
2.5.2 Biological Scaffolds 
 Biological scaffolds are normally fabricated from one or all the 
components such as elastin, collagen, glycosaminoglycans and more recently 
fibrin, which has been clinically approved for promotion of elastin biosynthesis 
when incorporated in a three dimensional (3D) arrangement within scaffolds. 
Each of these components differs in the levels of elastin biosynthesis they elicit. 
Previous studies have shown enhanced elastin biosynthesis by rat neonatal 
SMCs cultured onto hyaluronic acid gel scaffolds as compared to controls 
(plastic) (84). Collagen scaffolds fail to regenerate substantial elastin in vitro even 
in presence of seeded vascular SMCs. Long and Tranquillo showed higher levels 
of elastin biosynthesis by neonatal vascular SMCs seeded onto fibrin scaffolds 
and within fibrin-collagen constructs (86). Cells entrapped and cultured within 3D 
fibrin gels allowed formation of complex elastin geometries similar to that 
observed in native elastin. Although promising, above results were generated by 
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neonatal SMCs and dermal fibroblasts; both cell types that retain high 
elastogenic potential, unlike adult SMCs (87). Also, the organization of elastin 
fibers into structural networks, and their mechanical properties were not 
characterized. This study validates previous claims as to the overall superiority of 
3D, ECM-based cell scaffolds over 3D synthetic scaffolds or two dimensional 
(2D) monolayer cell cultures to efforts to simulate the chemical and physical 
environment of tissues (86, 88). Cells within 3D scaffolds come into contact with 
other cells and ECM in three dimensions and are therefore expected to more 
closely evoke native cell responses than 2D substrates. 
 Lee et al. has demonstrated in a study involving SMCs seeded onto ECM 
scaffolds that the phenotype of SMCs in engineered tissues is strongly regulated 
by the chemistry of scaffold in vitro, as a result of which SMCs exhibited a 
differential cell growth and ECM production depending upon the scaffold to which 
they adhered (89). More specifically elastin production was stimulated on PGA 
scaffolds, used as controls in comparison to enhanced collagen production onto 
collagen I scaffolds (89). In this study 2D culture models still provide useful 
information since trends in scaffold chemistry-dependent variations of cell 
phenotype and matrix synthesis are maintained, but not necessarily to the same 
levels, when translated into a 3D culture system. The physical and mechanical 
characteristics of the scaffold are important only to exaggerate or dampen 
scaffold-chemistry-dependent cell responses or direct the structural organization 
of the synthesized matrix towards defined end goals (89). Since gene expression 
of cells cultured within 3D scaffolds, as within native tissues, can be regulated by 
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various scaffold-derived cues including cell adhesion molecules, growth factors, 
and mechanical stimuli, ECM-based scaffolds are more likely to evoke native 
integrin-ECM interactions and preserve the native cell phenotype; similar 
variations in the type and extent of cell receptor-ECM ligand interactions with 
different ECM molecules can profoundly influence cell phenotype and matrix (e.g., 
elastin) synthesis (86, 88, 90). Successful upregulation of elastin synthesis and 
organization into mature elastic tissue is contingent on the selection of an 
appropriate scaffold material from among a subset of ECM molecules shown to 
actively facilitate elastogenesis in vivo  
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CHAPTER THREE 
A CYTOKINE AXIS REGULATES ELASTIN FORMATION AND DEGRADATION 
 
 Elastogenesis is the process by which elastin-containing fibers and 
lamellae are formed. The process is subject to dynamic regulation during the 
development of tissues such as the lung and aorta where elastin biosynthesis is 
active in late stages of development and in the early postnatal period but is 
subsequently attenuated (91-93). Steady state, basal levels of elastin expression 
and breakdown remain low in adult tissues as well as in cells isolated from adult 
tissues (94, 95). Elastin expression is reactivated in diseases such as pulmonary 
hypertension, dermal elastosis, pseudoxanthoma elasticum, Buschke–Ollendorff 
syndrome, Moyamoya disease, cigarette smoke- induced emphysema, severe 
chronic obstructive pulmonary disease (COPD) and forms of progeria (34, 96-
103), although in many of these disorders the elastin produced is disorganized 
and dysfunctional (32-34). 
 Much is known about the molecular mechanisms underlying elastin 
formation in development and disease. This understanding has been advanced 
through studies of the many human genetic disorders and pathologies of elastin-
rich tissues e.g., Costello syndrome (104), cutis laxa syndrome (105) and 
Ehlers–Danlos syndrome (106). Studies of mouse models have contributed 
greatly to our understanding of the genes involved in developmental elastin 
formation (107-109). In addition, numerous positive and negative effectors of 
tropoelastin expression and elastin formation have been identified through in vitro 
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experimentation (Tables 3.1 and 3.2). Emerging from studies of elastin 
biology/pathobiology is a cytokine regulatory axis comprised of pro- and anti-
elastogenic cytokines. In the present review we focus on highlighting salient 
components of this regulatory axis and their mechanisms of action on elastin 
biosynthesis and degradation. 
 
3.1 Cytokines that promote elastin formation 
3.1.1 Transforming growth factor β-1 (TGFβ1) 
 TGFβ1 is a member of the TGFβ superfamily of cytokines. TGFβ 
activation is normally kept under tight negative control through the process of 
extracellular matrix sequestration/latency (110). Increased TGFβ1 signaling 
drives pathogenesis of multiple diseases (e.g., fibrotic diseases of the liver, 
kidney, lung and skin), most of which impact elastin formation and breakdown. 
For example, TGF-β1 overexpression results in severe interstitial and pleural 
fibrosis accompanied with increased deposition of elastin (111). Overexpression 
of active TGFβ1 in experimental abdominal aortic aneurysms is associated with 
preservation of medial elastin (112) Indeed, numerous studies have established 
that TGFβ1 augments both tropoelastin mRNA abundance (113-116) and elastin 
formation (115, 117). Mechanistically, TGFβ1 mediates these effects by 
modulating tropoelastin promoter activity, mRNA stability and elastin degradation. 
 A number of studies demonstrate that TGFβ1 exerts positive effects on 
tropoelastin transcription. In human embryonic lung fibroblasts, TGFβ1 activates 
tropoelastin transcription via the phosphatidylinositol 3-kinase/Akt/p38 signaling 
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pathway (118). In transgenic mice expressing a chloramphenicol 
acetyltransferase (CAT) reporter gene under control of the human elastin 
promoter, CAT activity is greatly elevated in the skin of TGFβ1 treated animals 
(119). Furthermore, in chick embryo aorta cells transfected with an elastin 
promoter-CAT construct, CAT activity is increased by addition of TGFβ1 (120). 
By contrast, elastin promoter/CAT reporter studies performed in skin fibroblasts 
showed that TGFβ1 did not change the promoter activity (121). These and other 
findings indicate that the effects of TGFβ1 on elastin transcription are cell-type 
specific. Consistent with this conclusion are findings of McGowan (122) showing 
that TGFβ1 stimulates elastin formation in neonatal lung fibroblasts but not in 
adult lung fibroblasts or adult lung smooth muscle cells. Furthermore, embryonic 
aorta cells and tendon fibroblasts also display differential responsiveness to 
TGFβ1 (120). These differential effects have been attributed to cell type-specific 
nuclear transcription factors that bind to a TGFβ1-responsive element located in 
the −196 to −12 region of the elastin promoter (120, 123). 
 TGFβ1 also acts post-transcriptionally to stabilize tropoelastin mRNA 
transcripts (121, 124). Indeed, TGFβ1 can relieve tropoelastin mRNA instability in 
cutis laxa fibroblasts in which tropoelastin mRNA is highly unstable (116). 
Mechanistically, this involves a regulatory GA-rich sequence located in the 3′ 
UTR of the tropoelastin transcript referred to as the G3A site (125, 126). 
Individuals of several families with inherited cutis laxa have mutations in the 
tropoelastin gene located in the vicinity of the coding sequencing for this 
regulatory element (i.e., located near the 5′ end of exon 30) (125). Elements 
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related to the elastin GA-rich sequence are enriched in stable RNAs of other 
genes and mediate binding of mRNA stability factors, including CUGBP1 (127). 
Whether CUGBP1 or another such protein binds to the G3A site and influences 
decay of the tropoelastin mRNA and whether TGFβ1 influences binding to the 
site remain to be established. 
 The tropoelastin mRNA stabilization effects of TGFβ1 are mediated 
through several TGFβ signaling pathways including the Smad signaling pathway, 
the phosphatidylcholine (PC)-specific phospholipase C (PLC)-protein kinase C 
(PKC)-delta pathway and the TGFβ-activated kinase (TAK1)-stress-activated 
protein kinase p38 pathway (124, 128). This is supported by evidence showing 
that TGFβ-stimulated tropoelastin mRNA accumulation can be blocked by 
inhibitors of PLC, PKC and p38 as well as by transgenic expression of the 
inhibitory Smad, Smad7 (128). 
 TGFβ1 may also stabilize elastin mRNA by reducing the expression of 
microRNAs. Recent studies show that expression of the microRNA, miR-29, is 
reduced by TGFβ1 (129) and that the 3′UTR of elastin mRNA is a target of miR-
29 (130, 131). Furthermore, miR-29 mimics decrease elastin mRNA levels in 
dermal fibroblasts and vascular smooth muscle cells (132). Moreover, in the 
developing mouse aorta, an upregulation in the expression of miR-29 as well as 
several other microRNAs that have targets in the elastin mRNA (i.e., the miR-15 
family members miR-195 and miR-497) accompanies the downregulation of 
elastin mRNA in the period between the newborn and adult (130, 131). 
 The ability of TGFβ to augment elastin expression also relates to 
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hyaluronan signaling. Studies have shown that TGFβ1 and hyaluronan oligomers 
(consisting of 3 to 9 glucuronate and N-acetylglucosamine disaccharides) act 
synergistically to enhance elastin levels in the extracellular matrix of cultured 
vascular smooth muscle cells (133). Intriguingly, TGFβ treatment of vascular 
smooth muscle cells from experimentally induced aortic aneurysms does not 
elicit a change in elastin synthesis, but treatment with a combination of TGFβ and 
hyaluronan oligomers enhances elastin protein levels in the extracellular matrix 
(134). Hyaluronan oligomers interact with the major receptor for hyaluronan, 
CD44, and it is thought that hyaluronan oligomers disrupt endogenous 
hyaluronan interactions with CD44 (135). Since CD44 has direct and indirect 
interactions with other signaling receptors, including TGFβ receptor type I and 
epidermal growth factor receptor (EGFR), disruption of hyaluronan-CD44 binding 
can influence the activity of a variety of downstream signaling pathways. The 
CD44-EGFR interaction may be of particular relevance to the pro-elastin effects 
of hyaluronan oligomers since EGFR signaling appears to be anti-elastogenic 
(136). Thus, hyaluronan oligomers may interfere with suppressive effects of 
EGFR signaling on elastin expression. Studies describing EGFR signaling effects 
on elastin are discussed below. 
 TGFβ1 also limits elastin degradation by decreasing levels and activity of 
elastolytic proteases including matrix metalloproteinase (MMP)-2 and -9 (112). 
Indeed, TGFβ blockade exacerbates elastin degradation and decreases levels of 
elastin in medial layers of blood vessels (137). By contrast, overexpression of a 
mutated, active form of TGFβ1 in animals having experimentally induced aortic 
 50 
aneurysms leads to reduction in the expression of elastolytic MMPs and 
preservation of elastic fibers in the medial layers of injured aortas (112). TGFβ1 
also elicits effects on MMP activity by augmenting expression of tissue inhibitors 
of MMPs (TIMPs) (138). Similarly, TGFβ1 sustains levels of the plasmin inhibitor, 
PAI-1, which prevents activation of the elastolytic protease MMP-9 (137, 139). 
 
3.1.2 Insulin-like growth factor-I (IGF-I) 
 IGF-1 has been implicated as a positive regulator of elastogenesis 
occurring in the developing aorta (140, 141) and in pathologies including 
atherosclerosis (142). Like TGFβ, IGF-I elicits positive effects on elastin 
expression (143-145). Also similar to TGFβ, the effects of IGF-I on elastogenesis 
appear to be cell type specific. For example, IGF-I increases steady state levels 
of tropoelastin mRNA and soluble elastin production in neonatal aortic smooth 
muscle cells, but it elicits no change in tropoelastin expression in pulmonary 
fibroblasts, which also express the type I IGF-I receptor (144). 
 IGF-I regulation of elastin expression involves the interaction of two 
members of the Sp-family of transcription factors, Sp1 and Sp3, with elements of 
the elastin promoter (142, 145-147). These transcription factors have opposing 
effects on elastin transcription such that Sp1 promotes elastin transcription 
whereas Sp3 represses Sp1-mediated enhancement of elastin transcription. IGF-
I acts to both promote Sp1 binding to the elastin promoter and abrogate Sp3 
interaction with the elastin promoter (142). 
 Key to the process by which IGF-I mediates Sp1 interaction with the 
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elastin promoter is the formation of a complex between Sp1 and phosphorylated 
retinoblastoma protein (Rb) (142, 145-147). IGF-I acts to promote the formation 
of a cyclinE–cyclin-dependent kinase 2 (cdk2) complex, which mediates cdk2-
dependent phosphorylation of Rb on threonine-821 (Thr821) (147). 
Phosphorylation of Rb(Thr821) recruits Sp1 to Rb. The resulting complex binds 
to a retinoblastoma control element within the elastin gene promoter and 
stimulates tropoelastin transcription (147). 
 Intriguingly, the IGF-I-induced effects on Rb phosphorylation and elastin 
expression are counter balanced by pro-proliferative stimuli transmitted through 
the mitogenic Ras/MEK/ERK pathway. For example, dermal fibroblasts treated 
with the mitogen, PDGF-BB, display decreased levels of phosphorylated 
Rb(Thr821) and reduced elastin deposition (147). PDGF-BB also increases 
Table 3.1: Effectors that augment elastin biosynthesis in cultured cells. 
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levels of phosphorylated Rb(Ser780), which is elevated in Costello syndrome 
fibroblasts that display H-Ras driven proliferation and decreased elastogenesis. 
Quenching of the increased proliferation of Costello syndrome fibroblasts by 
treatment with inhibitors of Ras, MEK or cdk4 induced up-regulation of 
Rb(Thr821) phosphorylation, decreased Rb(Ser780) phosphorylation and 
recovery of their elastogenesis deficiency (147). These findings fit with 
observations indicating that an inverse relationship exists between elastin 
deposition and cell proliferation (14).  
 
3.2 Cytokines that inhibit elastin formation 
3.2.1 Basic fibroblast growth factor (bFGF) 
 Basic fibroblast growth factor (bFGF, also known as FGF2) is a major 
negative regulator of elastogenesis. bFGF decreases elastin gene transcription in 
aortic smooth muscle cells (148) and pulmonary fibroblasts (149). Furthermore, 
in mice bearing compound deficiency of the FGF receptors, 3 and 4, elastin 
deposition is not downregulated postnatally in the lungs (150). While these 
findings highlight that FGF signaling plays a role in attenuating developmental 
elastogenesis in the lung, it is unclear whether this involves bFGF or other FGFs. 
bFGF is the candidate elastin suppressor in the periodontal ligament (PDL), in 
which elastin expression is normally negligible. bFGF is expressed in the PDL 
(151) and has been shown to suppress transcription of tropoelastin in cultured 
PDL cells (152). Interestingly, PDL cells grown in culture express tropoelastin 
mRNA (152), suggesting that the suppressive mechanism operative in the PDL in 
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vivo is released when the cells are placed in culture. 
 bFGF represses elastin gene transcription by augmenting expression of 
the transcription factor Fra-1 (also known as fos-like antigen 1), that 
subsequently binds to a sequence located at −564 to −558-bp in the elastin 
promoter, heterodimerizing with c-Jun to form an inhibitory complex (153). bFGF-
dependent repression of tropoelastin mRNA expression can be blocked by 
inhibition of MEK1, indicating that the MEK/ERK pathway mediates the response 
of the growth factor (154). 
 The potent suppressive effects of bFGF may underlie attenuated/ 
defective elastogenesis observed in wound healing processes in which bFGF 
levels are increased, such as in dermal, cerebral, hepatic, renal and tendon 
wound healing (155). bFGF expressed in these in vivo settings or even in 
cultured cells may oppose the action of positive effectors of elastogenesis. 
Indeed, bFGF has been shown to inhibit the ability of TGFβ1 to induce elastin 
expression by vascular smooth muscle cells (156). The suppressive effects of 
bFGF on elastogenesis would appear to be an unfavorable consequence to 
therapeutic use of bFGF in wound healing, if elastin synthesis is a desired 
endpoint. 
 bFGF has also been shown to decrease the expression of mRNA 
encoding lysyl oxidase (157), the enzyme that catalyzes tropoelastin crosslinking. 
Interestingly, lysyl oxidase inactivates bFGF through promoting covalent 
crosslinking of bFGF monomers to form multimers (158). It is not known whether 
lysyl oxidase might cross link bFGF to elastin, but bFGF is released by elastase 
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treatment of cultures of pulmonary fibroblasts and pulmonary artery smooth 
muscle cell (149, 159), suggesting that the growth factor may be bound to elastin. 
Release of extracellular matrix-bound bFGF has also been reported to occur in 
response to burn injury of skin, another tissue rich in elastin (160). Elastase 
release of bFGF could contribute to impaired elastin synthesis in pulmonary 
obstructive diseases in which elastase degradation of elastin is operative. 
 
3.2.2 Heparin-binding epidermal growth factor (HB-EGF) 
 HB-EGF is an EGF receptor (EGFR/ErbB1) ligand that reduces 
tropoelastin mRNA expression and matrix accumulation of elastin protein (161, 
162). HB-EGF mediates these effects through a mechanism that, like bFGF, 
involves stimulation of ERK1/2 phosphorylation and nuclear accumulation of Fra-
1 (162). This is supported by findings showing that siRNA suppression of HB-
EGF expression leads to increased levels of elastin protein and decreased levels 
of Fra-1 protein (161). In addition, other findings show that inhibition of ERK1/2 
activation using MEK1/2 inhibitors reduces both HB-EGF-induced Fra-1 
accumulation and HB-EGF-downregulation of tropoelastin mRNA expression 
(162). HB-EGF also induces the expression of bFGF, which could amplify the 
suppressive effects of HB-EGF on elastin expression (162). 
 
3.2.3. Epidermal growth factor-like growth factor (EGF) 
 EGF is a cytokine produced in response to injury (163, 164). EGF and 
TGFα-like cytokines are released by neo- natal rat lung fibroblasts treated with 
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neutrophil elastase, a protease associated with excessive elastolysis in 
emphysema (165). Similar to the action of HB-EGF, EGF causes decreases in 
tropoelastin mRNA stability and insoluble elastin deposition (136, 166). 
Tropoelastin mRNA destabilization by EGF can be blocked by the EGFR inhibitor, 
AG1478, and the MEK/ERK inhibitor, U0126 (136). Dicamillo et al. (2006) 
concluded that the EGFR/MEK/ERK signaling cascade acts in opposition to 
TGFβ1 signaling to override the positive effects of TGFβ1 on tropoelastin mRNA 
stability. 
 
3.2.4 Transforming growth factor-α (TGFα) 
 TGFα is an EGFR ligand that is expressed by airway epithelial and 
interstitial cells following lung injury (164, 167, 168), including the pathogenesis 
of cystic fibrosis lung disease (169). TGFα is thus implicated in the elastolysis 
and defective elastin repair associated with pathological remodeling of the lung. 
Indeed, overexpression of TGFα in the neonatal lung leads to disorganized and 
fragmented elastin fibers in the alveolar septae (170). Like EGF, TGFα is 
released by lung fibroblasts in response to neutrophil elastase treatment, causing 
tropoelastin mRNA destabilization via activation of the EGFR/MEK/ERK signaling 
cascade (136, 171). 
 
3.2.5 Tumor necrosis factor-alpha (TNF-α) 
 TNF-α, a proinflammatory cytokine, suppresses tropoelastin mRNA levels 
in skin fibroblasts, aortic smooth muscle cells and lung fibroblasts (121, 165). 
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Conversely, TNF-α knock- out mice display increased vascular elastin expression 
(172), which may account for findings that TNF-α-deficient mice are resistant to 
aneurysm formation (173). 
 In cultured aortic smooth muscle cells, the inhibitory effects of TNF-α on 
elastin gene expression involve the transcription factor AP-1 binding to a region 
in the elastin promoter located between −290 and −198 bases pairs (113). AP-1 
complexes are heterodimers of Jun and Fos family members, each activated via 
the MAP kinase signaling pathway. As mentioned above, bFGF exerts its 
repressive effects on elastin transcription via the Fos family member Fra-1 (153), 
downstream of MEK1/ERK1/2 pathway signaling (154). It is therefore possible 
that TNF-α also downregulates tropoelastin transcription via MAP kinase 
pathway effects on AP-1. 
 Another dimension to the relationship between TNF-α and elastin is that 
TNF-α promotes elastin breakdown through enhanced release of elastolytic 
enzymes (174-176). For example, TNF-α induces production of the elastolytic 
MMPs, MMP-2 and MMP-9, by vascular smooth muscle cells (177). 
 Like EGF, TNF-α is released by lung fibroblasts in response to neutrophil 
elastase treatment and has been shown to abrogate TGFβ-induced 
enhancement of tropoelastin mRNA expression (121, 165). Enhanced TNF-α 
expression also occurs in response to cigarette smoke exposure and its increase 
correlates with pulmonary elastin breakdown, a precursor to emphysema (178). 
TNF-α induced elastin degradation is also linked to vasculitis stemming from 
Kawasaki disease as well as vascular aneurysms (179). In fact, in Lactobacillus 
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casei cell wall extract-induced coronary arteritis, abrogation of TNF-α activity by 
TNF-α-blocking agents or deletion of the TNF receptor-1 protects against elastin 
degradation and aneurysm formation (179). Furthermore, doxycycline, which 
inhibits MMP-9 enzymatic activity, can mitigate TNF-α-induced coronary elastin 
breakdown (180). 
 
3.2.6 Interleukin (IL)-1β 
 IL-1β is a pro-inflammatory cytokine released in pathologies involving 
elastin-rich tissues (e.g., COPD and asthma) (181). Similar to TNF-α, IL-1β 
enhances the release of elastases in skin and uterine fibroblasts (182, 183). 
Induction of elastase expression may underlie the disruption of elastin fibers 
observed in alveolar septa of mouse lungs induced to express IL-1β (184, 185). 
Moreover, mice deficient in a negative regulator of IL-1β signaling, interleukin-1 
receptor antagonist, develop femoral artery aneurysms displaying degradation of 
both the internal and external elastic lamina (186). 
 In addition to its effects on elastase expression, IL-1β causes changes in 
elastin transcription. In neonatal lung fibroblasts IL-1β reduces elastin gene 
transcription (187, 188). The mechanism by which elastin transcription is 
negatively regulated in response to IL-1β is most thoroughly defined in neonatal 
lung fibroblasts. In these cells, IL-1β promotes nuclear localization of the p65 
subunit of NF-κβ that subsequently interacts with Sp1 to downregulate elastin 
transcription (188). This is supported by findings showing that: 1) overexpression 
of p65 downregulates tropoelastin mRNA levels (188), and 2) that inhibition of 
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NF-κβ blocks the effects of IL-1β on elastin transcription in neonatal rat lung 
fibroblasts (189). Similarly, other studies show that p65 binds Sp1 proteins and 
interferes with transcription of at least one other extra- cellular matrix protein, 
type α1(I) collagen (190).  
 The effect of IL-1β on NF-κβ also increases the expression of the 
transcriptional repressor CCAAT/enhancer-binding protein (C/EBP)-β (LIP), 
which binds to a GCAAT-containing sequence located at −56 to −62 bp in the 
elastin promoter (189). Like IL-1β, C/EBPβ protein levels are increased in lung 
Table 3.2: Effectors that inhibit elastin biosynthesis in cultured cells. 
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fibroblasts exposed to cigarette smoke (191). Importantly, levels of C/EBPβ 
proteins are regulated in lung fibroblasts by the ubiquitin-proteasome path- way, 
and proteasome inhibitor treatments downregulate tropoelastin mRNA 
expression (192). C/EBP family members also bind to Rb, and the complexes 
bind to C-EBP binding sites on DNA (193). Whether Rb-C/EBP proteins interfere 
with the pro-elastin transcriptional activity of Rb-Sp1 remains to be determined. 
 
3.3 Cytokines that have dual effects on elastin formation 
3.3.1 IL-1β 
 By contrast to the anti-elastogenic effects exerted by IL-1β on neonatal 
lung fibroblasts, several studies show that IL-1β promotes tropoelastin mRNA 
expression in adult dermal fibroblasts (194, 195). For example, in dermal 
fibroblasts isolated from transgenic mice expressing the human elastin promoter 
linked to a CAT reporter, IL-1β increases CAT activity (194). Furthermore, 
subcutaneous IL-1β injection into these transgenic mice increases CAT activity in 
the skin, indicative of a robust positive effect on elastin transcription (196). The 
molecular basis for the effects of IL-1β on elastin expression in skin fibroblasts is 
not clear. 
 
3.3.2 TGFβ 
 Despite the preponderance of evidence indicating that TGFβ is a pro-
elastogenic factor, increased TGFβ activity as seen in Marfan syndrome (MFS) 
(197) is associated with elastic fiber degeneration and decreased tropoelastin 
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mRNA levels (198). This, together with the fact that noncanonical, Smad- 
independent, TGFβ-mediated Erk1/2 activation drives aortic aneurysm 
progression in MFS (199), appears to indicate that TGFβ signaling through the 
noncanonical, Smad-independent, MAP kinase pathway has suppressive effects 
on elastin RNA levels. 
 
3.4 Conclusions 
 The cytokine-governed elastin regulatory axis is comprised of pro- and 
anti-elastogenic cytokines that control the biosynthesis and break- down of 
elastin through transcriptional and post-transcriptional mechanisms. How 
cytokines exert opposing effects on elastin transcription (Fig. 1) hinges on the 
 
Figure 3.1. Cytokine signaling cascades that influence tropoelastin transcription. 
Cytokines and signaling pathway intermediates highlighted in red act to suppress tropoelastin 
transcription. Cytokines and signaling pathway intermediates highlighted in green act to 
promote tropoelastin transcription. RTK, receptor tyrosine kinases. 
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way in which they influence cell cycle regulatory constituents, particularly cyclin-
cyclin dependent kinase complexes and their substrates. For example, cytokines 
such as IGF-I induce tropoelastin transcription by promoting cyclin E/cdk2-
dependent phosphorylation of Rb(Thr821) which recruits Sp1 to bind the elastin 
gene promoter and stimulate transcription (147). Counterbalancing this process 
is mitogenic cytokine signaling via the Ras/MEK/ERK cascade. Cytokines such 
as EGF, HB-EGF and TGFα, which stimulate this cascade through activation of 
EGFR, exert suppressive effects on elastin biosynthesis and/ or catabolism. 
Likewise, Ras/MEK/ERK pathway signaling mediated by bFGF, PDGF-BB and 
TNF-α also elicit suppressive effects on elastin expression, as does noncanonical, 
Smad-independent Ras/MEK/ERK signaling stimulated by TGFβ1. Importantly, 
cytokine stimulated Ras/MEK/ERK signaling acts in opposition to the pro-elastin 
effects of canonical TGFβ1 signaling, possibly through attenuation of nuclear 
accumulation of activated SMADs (200). Similarly, Ras/MEK/ERK-mediated 
initiation of the cell-cycle progression acts to attenuate the elastin transcription-
promoting effects of IGF-I. 
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CHAPTER FOUR 
DNA MICROARRAY BASED TRANSCRIPTOMIC PROFILING TO IDENTIFY 
GENES THAT ARE SIMILARLY REGULATED IN PROCESSES IN WHICH 
ELASTOGENESIS IS A KEY COMPONENT 
 
4.1 Introduction 
 DNA microarray technology is a high-throughput quantification of the 
expression of thousands of genes at the same time within a sample. The 
technology is based on a DNA chip containing thousands of DNA probes (oligos), 
each containing on the order of picomoles of a section of DNA sequence 
localized to a specific location on the chip. The chip comes into contact with copy 
DNA (cDNA) created from an experimental sample and cDNAs hybridized to the 
probes. Probe-target hybridization can then be detected and quantified by 
fluorophore-labeled targets. DNA microarray analyses generate vast amounts of 
data on expression intensities within the sample for each DNA probe present on 
the chip. The advent of this massive data-generating assay results in endless 
approaches to data analysis. 
 This technology is novel in that it enabled quantification of the co-
expression of sets of genes in a given tissue in given conditions that can be 
analyzed to predict gene regulatory networks. DNA Microarray studies suggest a 
correlated action of different elements of the gene regulation machinery and their 
potential interaction. The information gained offers an unprecedented opportunity 
to fully characterize biological processes.  
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4.2 Materials and Methods 
4.2.1 Identification of Processes in which Elastogenesis as a Key Component. 
 The formation of elastic fibers, elastogenesis, is prominent in fetal and 
postnatal development but adult fibroblasts do not assemble elastic fibers under 
normal conditions (201, 202). During elastogenesis the elastin gene is 
upregulated from a quiescent state and then returns to a baseline level. We 
identifie processes where the elastin gene is upregulated as in the window of 
development. 
 Elastic fibers synthesized during development are considered the gold 
standard by which wound injury elastic fibers and in vitro elastic fibers are 
compared and of the quality that tissue engineers aspire to synthesize. However, 
considering other processes in which elastin is a key component is essential in 
order to further refine the “elastogenic developmental set” and to eliminate genes 
that are specific to development and inessential to elastogenesis. In vivo 
processes for consideration occurred in tissues in which mature elastic fibers are 
a primary component. Microarray data from in vitro cell culture was selected in 
cells that synthesize elastic fibers in their derived tissue in vivo (i.e., vascular 
smooth muscles cells (VSMCs), fibroblasts, etc.) (21-24). 
 Criteria for determining processes in which elastogenesis is a key 
component relied upon 1) the process occurs in a recognized elastic fiber 
containing tissue or elastin producing cell as determined by histological literature 
and 2) the elastin gene is significantly upregulated over a time course. 
 It is a recognized risk that comparison of commonly regulated genes from 
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lower quality or defective elastic fibers may exclude certain critical genes. It is 
also a possibility that identification of significantly regulated genes in an opposing 
direction to development may elucidate genes responsible for elastic fiber 
defects in wound repair and in vitro.  
 
4.2.2 Transcriptomic Profiling During Developmental Models 
 The formation of elastic fibers, elastogenesis, is prominent in fetal and 
postnatal development and developmental elastin fibers are the gold standard by 
which tissue engineered elastin fibers are compared. It is therefore essential to 
understand the biological processes occurring during elastogenesis through DNA 
microarray analysis of simultaneous gene expression during development of 
elastin-containing tissues of animal models. 
 
4.2.2.1 Transcriptomic Profiling of the Developing Lung 
 Elastogenesis primarily occurs during development with elastin produced 
in the lung during late fetal, neonatal, and early postnatal growth coinciding with 
alveolarization (91). Tropoelastin mRNA is barely detectable in the adult lung. 
We isolatee RNA from C57BL/6 
mouse lung tissue from 
postnatal day (d) 5 to adult (8 
months) at 5 developmental 
stages (4 samples/stage) before, 
during and after elastogenesis.  
 
Figure 4.1. Elastin expression profile in 
developing rodent lung. A study by Chailley-Heu 
illustrates a developmental peak in elastin 
expression profile in postnatal rat lung by Northern 
blot showing an increase in elastin expression 
corresponding to alveolar septation in the rat (1) 
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4.2.2.1.1 RNA Preparation from Developing Lung Tissue 
 Lungs from wild type C57BL/6 mice were extracted for RNA preparation at 
5, 7, 10, 14, and 225 days postnatal (n = 3 for each time point, n = 4 for 225 
days). Mice aged 5, 7, and 10 days postnatal were sacrificed by decapitation, 
mice aged 14 days were sacrificed by CO2 inhalation followed by cervical 
dislocation, and adult mice aged 225 days postnatal were sacrificed by isoflurane 
inhalation followed by cervical dislocation according to standard laboratory 
protocols approved by the Animal Research Committee at the Medical University 
of South Carolina and at Clemson University. For each mouse, the left lung was 
removed and stored in RNALater® solution pending RNA extraction. Due to 
protocol concerning differences in lung function at various time points, It was not 
possible to control the euthanation procedure variations prior to lung tissue 
extraction. Neonatal animals have underdeveloped lungs that would not respond 
to CO2 inhalation while it would be inhumane not to treat adult animals otherwise. 
It is possible that the inhalation procedure variations could contribute to 
differences in gene expression but efforts were taken to act fast minimizing the 
effects of chemicals on lung tissue. 
 For each mouse, a maximum of 30 mg lung tissue was homogenized in 
Trizol® reagent and extracted with 0.2 mL chloroform per mL Trizol. Total RNA 
was extracted from the aqueous phase of each sample with a Qiagen RNeasy® 
Plus Mini Kit according to the manufacturer’s instructions. The RNeasy 
technology combines the selective binding properties of a silica-based 
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membrane with the speed of microspin technology. Genomic DNA was removed 
in a single, rapid centrifugation step by passing each sample over a gDNA 
eliminator column. RNA longer than 200 bases within the sample is then bound 
to the RNeasy silica membrane with a specialized high-salt buffer system while 
contaminants are efficiently washed away. High-quality RNA was eluted in 30 µl 
water of which 1 uL was used to measure concentration and quality with a 
Bioanalyzer 2100  (Agilent Technologies, Palo Alto, CA). 
 
4.2.2.1.2 Synthesis of Biotin-Labeled cRNA Targets and Hybridization to 
Affymetrix Gene Chips 
 Synthesis of double-stranded cDNA from RNA, in vitro transcription of 
biotin-labeled cRNA targets, and fragmentation of target cRNA were performed 
as outlined by Affymetrix protocols (Affymetrix, Santa Clara, CA). Fragmented 
cRNA samples were hybridized overnight at 45°C to Affymetrix Mouse GeneChip 
MG_U74Bv2. Posthybridization washing and phycoerythrin-streptavidin staining 
and fluorescence scanning were performed using Affymetrix instrumentation in 
accordance with manufacturer protocols. 
 
4.2.2.1.3 Analysis of DNA Microarray Data 
 The resulting scans (CEL files) containing gene hybridization intensities 
were normalized using Robust Multichip Average (203) implemented with the 
ArrayQuest web-based analysis system. Normalized hybridization values were 
imported into the analysis tool dChip 2005 (204) for subsequent analysis. Gene 
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probe IDs differentially expressed during lung development were identified using 
both statistical analysis and presence thresholds. Statistical analysis was 
performed with Significance Analysis of Microarrays (SAM, www-
stat.stanford.edu). In this analysis, a gene was determined to be differentially 
regulated if the false discovery rate (FDR) < 5%. A gene was considered 
“present” if at least two of three samples per timepoint had non-absent calls (P or 
M) in at least one timepoint. 
 
4.2.2.2 Transcriptomic Profiling of Developing Aortic Tissue 
 Tropoelastin expression in the aorta occurs at the end of embryonic 
development through one month postnatal development in mice (205, 206). Dr. 
Robert Mecham (Washington University School of Medicine, St. Louis, MO) 
contributed raw DNA microarray data on Affymetrix MG_U74Bv2 chips 
(unpublished) from an analysis of mouse aortae ranging from embryonic day 14 
to postnatal day 180. There was 1 sample (each a pool of 3 aortas) for each 
developmental stage. Statistical analysis was performed by standard deviation 
across a gene probe > 0.5 and having a gene presence call > 20% for 
developmental stages of a particular gene probe. 
 
4.2.3 Transcriptomic Profiling During Injury Models 
 One challenge to microarray analysis of developmental models is to 
distinguish which processes are important for specific elastic fiber formation and 
which represent general changes that occur during development. This issue was 
 68 
addressed with incorporation of additional animal models in which elastic fiber 
formation occurs such as during wound healing processes. The goal was how to 
distinguish the elastic fiber formation-specific pathways from developmental 
regulatory pathways. 
 
4.2.3.1 Transcriptomic Profiling of a Lung Injury 
 Transcriptome data was analyzed from a time course of mouse lung injury 
induced by intraperitoneal injection of naphthalene (31). Naphthalene injection 
had been shown to selectively kill Clara cells in the lung while leaving bronchiolar 
stem cells intact, allowing these cells to repair the damaged tissue and fully 
restore the epithelial layer (207). Due to the high levels of elastic fibers present in 
the lung, a model of lung repair that fully restores a normal epithelium should 
show significant expression changes in genes related to elastic fiber formation 
 Mouse lungs were injected with naphthalene and lungs collected in at 1 d, 
2 d, 3 d, and 6 d post-injection and compared to saline-injected control mice (n=4 
samples/timepoint) and microarray analysis was performed at the University of 
Pittsburgh Cance Center Clinical Microarray core using Codelink 20K Mouse 
Bioarrays (Applied Microarrays, Tempe, AZ). Microarray data files (CEL files) 
were obtained from the National Center for Biotechnology Information Gene 
Expression Omnibus (NCBI GEO) Datasets website. The processed data had 
been log2 transformed and normalized to the geometric mean across all 
samples. The online CNIO IDconverter tool was then used to obtain gene 
symbols and EntrezGene IDs from the provided GenBank Accessions for all 
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transcripts (208). Analysis of variance (ANOVA) was used to statistically 
compare each post-injury time point (n = 4 for each time point) and control lung 
samples (n = 4) with alpha set at 0.05. This means that if a p-value for a gene 
probe is < 0.05 then the null hypothesis that there is no difference between 
timepoints is rejected. A gene probe was determined to be “present” if at least 
two of four samples per timepoint had non-absent calls (P or M) in at least one 
timepoint. 
 
4.2.3.2 Transcriptomic Profiling of a Skin Injury 
 In order to eliminate organ specific gene expression in an injury model, we 
identified another injury model in an elastin-rich organ, the skin. Gene expression 
during wound healing by punch biopsy in the mouse skin was observed in 
various stages of healing from 1 to 6 days post-injury (209). The wound healing 
of the skin after an injury involves the formation of elastic fibers, however the 
quality of the fibers is less than optimal with disorganization and an increase in 
fibrosis resulting in some scar tissue. For our studies, we obtained the raw 
microarray data from the National Center for Biotechnology Information Gene 
Expression Omnibus (NCBI GEO) Datasets website. 
CEL files for the microarray analysis were downloaded from the NCBI 
GEO Datasets website and normalized by the Robust Multichip Average (RMA) 
method using Affymetrix Expression Console software. To be considered 
present, a gene must be called present in at least two of the three control 
samples and in at least two out of three samples in one of the post-injury time 
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points. Analysis of variance (ANOVA) was used to statistically compare each 
post-injury time point (n = 3 for each time point) and control lung samples (n = 3) 
with alpha set at 0.05. This means that if a p-value for a gene probe is < 0.05 
then the null hypothesis that there is no difference between timepoints is 
rejected. A gene probe was determined to be “present” if at least two of three 
samples per timepoint had non-absent calls (P or M) in at least one timepoint. 
 
4.2.4 Transcriptomic Profiling During In Vitro Elastic Fiber Formation 
 One challenge to microarray analysis of animal models is to distinguish 
which processes are important for specific elastic fiber formation and which 
represent general changes that occur in a complex living organism. This issue 
was addressed with incorporation of the following in vitro culture model in which 
versican variant V3 stimulates elastic fiber formation in vascular smooth muscle 
cells (VSMCs). The goal was how to identify the elastic fiber formation-specific 
pathways from the total changes in gene expression. 
 
4.2.4.1 Versican V3-transduction of Vascular Smooth Muscle Cells (VSMCs) 
 Versican, a large (>1000kDa) chondroitin sulfate proteoglycan is found in 
the extracellular matrix (ECM) of a variety of soft tissues. The smallest (73kDa) of 
the 4 identified splice variants has been reported to augment tropoelastin 
expression and elastic fiber formation in rat VSMCs(210), however the 
mechanism by which V3 overexperession upregulates elastogenesis is unclear. 
To identify changes in gene expression that may underlie V3 induced 
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elastogenesis, we employed DNA microarray expression analysis to quantify 
shifts in mRNA levels in V3 transduced and control ASMCs. 
 Primary rat vascular smooth muscle cells (VSMCs), passage 8-12, were 
transduced with lentiviral vector containing versican (V3) variant or control 
(empty vector) in the laboratory of Dr. Thomas Wight (Benaroya Research 
Institute at Virginia Mason, Seattle, WA). Of the six sets or pair of transductions, 
four pairs were cultured and harvested at the same time. One pair was from the 
same transduction but cultured at an earlier date. Another sample pair was from 
a different harvest of primary rat VSMCs and from a different transduction. All six 
sample pairs were grown for 15-21 days and the process of RNA extraction 
begun by the SolutionD method at the laboratory of Dr. Thomas Wight. The 
samples were then sent to Dr. Argraves lab for further RNA processing using 
RNeasy Plus Mini Kit (Qiagen) and integrity and concentration determined with a 
Bioanalyzer 2100  (Agilent Technologies, Palo Alto, CA).  
 
4.2.4.2 DNA Microarray of V3-transduced VSMCs 
 Messenger RNA (mRNA) for all sets of V3-transduced VSMCs and empty 
vector-transduced VSMCs were reverse transcribed at the same time, to control 
for RT variations. Synthesis of biotin-labeled cRNA targets were made from the 
mRNA and hybridized onto Affymetrix rat GeneChips, RAE230A. Data was 
normalized by the Robust Multichip Average (RMA) method using Affymetrix 
Expression Console software. A gene was considered “present” if at least three 
of six controls or three of six V3-transduced samples had non-absent calls (P or 
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M). Statistical analysis using a paired Student’s T test was performed for each 
gene probe to comparing the samples pairs each containing a control and 
experimental sample. A gene was considered statistically significant if it was 
“present” and p < 0.05. Additional analysis of the effects of V3 expression on 
VSMCs included a parameter to measure the ratio of average V3-transduced 
VSMCs gene expression vs. average empty vector-transduced VSMCs gene 
expression. Significance was set at a fold change of at least ±1.5 (at least 50% 
difference in expression levels). 
 An alternate approach to data analysis opted to average the normalized 
intensities from the 4 sample pairs cultured and harvested at the same time so as 
to treat the 4 samples as 1 sample pair. Subsequent statistical analysis was 
performed on the 3 sample pairs with a paired Students T-test across a gene 
probe and deemed significant if p<0.05 for a gene. 
 
4.2.5 Convergent Analysis of Microarray Datasets 
 Information from the five DNA microarrays studies in which elastogenesis 
is a key component are summarized below including the most appropriate 
statistical analysis method for the given data to identify genes significantly 
regulated in each process (Table 4.1).  Because the individual analyses were 
performed on various DNA microarray chips and identified by Probe Set IDs 
specific to their respective chip, a common ID for genes was needed to compare 
data from different microarrays. All Probe Set IDs from various chips were 
converted to gene symbols and re-identified as Mouse Genome 430 2.0 Probe 
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Set IDs using the Affymetrix NetAffx conversion tool. Using DChip microarray 
analysis software, the five gene sets were converged to determine the 
differentially regulated genes common to the 5 datasets. Heat maps for this set 
were created using GeneMesh to graphically represent expression patterns.  
 
4.2.6 Microarray Validation of Gene Expression with Quantitative RT-PCR 
 Quantitative real-time polymerase chain reaction (qRT-PCR) was used to 
confirm expression changes observed in the microarray analysis. First-strand 
cDNA was prepared from total RNA (1 µg) using the iScript cDNA synthesis kit 
(Bio-Rad, Hercules, CA) according to the manufacturer's specifications. cDNA 
preparations were diluted 1:10, and 3 µL was used in 10-µl reactions. 
Table 4.1. Microarray datasets in which elastogenesis is a key component used in 
the convergent analysis. 
 
1, Affymetrix MG_U74Bv2 chips 
2, Affymetrix RAE230A chips 
3, Applied Microarrays Codelink 20K Mouse Bioarrays 
4, Affymetrix MG430v2.0 chips 
E, embryonic day; P, postnatal; MUSC, Medical University of South Carolina; FDR, false 
discovery rate; StDev, standard deviation; NCBI GEO, National Center for Biotechnology 
Information Gene Expression Omnibus; ANOVA, analysis of variance 
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 The elastin gene was targeted with the TaqMan Gene Expression Assays 
(Applied Biosystems/Life Technologies, Grand Island, NY) containing primers for 
mouse/rat tropoelastin and a probe spanning the tropoelastin exon boundary 36-
37. Other primers designed by Primer3 and NCBI Blast for genes identified by 
DNA microarray expression profiling to be regulated by microarray analysis were 
used in 10 µL reactions with the iQ SYBR green Supermix reagent (Bio-Rad, 
Hercules, CA). 
 Reactions were amplified in an iCycler real-time PCR detection system 
(Bio-Rad, Hercules, CA). The resulting data were analyzed with the PCR Miner 
software, which calculates individual threshold cycle values and gene efficiency 
for a set of primers. All gene expression levels were normalized to a 
housekeeping gene that is constitutively expressed at a relatively constant level 
across many or all known conditions. (e.g., βactin, GAPDH, and TATA-box 
binding protein) expression levels. 
 
4.2.7 DNA-Chip Analyzer (dChip) 
 DNA-Chip Analyzer (dChip) (www.dchip.org) is a Windows software 
package for probe-level (e.g. Affymetrix platform) and high-level analysis of gene 
expression microarrays and SNP microarrays (211, 212). Gene expression or 
SNP data from various microarray platforms can also be analyzed by importing 
as an external dataset. dChip displays normalized probes from CEL files and can 
pool information across multiple arrays and automatic probe selection to handle 
cross-hybridization and image. Many high-level analyses are available in dChip, 
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but for our studies we utilized sample comparison, hierarchical clustering, SNP 
data visualization along the chromosome, and linkage analysis. In these 
functions the gene and sample information are correlated with the analysis 
results. 
 
4.2.8 GeneMeSH 
Another microarray analysis tool integrates categories available in the 
Medical Subject Headings (MeSH) hierarchical index with a given query set of 
genes. Additional tools are embedded as links to Entrez Gene information, Gene 
Ontology information, KEGG metabolic pathway diagrams, and intermolecular 
interaction information. An important visualization tool generates heat maps of Z- 
score normalized expression intensity values organized into MeSH clusters 
Figure 4.2. Transcriptomic profiling of differentially regulated genes in normal 
development reveals 502 unique genes. This group of genes known to regulate 
elastogenesis (i.e., elastin). There are likely genes not yet identified as regulating 
elastogenesis as well as genes incidental to elastic fiber assembly and common to 
development. A represents a schematic of convergent analysis to identify 502 genes common 
to the “developmental set” and B graphically depicts the heatmap of differential gene 
expression. There are many similar expression patters in the set. 
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(213). GeneMesh makes use of the heatmap.2 function in the R gplots package 
and probe pair annotations available through Bioconductor (214). GeneMeSH 
operates on gene expression data derived from microarray platforms Affymetrix, 
Agilent, and Illumina 
 
4.3 Results  
4.3.1 Transcriptomic Profiling of Developing Elastic Tissues 
 Convergent analysis of the developing mouse lung and developing mouse 
aorta revealed a common “developmental set” of 502 unique genes significantly 
regulated (Figure 1). Many of the genes have previously been associated with 
elastogenesis, while many may represent regulatory genes yet to be implicated 
in elastogenesis. It is unlikely that all 502 are involved in elastogenesis and may 
be an artifact of genes commonly regulated in development. 
 
4.3.2 Transcriptomic Profiling of V3-transduced VSMCs Analysis of DNA 
microarray expression profiling data revealed that V3 significantly regulated 
expression of 783 genes (1090 probes) (Figure 1). 
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V3 up-regulated the expression of 
elastin (Eln) (3.3 fold) as well as a 
number of genes previously shown to 
be critical for elastogenesis including 
fibulin-5 (Fbln5) (7 fold), fibulin-2 
(Fbln2) (2 fold), and neuraminidase 
(Neu1) (8.7 fold). Several other genes 
known to promote elastogenesis were 
down-regulated in V3 transduced 
ASMCs including transforming growth 
factor beta 1 (Tgfb1) (-1.5 fold) and 
microfibrillar associated protein 5 
(Mfap5/Magp-2) (-2.4 fold). No 
change was detected in the 
expression of transcripts encoding a number elastin-related genes including lysyl 
oxidase (Lox), Lox-like protein (Loxl), Loxl2, fibulin-3, fibulin-4, fibrillin-1, fibrillin-
2, Magp1, Mfap1, Ltpb4, emilin-1 and Igf-1. Together, these data demonstrate 
that versican V3 induces significant changes in mRNA expression of genes 
associated with elastogenesis. 
 
 
 
 
Figure 4.3. Heatmap displaying 
significantly regulated genes in 
response to Versican V3 expression in 
vascular smooth muscle cells (VSMCs). 
1090 differentially expressed probes (783 
individual genes) in aortic smooth muscle 
cells transduced to express versican V3 
variant or with empty viral vector (Control). 
Fold change ≥1.5, p-value<0.05. 
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4.3.3 Determination of the Elastogenic Gene Set 
 The process used to analyze the data from each microarray study and to 
combine the data from the five studies is summarized in Figure 4.5. Individual 
gene probes were determined to be significantly regulated within individual DNA 
microarray datasets as described previously in Table 4.1. Each of the five lists of 
gene probe ids were converted first to gene symbols and then converted into lists 
of all possible Mouse Genome 430 2.0 Probe Set IDs for those genes using the 
Affymetrix NetAffx conversion tool.  Using DChip microarray analysis software, 
the intersections of the five gene sets were found as depicted in the Venn 
Diagram (Figure 4.5). Heat maps were created using DChip to examine their 
expression patterns over time. 
 
4.3.4 Subsets of 
Elastogenic Gene 
Set  
 The 
convergent set of 
commonly 
regulated genes in 
the elastogenic 
gene set showed 
some similarities in 
the hierarchical 
 
Figure 4.5. Convergent Venn diagram of differentially 
expressed gene sets in five processes containing 
elastogenesis to yield a 63-gene elastogenic gene set. The Venn 
diagram illustrates the intersection of five individual microarray 
analyses in which elastogenesis is a key component to yield 63 
unique candidate elastogenic genes. The 63  genes within the 
“elastogenic gene set” are differentially regulated in all five 
processes as determined by statistical analysis specific to each 
process. 
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clustering, however consistent expression patterns were not maintained 
throughout the injury models and the in vitro model. Because elastogenesis is 
prominent in fetal and postnatal development, developmental elastin fibers are 
the gold standard by which tissue engineered elastin fibers are compared. The 
expression patterns of the 63 elastogenic gene set in developing elastic tissues 
was used as the basis for subsequent categorization of the 63 candidate 
elastogenic genes into subsets for further analysis. 
 
4.3.4.1 Heatmap of Developing Elastic Tissues 
 The expression patterns of the 63 elastogenic gene set in developing 
elastic tissues was used to create a subset of potential enhancers and potential 
inhibitors of elastogenesis. The heatmap was generated using dChip that 
 
Figure 4.6. Expression patterns of the 63 candidate elastogenic genes. Convergent 
analysis revealed 63 genes commonly regulated genes in five processes in which 
elastogenesis is a key component. 
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organized genes into a specific order by a hierarchical clustering algorithm (215) 
by using an average linkage method (216). The resultant heatmap depicted a 
clear distinction of two groups of similarly regulated genes as indicated at the 
horizontal green line (Figure 4.7). 
The elastin gene was found in the top group along with other genes 
expressed at high levels in adult tissue. In the early lung and aortic development 
elastin is expressed at undetectable to low levels. As development progresses, 
elastin expression increases to a peak during the height of elastic fiber formation 
(10-14 days), and then returns to baseline levels in the adult tissue. Genes that 
followed a similar pattern of low to undetectable expression in both the early 
embryo and late adult with a peak of increased expression around day 10-14 
were considered to behave in a similar expression pattern as elastin. Other 
genes known to 
enhance elastogenesis 
(Neu1, Fbln5) also 
follow this pattern. The 
group of 29 genes of the 
63 “elastogenic gene 
set” were categorized 
into a subset of 
“potential enhancers” of 
elastogenesis. The 
bottom group of 34 
Figure 4.7. Heat map of potential enhancers and inhibitors 
of elastogenesis in the “elastogenic gene set.” The 
graphical representation of the expression intensity values of 
the “elastogenic gene set” in the developing processes shows 
two distinct groups of similarly regulated genes 
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genes follows 
an expression 
pattern 
different from 
elastin with 
lower 
expression 
levels during 
development 
and higher expression levels during adult. These genes were categorized into a 
subset of “potential inhibitors” of elastogenesis. 
 
4.3.4.2 Subsets of Elastogenic Gene Set from Computational Analysis 
 The criteria employed on intensity values from microarray datasets in 
which  elastogenesis is a key component to determine whether the gene probe of 
interest behaves in a similar or different manner as elastin is presented in Table 
4.2. The raw intensity values from each gene probe of the 63 candidate elastin 
regulatory genes was subjected to the criteria above. If a gene probe does not 
meet the criteria for behaving similar to elastin then it is determined to behave 
different from elastin.  In order for a gene probe to be categorized as having an 
expression pattern similar to elastin during the process of Development, it must 
meet the criteria for a similar expression pattern as elastin for both Lung 
Development and Aortic Development. Conversely, a gene probe must not meet 
Table 4.2. Criteria to Determine Subsets of the Elastogenic Gene Set 
 
 Average Intensity Values 
Equation 
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Elastin 
Different from 
Elastin 
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Develop- 
ment: 
Lung 
Development 
Day 10 & 14 > 
Adult 
Day 10 & 14 < 
Adult 
Aorta 
Development 
Day 7-14 > Day 
30-6 mo 
Day 7-14 < Day 
30-6 mo 
Injury: 
Lung Injury 
Day 2-3 > 
Unwounded 
Day 2-3 < 
Unwounded 
Skin Injury 
Day 5-10 > 
Unwounded 
Day 5-10 < 
Unwounded 
V3-Transduced 
VSMCs 
V3-transduced 
> Control vector 
transduced 
V3-transduced 
< Control vector 
transduced 
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the criteria in both Lung Injury and Skin Injury to be categorized as having a 
different expression pattern as elastin during the Injury Process. These criteria 
provided the basis for hierarchal classification of genes as depicted in Appendix 
A.  
The hierarchical analysis of the 63 genes identified in the convergent 
microarray analysis classified genes into groups based upon how similar or 
different its expression pattern was to the elastin gene’s expression pattern in all 
five processes in which elastogenesis is a key component (Appendix A). The list 
of 63 genes was further subdivided based on expression patterns during 
development, the period at which native elastic fiber formation occurs. Table 4.3 
Table 4.3. Similar/Different Subset of Candidate Elastogenic Genes 
A B 
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identifies the genes that behave 
similar to elastin expression in 
the process of Development 
(both Lung Development and 
Aorta Development) as 
determined by the equations in 
Table 4.2.  The genes that 
behave different from elastin 
expression during Development 
are listed in Table 4.2B. 
Subsequent promoter analysis 
was performed based upon 
these subsets.  
 
4.3.5 Validation of Genes Identified in Microarray Analysis  
 Validation of elastin expression 
in microarray analysis was performed 
with cDNA from developing mouse 
lung. Figure 4.8 illustrates the 
expression profile depicting a peak 
elastin expression at day 14 and no 
measurable expression in the adult 
lung.  
 
Figure 4.9. qRT-PCR validation of genes 
significantly regulated in V3-transduced 
VSMCs. Bars represent the ratio of  gene 
expression in Versican V3-transduced 
vascular smooth muscle cells (VSMCs) 
compared to empty vector-transduced 
VSMCs (control). 
A 
 
B 
 
Figure 4.8. Validation of microarray elastin 
expression in developing mouse lung.  
A, The DNA microarray expression profile of relative 
elastin in mouse lung development correlates with 
qRT-PCR validation of developing mouse lung 
cDNA in B. The expression profile demonstrates a 
rise in elastin expression up to its peak around day 
14 and no measurable expression in the adult lung.  
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 Additional qRT-PCR was performed on cDNA from V3-transduced VSMCs 
and empty vector-transduced VSMCs using primers generated by Primer3 for 
genes identified as significantly regulated in the microarray dataset of V3-
transduced VSMCs. The fold change of V3-transduce VSMCs vs. empty vector-
transduced VSMCs calculated from qRT-PCR validation can be can be seen in 
Figure 4.9. Table 4.4 
compares of the fold 
change of expression 
from qRT-PCR to the 
fold change 
calculated from DNA 
microarray 
expression 
intensities. 
 
 
 
Table 4.5. 63 genes can be placed into statistically 
significant functional categories. Highlighted genes are known 
to e involved with elastic fiber formation. 
Table 4.4. qRT-PCR Validation of Genes Expressed in V3-Induced VSMCs 
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4.3.6 Functional Analysis of Convergent Genes using Gene Ontology.  
 Convergent analysis produced 63 genes that represent “candidate 
elastogenic genes.” Among these 63 were genes well established to effect 
elastogenesis, including tropoelastin, Lox, Mfap2 and Mfap5. Ontological 
analysis of the 63 genes revealed that the functional categories with highest 
significance were the “extracellular matrix” category (p=1.20E-05) and the 
“secreted protein” category (p=6.60E-05) (Table 4.5A). In addition to the elastin-
related genes mentioned above, the ECM gene set included genes encoding 
Timp2, Timp3, laminin β2, ColVα1, ColVα2 and ColXIVα1 (Table 4.5B). The 
mechanism of elastic fiber formation may involve multiple signaling pathways that 
may not be normally activated due to the particular injury. It is also possible that 
not all genes involved in elastogenesis may be regulated on a transcriptional 
level. 
 
4.4 Discussion 
 Microarray analysis was performed on five different processes in which 
elastogenesis was a key component. Two processes occur in elastin-rich tissues 
during the period of development, the gold standard of elastic fiber quality that 
tissue engineering applications strive to replicate. In order to distinguish 
commonly regulated genes involved in elastogenesis from genes specific to 
tissue development the DNA microarray analysis was expanded to include 
models of adult elastogenesis in response to an injury of an elastin-rich tissue. 
And finally, an in vitro model of a specific cell type was incorporated to 
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distinguish genes regulating elastogenesis from genes that are regulated in 
coordination of complex biological processes in an animal model. Five microarray 
sets were selected in which active elastin transcription had occurred over a 
length of time: 1) Developing lung, 2) Developing aorta, 3) Lung wound healing, 
4) Skin wound healing, and 5) Versican V3-transduced vascular smooth muscle 
cells (VSMCs). Each dataset was analyzed for significantly regulated genes and 
through the used of dChip, convergent analysis of the five microarray datasets in 
which elastogenesis is a key component yielded a common set of 63 candidate 
elastogenic genes. 
 The list of 63 genes was further classified using gene ontology to be 
significantly enriched in extracellular matrix (ECM) genes. Elastic fiber assembly 
occurs at the cell surface within the ECM and mature elastic fibers reside within 
the ECM to play a role in mechanical motion and cellular signaling so it would 
follow that potential gene regulators in the 63-gene candidate gene set would be 
enriched in the ECM ontology. Coordinately the gene ontological function of 
secretion would match potential gene regulators of elastic fiber assembly and 
ECM signaling. 
 Further investigation into significant ontological processes indicates 
enrichment for oxidoreductase. This group comprises a set of enzymes that 
catalyze oxidation-reduction reactions that may prove to be a hindrance to 
elastogenesis. It is possible that oxidative and nitrosative modification of 
tropoelastin within the in vitro model are preventing elastic fiber assembly (28). In 
a study by Akhtar et al. oxidation reduced crosslinking and interactions with other 
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proteins required for elastic fiber assembly, including fibulin-4, fibulin-5, and 
fibrillin-2. Measurement of exogenously added oxidized tropoelastin showed less 
incorporation into the preexisting microfibrils of human retinal pigmented 
epithelial ARPE-19 cells compared to unoxidized tropoelastin as detected by 
immunofluorescence microscopy (28). Nitration of TE was confirmed using the 
rabbit anti-N-Tyr antibody, followed by a FITC-conjugated anti-rabbit secondary 
antibody (28). If the in vitro culture model for the elastin ELISA is undergoing any 
oxidative stress, it would follow that elastic fiber assembly may be impaired. 
 
4.5 Conclusion 
 DNA microarray technology allowed for the use of high-throughput 
quantification of the concurrent expression of thousands of genes. Analysis of 
DNA microarray processes in which elastogenesis is a key component combined 
five processes to determine commonly regulated genes for elastic fiber formation 
and to distinguish those genes from coordinately regulated gene networks 
specific to a biological process or tissue. All five processes occurred in elastin 
rich tissues or cells and displayed an upregulation of the elastin gene. A 
convergent list of 63 differentially expressed genes was gleamed from the five 
processes: 1) Developing lung, 2) Developing aorta, 3) Lung wound healing, 4) 
Skin wound healing, and 5) Versican V3-transduced vascular smooth muscle 
cells (VSMCs). 
 Gene ontological analysis highlighted functional categories of extracellular 
matrix (ECM) and secretion, which follow the elastin gene beginning with 
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secretion of a tropoelastin monomer and subsequent assimilation into mature 
elastic fibers comprising the ECM. The enrichment for the ontological group of 
oxidoreductase enzymes may prove to be a hindrance to elastogenesis as 
oxidation of tropoelastin prevents proper elastic fiber assembly. This may pertain 
primarily to the elastogenic processes of wound healing that are undergoing 
oxidative stress and ultimate assembly of inferior elastic fibers compared to 
developmental elastic fibers. 
 The process of combining similar DNA microarray processes containing a 
shared element of elastic fiber assembly provides insight into novel gene 
regulatory networks involved in elastogenesis. Comparison within sets may also 
elucidate differences in elastic fiber quality among different processes. The 
information gained offers an unprecedented opportunity to fully characterize 
elastogenesis.  
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CHAPTER FIVE 
TRANSCRIPTIONAL REGULATORY NETWORK ANALYSIS TO DETERMINE 
CANDIDATE GENE REGULATORY NETWORKS 
 
5.1 Introduction 
 DNA microarray technology allows the simultaneous measurement of the 
expression of many thousands of genes. The challenge to analyzing vast 
datasets to characterize biological processes relies on tools for the efficient 
integration and interpretation of large datasets. Analysis of gene regulation can 
be expanded to include computational tools to combine other databases with 
known information on gene regulation. 
 One such computational tool, pathway analysis, involves looking for 
consistent but subtle changes in gene expression by incorporating either 
pathway or functional annotations. Pathway analysis is a promising tool to 
identify the mechanisms that underlie diseases, adaptive physiological 
compensatory responses and new avenues for investigation (217). 
 Other computational tools integrate functional genomics data, for example, 
from microarray-based gene-expression analysis with genomic sequence data to 
carry out transcriptional regulatory network analysis (TRNA) (218). TRNA 
combines bioinformatics to identify and analyze regulatory regions of genes with 
statistical significance testing to determine the likelihood of the binding of 
transcription factors (TF). We further refined our set of candidate elastogenic 
genes with TRNA to identify potential regulatory pathways for elastogenesis. 
 90 
 
5.1.1 Gene Regulation 
An organism is comprised of many different tissues that perform a wide 
range of functions yet the entire genome encoding these functions is found in 
every cell within the organism. This phenomenon is due to a process known as 
gene regulation, whereby only a fraction of genes in the genome are expressed 
in a given cell. Gene regulation occurs throughout the entirety of gene expression 
from chromatin organization, transcription, pre-mRNA processing, translation, 
and post-translational modifications but chiefly at the transcriptional level (219). 
Transcription involves the conversion of the genetic code comprised of 
deoxyribonucleic acid (DNA) into messenger RNA (mRNA), which can then serve 
as a template for protein synthesis. The biological mechanism of transcription is 
regulated by an extensive network of proteins known as transcription factors 
(TFs) that bind to a complementary DNA sequence binding sites or 
transcriptional regulatory elements (TREs). The TREs are primarily located in the 
cis-regulatory region (promoter) of a gene approximately 100-1000 base pairs 
upstream (towards the 3’ region of the anti-sense strand, or non-coding strand) 
(220), however some TREs have been found from 200bp downstream of the 
origin of replication (ORI), up to tens of thousands of bp upstream (219). When a 
TF binds to a corresponding TRE the level of transcription of the downstream 
gene can be initiated, stopped, up or down-regulated. Figure 5.2 shows the 
interaction of TFs/TREs with the promoter of a gene to regulate transcription.  
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5.1.2 Gene Regulatory 
Network 
A multitude of 
genes interact in a 
systematic and 
interconnected network to 
regulate complex cellular 
processes such as development, differentiation, proliferation, cell cycle, and 
extracellular matrix organization.  Transcription factors (TFs) serve as an 
important component of this network, responding to changes in the cellular 
environment by altering the gene expression of relevant genes (221). TFs 
specifically bind to a corresponding sequence of a TRE however TREs are not 
specific to a single gene. Multiple genes have the same TREs present resulting 
in an interconnected transcriptional regulatory network where TFs bind and 
regulate many different genes. 
Understanding the complexity of these gene regulatory networks relies on 
the compilation of technological developments such as gene expression changes 
from microarrays, protein–DNA interaction and transcription factor activity data 
from protein binding assays, chromatin immunoprecipitation (ChIP) experiments 
(222), and DNA footprinting (223, 224), protein–protein interactions from two 
hybrid experiments and coimmunoprecipitation, and genomic sequence and 
ontology information in public databases (www.geneontology.org) (220). By 
 
 
Figure 5.1. Gene Regulation. Transcription factors (TFs) 
bind to corresponding transcriptional regulatory elements 
(TREs) .The TFs/TREs interact with the promoter region 
upstream to the start of transcription to initiate, stop, up or 
down-regulate the level of transcription of the downstream 
gene. 
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analyzing data from multiple sources of regulatory assays, we may achieve a 
better understanding of the dynamic systems of the gene regulatory network. 
 
5.2 Materials and Methods 
5.2.1 Promoter Analysis Technology 
The binding of TFs to TREs is the crux of the biological mechanism of 
transcriptional regulation. Because these reactions are sequence specific, 
bioinformatics tools are able to access available databases containing annotated 
sequences for gene sequences and cross-compare databases of annotated 
TREs. By scanning the genome for sequence recognition, new technology is able 
to identify the presence of a TRE in the promoter region of a gene thus predicting 
the possibility of TF-TRE binding. 
Many studies have taken this direct approach to promoter analysis to 
identify a good candidate set of network interactions (225-227). Promoter 
analysis has been utilized most successfully in yeast to develop sets of 
coregulated genes (67) and detailed gene regulatory networks for the galactose-
utilization pathway (68). Promoter analysis can also be used to identify genomic 
regions containing unusually high concentrations of predicted TREs. One study 
in the developing Drosophila embryos identified enriched genomic regions for 
five active TFs of interest (228). Gene regulatory networks are also at play during 
development in to regulate cell fate in the embryo of sea urchins to control the 
specification of endoderm and mesoderm (229). The first study to employ 
promoter analysis to identify regulatory gene networks in higher order species 
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focused on transcriptional mechanisms that control cell cycle progression in 
humans (230). By analyzing the promoters in a set of genes whose expression is 
cell-cycle-dependent, Bury identified a set of 8 transcriptional factors whose 
binding sites were overrepresented. 
Promoter analysis is able to identify transcription factor (TF) binding 
regions within the genetic code and thus predict binding of TFs that regulate 
gene expression. Through analysis of the promoter regions of the candidate 
elastogenic gene set, we analyzed the TF-binding site occurrences for 
over/under representation within our 63 candidate elastogenic genes. 
Transcriptional regulatory network analysis (TRNA) combines pathway analysis 
and statistical significance testing to identify potential transcription factor 
regulators of elastogenesis. 
 
5.2.2 PAINT: Promoter Analysis and Interaction Network Generation Tool 
The Daniel Baugh Institute for Functional Genomics/Computational 
Biology at Thomas Jefferson University developed a bioinformatics tool PAINT: 
Promoter Analysis and Interaction Network Generation Tool to automate the 
analysis of a given set of genes to produce an interaction matrix that represents 
a candidate set of interactions between the transcription factors and the genes. 
PAINT is able to identify potential regulatory networks given an input set of 
genes of interest. PAINT processes a list of unique identifiers representing the 
genes of interest by referencing the database UpstreamDB to identify 5000 bp 
upstream and 100 bp downstream of a gene. This process is not organism-
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specific as the key requirements are the availability of an annotated genome 
sequence. UpstreamDB was constructed for all the known and putative 
annotated genes in the Ensembl genome database for Mus musculus. This 
promoter sequence database is periodically updated by PromoterID/DBSync, 
which also serves to identify the transcription start site. The TFRetriever module 
makes use various transcription factor inspection/discover programs that can 
retrieve and process the sequences for TREs of known TFs.  The unique gene 
sequences are processed by the FeasNet Builder component that produces a 
Candidate Interaction Matrix (CIM) for the genes of interest. Statistics are also 
generated within this module to compare the over-representation of the TREs in 
the set of given promoters with respect to a background set of promoters. The p-
values are calculated using hypergeometric distribution (230-232) to give the 
probability that the observed counts for the TREs in the set of promoters could be 
explained by random occurrence in the reference set of promoters. The final 
PAINT component FeasNetBuilder constructs an interaction matrix representing 
a candidate set of connections in the regulatory network with the input genes of 
interest organized into rows and the columns corresponding to the TREs. The 
regulation of a gene is represented by the color of the box at the intersection of a 
row and column: red if a TRE was identified as over-represented in that gene’s 
promoter, blue for under-representation, and black otherwise. The lower p-value 
(0 < p < 0.01) indicating a higher degree of significance for a particular TRE in a 
CIM are indicated in a brighter/lighter shade of red for over-representation or 
cyan for under-representation (220). The organization of the PAINT modules 
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from the input gene list to the visualization of a candidate regulatory network can 
be seen in Figure 5.1. In summary, the bioinformatics tool PAINT is able to 
process a given set of genes to generate a pruned list of transcription factors that 
are ranked on the likelihood 
of the involvement. The 
resultant data can be 
examined in detail in further 
experimental studies on 
gene regulation (220). 
In order to identify 
potential transcriptional 
regulators of elastogenesis 
in the 63 gene “elastogenic 
gene set” the bioinformatics 
tool PAINT (218, 220) was 
used to analyze the promoter sequences. Optimal parameters and input gene 
sets were determined with the assistance of Dr. Jeremy Barth in the COBRE 
Proteogenomics Facility at the Medical University of South Carolina. Because 
developmental elastogenesis is considered the gold standard for elastic fiber 
quality, PAINT analysis was performed on the “elastogenic gene set” subsets of 
“potential enhancers” and “potential inhibitors” derived from the microarray 
datasets from developing lung and developing aorta described in 4.3.1. 
Transcriptional regulatory elements (TREs) were identified as being significantly 
Figure 5.1. Flow of Data through the Bioinformatics 
Tool PAINT. The input and intermediate outputs are 
organized on the left. The five core components of 
PAINT are boxed in: UpstreamDB, PromoterID/DBsync, 
TFRetriever, FeasNetBuilder, FeasNet Viewer. Dash-
outlined boxes represent external databases and 
programs utilized by PAINT. 
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overrepresented in the promoters of the enhancer or inhibitor subset with respect 
to a background set of promoters (p<0.05). Dr. Barth was able to access the 
TRANSFAC Pro licensed database to find TREs and he suggested analyzing a 
promoter region limited to 2000 bp upstream of the transcription start site and a 
False Discovery Rate (FDR) < 0.10. 
 
5.2.3. UCSC Genome Browser 
 Transcription factor analysis using PAINT indicates the presence of a 
transcription factor (TF) binding sites (TREs) within the given parameter of base 
pairs designated during the search described previously. Resultant displays 
indicate the presence of a TRE but not the specific location. The University of 
California at Santa Cruz (UCSC) Genome Browser provides a way to examine 
genomic data and map specific TF binding sites. UCSC Genome browser can 
also include extensive annotation tracks for various data types including known 
chromatin immunoprecipitation (ChIP) datasets. The ENCODE function links to 
downloadable tracks and files corresponding to searchable terms. We 
downloaded BroadPeak ENCODE files for transcription factors regulated in 
PAINT analysis.  
 
5.2.4 MicroRNA Analysis of Elastogenic Gene Set 
MicroRNAs (miRNAs) are short, single-stranded RNAs that bind to 
messenger RNA (mRNA) to regulate gene expression, usually by blocking 
translation. A wide range of biological processes involve miRNA-mediated 
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regulation as a key component such as developmental timing, metabolism, 
apoptosis, cardiac and skeletal muscle proliferation (233) and neuronal gene 
expression (234). Changes in expression, copy number or mutations of miRNA 
can lead to diseases in humans including cancer. MicroRNA expression is 
prevalent in almost all cell types and conserved among most species suggesting 
miRNAs are vital to biological processes. 
Recent studies show that expression of the microRNA, miR-29, is reduced 
by TGFβ1 (129) and that the 3′UTR of elastin mRNA is a target of miR-29 (130, 
131). Furthermore, miR-29 mimics decrease elastin mRNA levels in dermal 
fibroblasts and vascular smooth muscle cells (132). Moreover, in the developing 
mouse aorta, an up regulation in the expression of miR-29 as well as several 
other microRNAs that have targets in the elastin mRNA (i.e., the miR-15 family 
members miR-195 and miR-497) accompanies the down regulation of elastin 
mRNA in the period between the newborn and adult (130, 131). 
Numerous resources exist predicting miRNA binding based on sequence 
complementarity. One such tool is microRNA.org, a resource for microRNA 
target predictions and microRNA expression that uses the miRanda algorithm 
that computes optimal sequence complementarity between a set of mature 
microRNAs and a given mRNA using a weighted dynamic programming 
algorithm (235). The microRNA expression profiles were taken from a recent 
profiling study across ∼250 small RNA libraries collected from human, mouse 
and rat tissues and cell lines (236). 
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Target mRNA searches were performed on each of the 63 genes in the 
candidate elastogenic gene set. All isoforms of miRNAs were collected for the 
mouse genome and organized based on number of occurrences. Additionally, 
genes were sorted based upon number of miRNA. 
 
5.3 Results 
5.3.1 Defining Candidate Regulatory Interactions  
Transcriptional regulatory network analysis revealed potential transcription 
factor (TF) regulators of the subsets of the candidate elastogenic genes as 
Figure 5.2. Transcription factor binding regions are predicted potential enhancers and 
potential inhibitors of elastogenesis. The remaining transcription factors have not been 
associated with regulating elastin or elastogenesis to date. We’re interested to determine 
whether they represent novel regulatory factors in the process of elastogenesis. Several of 
these have pharmacological antagonists and agonists that can be tested to see if they exert 
effects on elastogenesis. 
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determined by dChip heatmap categorization. Among the genes whose 
expression pattern is similar to elastin, eleven TREs were significantly enriched. 
Importantly, four of the eleven transcription factors (TFs) binding to the TREs, B-
Myb Sp1, cKrox and PPAR, have been previously implicated in elastogenesis 
(146, 237-239). For example, studies have shown that B-Myb represses 
expression of elastin in VSMCs (237) and lysyl oxidase (Lox) expression in 
fibroblasts (240). cKrox also repress elastin expression in fibroblasts (36), while 
Sp1 stimulates elastin expression in fibroblasts (147). PPAR has dual effects on 
elastin transcription: both increasing (241) and repressing elastin expression in 
fibroblasts (238, 242). To 
date, these regulators have 
not been targeted in tissue 
engineering approaches.  
 
5.3.2 TREs identified within 
the Elastin Promoter 
 PAINT analysis 
determined five DNA 
sequences corresponding to 
TREs to be significantly 
overrepresented within the 
elastin promoter region 
analyzed (Figure 5.3). Two 
 
Figure 5.3. PAINT analysis determined five DNA 
sequences corresponding to TREs to be significantly 
overrepresented within the elastin promoter region 
analyzed. Two of the five TREs are known to regulate 
elastin: PPAR and Sp1. The other three TREs have not 
be associated with elastin to date: WT1, ZF5, and Ckrox. 
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of the five TREs are known to regulate elastin: PPAR and Sp1 while the 
remaining three TREs have not be associated with elastin to date: WT1, ZF5, 
and Ckrox. Given that 2 of the 5 TREs identified on the elastin promoter through 
the PAINT analysis have already been demonstrated to regulate elastin 
transcription, the use of promoter analysis technology is validated to predict 
candidate regulatory interactions. It would follow that the WT1, ZF5, and Ckrox in 
the elastin promoter are worth investigating, along with other TREs regulating the 
genes which are regulated similar to elastin during development. 
 
5.3.3 UCSC Genome Browser Mapping of Transcription Factor Binding Sites 
 Previous chromatin immunoprecipitation (ChIP) studies using PPARα chip 
were uploaded to the USCS Genome Browser in the form of broadPeak tracks. 
Using the UCSC Genome Browser and the ENCODE search function to align 
 
Figure 5.4. Transcription factor binding sites for p300, a PPAR coactivator, are located 
close to the transcription start site of the human elastin gene. The UCSC Genome 
Browser allowed visualization of transcription factor binding sites along the elastin gene as 
compiled from multiple chromatin immunoprecipitation (ChIP) studies. 
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tracks from PPAR ChIP studies, we located a PPARα transcription factor binding 
site closest to the start site of elastin transcription approximately 50 kilobasepairs 
(kbp) upstream. Expansion of the elastin gene in the UCSC Genome Browser 
also demonstrates multiple binding sites for the PPAR coactivator p300 (243) 
(Figure 5.4). 
 Previous chromatin immunoprecipitation (ChIP) studies indicate 
transcription factor binding sites close to the transcription start site of the elastin 
gene as seen in Figure 5.5. Two binding sites interchangeable for transcription 
factors WT1 and EGR-1 are located upstream of the transcription start site within 
the elastin promoter 
(< 5 kbp) and 
downstream of the 
transcription start 
site (< 2.5 kbp). 
 
 
5.3 4 MicroRNAs Common to Elastogenic Gene Set 
 MicroRNA analysis of candidate elastogenic gene set identified 177 
different miRNAs known to regulate the 63 genes commonly regulated in all five 
elastogenic processes, of which 112 miRNAs have at least 5 binding sites within 
the set, and 31 miRNAs bind at least 10 sites. Table 5.2 is organized horizontally 
by miRNAs in decreasing number of total miRNA binding sites and organized 
vertically in ascending order from genes with the most number of miRNA binding 
 
Figure 5.5. Previous chromatin immunoprecipitation (ChIP) 
studies indicate 2 EGR-1/WT1 Binding Sites within 5kb from 
the human elastin gene transcription start site. 
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sites down to the least regulated genes. The most represented miRNA is miR-
200 with 31 binding sites in 16 different genes, followed by miR-181 with 28 
binding sites in 7 different genes, and miR-29 with 27 binding sites in 9 different 
genes. The gene regulated by the most binding sites for miRNA is Hnrnpa2b1 
with 53 miRNA binding sites for 43 different miRNAs, followed by Marcks with 43 
miRNA binding sites for 34 different RNAs, and lysyl oxidase (Lox) with 42 
miRNA binding sites for 32 different miRNAs. The largely regulated Lox, an 
important crosslinker of elastin fibers and significant presence of miR-29, a 
known regulator of elastogenesis, within the 63-gene elastogenic gene set 
indicate miRNAs play a likely role in the regulation of elastogenesis. 
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Only four genes of the 63 were not known to be regulated by any miRNAs 
including AE binding protein 1 (Aebp1), apolipoprotein E (Apoe), and cell division 
cycle 20 homolog (Cdc20), and FXYD domain-containing ion transport regulator 
1 (Fxyd1).  
  
Table 5.2. MicroRNAs Common to Elastogenic Gene Set 
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5.4 Discussion 
Transcriptional regulatory network analysis tool PAINT utilized databases 
containing sequences of gene regulatory regions and transcription factors to 
detect transcription factors overrepresented in the 63 candidate elastogenic 
genes. Promoter analysis was performed on the two subsets of genes as 
determined by dChip heatmap categorization and a total of 28 transcription 
factors were identified as potential regulators of elastogenesis. In the subset of 
genes whose expression pattern is regulated similar to elastin and categorized 
as potential “enhancers” of elastogenesis, eleven transcription factors were 
overrepresented compared to a reference set of genes. Four of the eleven 
transcription factors have been previously implicated with elastogenesis (B-Myb 
Sp1, cKrox and PPAR while the remaining seven have yet to be associated with 
elastogenesis. The finding of transcription factors known to regulate elastin 
transcription validated this approach for finding transcriptional regulators of 
elastogenesis. This finding also increases the likelihood that the 63-gene 
“elastogenic gene set” group represents a true core of elastogenesis related 
genes. By extension, the 11 TFs identified by this analysis may represent an 
elastogenesis regulatory network. 
PAINT analysis of the genes whose expression pattern is different from 
elastin distinguished 17 transcription factors to be enriched, including, v-Myb, 
which binds TREs in 23 of the 35 gene subset. Of importance to this set is the 
transcription factor early growth response 1 (EGR-1) that binds to the same 
consensus sequence as another transcription factor Wilms’ tumor 1 (WT-1) that 
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was enriched in the alternate subset. Both transcription factors are members of 
the family and are considered oncogenes and tumor suppressors (244). 
Wilms tumor regulates the expression of multiple growth factors including 
colony-stimulating factor (245), platelet-derived growth factor (246), and known 
modulator of elastin transcription insulin-like growth factor I (247). A mutation 
resulting in the loss of WT1 expression leads to up-regulation of these growth 
factors and the formation of Wilms tumor, thus its original classification as a 
tumor suppressor (248). However, subsequent studies have revealed a potential 
role for WT1 as an oncogene due to its upregulation in a variety of human 
cancers such as astrocytic tumors (87, 249), breast cancer (250), leukemia 
(251), and sporadic Wilms tumor (252, 253), which accounts for ∼85% of all 
Wilms tumors. 
Both WT1 and EGR1 are members of the family of zinc finger proteins 
(254) with similar structures and consensus sequences resulting in competition 
for transcription factor binding sites. WT1/EGR-1 binds 5'-GCG TGG GCG-3' 
(and similar ones like 5'-GCG GGG GCG-3') (255, 256). The effects of binding 
are most often mutually opposing whereby EGR1 activates the transcription of 
genes that WT1 represses (257, 258). Like WT1, EGR1 expression levels are 
atypical in multiple neoplastic cell types such as prostate cancer (259), 
glioblastoma (260), and Wilms tumor (253). Furthermore, EGR1 can also act as 
either an oncogene (259) or a tumor suppressor (248-253, 257-261) in different 
cell types. EGR-1 targets genes including immune effector genes, such as the 
cytokine IL‐2 (262, 263), the pro‐inflammatory immune mediator TNFα (264), a 
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known suppressor of elastin transcription (113) and promoter of elastin 
degradation (177). 
Similar structures and consensus sequences results in competition of 
binding for transcriptions factors WT1 and EGR-1. Binding often results in 
opposing regulation of the same gene (257, 258). The enrichment of both 
transcription factors in opposing subsets of the 63-gene elastogenic gene set 
validates the approach of transcriptional regulatory network analysis using PAINT 
to identify regulators of elastogenesis. It is likely that WT1 and EGR-1 coordinate 
the up-and down-regulation of elastogenesis. 
Analysis of WT1/EGR-1 consensus sequences using the UCSC Genome 
Browser and previous chromatin immunoprecipitation (ChIP) studies illustrated 
two binding sites close to the start site of elastin transcription. Additional ChIP 
studies indicate the binding sites for PPARα upstream of the elastin transcription 
start site as well as multiple PPAR coactivator p300 binding sites in closer 
proximity to the transcription start site. The findings from transcriptional 
regulatory network analysis indicating enriched transcription factor binding sites 
within the 63-gene elastogenic set and subsequent binding site mapping 
proximal to the elastin transcription start site using ChIP studies indicate PPAR 
and WT1/EGR-1 as potential regulatory transcription factors of elastogenesis.  
Other important regulators of transcription include microRNAs. Although 
elastin expression decreases shortly after the perinatal period and remains low in 
adult tissues (265), interestingly tropoelastin premRNA levels remain elevated in 
adult rat lungs despite considerably reduced steady-state mRNA levels. This 
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suggests posttranscriptional regulation of mRNA may be a predominant 
mechanism to regulate elastin mRNA (87). 
 Recent studies show that expression of the microRNA, miR-29, is reduced 
by TGFβ1 (129) and that the 3′UTR of elastin mRNA is a target of miR-29 (130, 
131). Furthermore, miR-29 mimics decrease elastin mRNA levels in dermal 
fibroblasts and vascular smooth muscle cells (132). Moreover, in the developing 
mouse aorta, an up regulation in the expression of miR-29 as well as several 
other microRNAs that have targets in the elastin mRNA (i.e., the miR-15 family 
members miR-195 and miR-497) accompanies the down regulation of elastin 
mRNA in the period between the newborn and adult (130, 131). 
 miR-29 was the third most occurring miRNA with binding sites in the 
elastin (Eln), lysyl oxidase (Lox), microfibrillar associated protein 5 (Mfap5) , and 
microfibrillar associated protein 2 (Mfap2) which are all known to be involved in 
elastogenesis. The predominate occurrence of miR-29 binding sites within the 
set of 63 candidate elastogenic genes supports the analysis of miRNA binding 
sites to predict regulation of elastogenesis. miR-29 also binds to collagen type V, 
alpha 2 (Col5a2), collagen type IV, alpha 5 (Col4a5), cysteine dioxygenase 1, 
cytosolic (Cdo1), ectonucleotide pyrophosphatase/phosphodiesterase 2 (Enpp2), 
and hexosaminidase A (Hexa) which have not previously been shown to regulate 
elastin but may warrant investigation. 
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5.5 Conclusion 
 The challenge to analyzing the copious amount of data within DNA 
microarrays is selecting the appropriate computational tools to integrate genomic 
and functional databases and interpret coordinately regulatory networks of 
genes. Promoter Analysis and Interaction Network Generation Tool, PAINT, 
utilizes a database of gene regulatory sequences located in the promoter region 
upstream of the transcription start site and cross-references with a database of 
know transcription factor binding sites or response elements (TREs) to predict 
the likelihood of transcription factor binding in a given set of genes. Enrichment of 
TREs in a given set of genes is compared to a random reference set of 
promoters to ensure statistically significant overrepresentation of TREs. Analysis 
of the subset of the 63-gene candidate elastogenic set in which expression 
patterns were similar to elastin characterized 11 overrepresented TREs of which 
four were previously known to regulate elastogenesis: B-Myb Sp1, cKrox and 
PPAR. A closer look at the TREs enriched within the elastin promoter revealed 
five overrepresented TREs, of which two were known form previous studies to 
regulate elastin: PPAR and Sp1. The finding of elastogenic transcription factors 
validates the use of PAINT to identify regulators of elastogenesis. Many new 
candidate elastin regulating transcription factors were identified for which 
pharmacological agents exist and can ultimately be tested for effects on 
elastogenesis. 
 Specific mapping of TREs using chromatin immunoprecipitation (ChIP) 
studies and the UCSC Genome Browser illustrated binding sites for PPAR, a 
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PPAR coactivator, and WT1/EGR-1 around the elastin transcription start site. 
The likelihood of TF/TRE binding in the elastin promoter indicates PPAR and 
WT1/EGR-1 as potential regulators of elastogenesis. 
 Additional gene regulation was assessed through target mRNA searches 
with microRNA.org. MicroRNA (miRNA) binding sites on the 63 genes in the 
candidate elastogenic gene set were particularly prevalent in Lox, an important 
crosslinker of elastin fibers. Additionally miR-29, a known regulator of 
elastogenesis, was significantly predominant within the 63-gene elastogenic 
gene set. It is likely that other miRNAs highlighted in the miRNA analysis play a 
likely role in the regulation of elastogenesis. 
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CHAPTER SIX 
MODULATORS OF TROPOELASTIN EXPRESSION IN AN IN VITRO 
CULTURE MODEL  
 
6.1 Introduction 
 Prior studies have shown that elastin matrix synthesis is regulated by 
numerous biochemical factors that may be promote elastin synthesis (Table 5.2) 
or inhibit or degrade elastin (Table 5.3) as summarized previously in Chapter 3. 
Convergent microarray analysis identified 63 genes as candidate regulators of 
elastogenesis which can be tested in vitro through pharmacological agonist or 
antagonists. Subsequent transcriptional regulatory analysis with PAINT identified 
potential regulatory transcription factors that if targeted with pharmacological 
agonists or antagonists may prove to regulate multiple elastogenesis regulating 
genes within the set of 63 candidate regulators. In the case that agonists or 
antagonists are unavailable, transfection of a plasmid expression vector 
containing the genetic sequence for a gene or transcription factor of interest can 
be used to upregulate expression. Conversely, transfection of small interfering 
RNA (siRNA) can be used to downregulate expression. 
 
6.2 Materials and methods 
6.2.1 Cell Culture 
 Human foreskin fibroblasts (HFF, ATCC no. SCRC-1041) were obtained 
as a generous gift from Dr. LaRue. HFFs were expanded in Dulbecco’s Modified 
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Eagles Medium (DMEM) High; with Sodium Pyruvate and without L-glutamine 
(Fisher Scientific) supplemented with 15% v/v FBS (Atlanta Biologicals), 1% v/v 
GlutaMAX (Life Technologies, Grand Island, NY), and 1% v/v 
penicillin/streptomycin (Fisher Scientific). Media was changed every 3 days and 
cells were passaged at 80-90% confluence with TrypLE Express (Life 
Technologies, Grand Island, NY). Low passage (6-8) HFFs were used for the 
following studies. 
 Neonatal rat aortic smooth muscle cells (nRASMCs) were isolated by a 
method based on that described by Oakes et. al.(266). Three litters of neonatal 
Sprague-Dawley rats (~21 rats aged 3 days postnatal) were sacrificed previously 
by CO2 asphyxiation and decapitation as per protocols approved by the Animal 
Research Committee at the Medical University of South Carolina and at Clemson 
University. Aortal segments were removed from euthanized rats, from arch to the 
celiac axis, under sterile conditions, and spliced lengthwise in petri dishes 
containing cold phosphate-buffered saline (PBS) containing 2 mM Ca2+. These 
spliced sections were then transferred to a dish containing 1-2 ml of collagenase 
(2 mg/ml; Worthington) and incubated for 10 minutes at 37 °C. Dulbecco’s 
Modified Eagles Medium (DMEM) supplemented with 15% FBS and 1% v/v 
penicillin/streptomycin (Fisher Scientific) that had been passed through a 0.22 
µm sterile filter was then added to these collagenase treated samples and mixed 
well with gentle pipetting. Isolated aortal segments were further chopped 
crosswise into 0.5 mm long pieces and transferred using fine needles onto sterile 
petri dishes, pre-scratched to facilitate cell attachment. The explants were 
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incubated in limited volumes of the above medium at 37 °C for a week, to 
establish primary culture. Cells were periodically observed microscopically in 
order to monitor attachment and proliferation. At the end of one week, the 
explants were removed carefully and sufficient media added to the dish to 
promote cell proliferation. After the 2nd passage, cells were proliferated in DMEM 
High; with Sodium Pyruvate and without L-glutamine (Fisher Scientific) 
supplemented with 10% v/v FBS (Atlanta Biologicals), 1% v/v GlutaMAX (Life 
Technologies, Grand Island, NY), and 1% v/v penicillin/streptomycin (Fisher 
Scientific). Media was changed every 3 days and cells were passaged at 80-90% 
confluence with TrypLE Express (Life Technologies, Grand Island, NY). Low 
passage nRASMCs (P4-8) were used for the following studies. 
 
6.2.2 Immunostaining Elastin Fibers. 
HFFs were cultured in DMEM previously described in 6.2.1 at a density of 
1.0x104 cells/cm2 in an 8-well chamberslide. After 3, 5, 7, and 14 days of culture 
cells were rinsed twice with PBS and fixed in cold methanol for 10 minutes. The 
monolayer was rinsed 3 times in PBS before incubation in blocking solution of 
5% goat serum in PBS for 30 minutes at room temperature (RT). Cells were then 
incubated overnight at 4ºC with 1:1000 primary anti-bovine elastin antibody (a 
generous gift from Dr. Mecham) in solution containing 1% goat serum in PBS. 
Cells were washed 3 times with PBS before secondary antibody labeling with 
Alexa Fluor 546-conjugated anti-rabbit IgG (Invitrogen, Carlsbad, CA) in 1% goat 
serum in PBS for 45 minutes at RT. All unbound antibody was washed away with 
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3 washes of PBS before nuclear staining with DAPI in Vectashield mounting 
medium (Vector Laboratories, Burlingame, CA) and coverslipped. Elastin fibers 
were detected by immunofluorescent imaging using a Leica sp5 confocal 
microscope with a 20X objective.  
 
6.2.3 Quantitative RT-PCR 
 RNA was extracted 24h after treatment using Qiagen’s RNeasy RNA 
extraction kit according to the manufacturer’s instructions. RNA integrity was 
assessed by a Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA), and 
cDNA was prepared using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) 
with 1 µg RNA according to the manufacturer’s instructions. 10 µL reactions of 
each sample were prepared using 5 µL SSO Fast EvaGreen supermix (Bio-Rad, 
Hercules, CA), 0.5 µL each 10 µM forward and reverse primers, 1 µL DEPC-
treated water, and 3 µL of the optimized dilution of cDNA. Reactions were 
amplified for forty cycles at optimized temperatures in an iCycler real-time PCR 
detection system (Bio-Rad, Hercules, CA). The resulting data were analyzed with 
the PCR Miner software, which calculates individual threshold cycle values and 
gene efficiency for a set of primers. All gene expression levels were normalized 
to a housekeeping gene that is constitutively expressed at a relatively constant 
level across many or all known conditions. (e.g., βactin, GAPDH, and TATA-box 
binding protein) expression levels. 
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6.2.4 Pharmacological Agonist/Antagonist Treatment. 
 In order to screen candidate genes and transcription factors of interest, an 
in vitro culture model was designed to test pharmacological agonists and 
antagonists. Human foreskin fibroblasts (ATCC no. SCRC-1041) (HFFs) were 
plated in 6-well plates at 1.0x104 cells/cm2 and allowed to attach overnight. In 
some experiments cells underwent serum starvation for 18 – 24 h in DMEM High; 
with Sodium Pyruvate and without L-glutamine (Fisher Scientific) supplemented 
with 0.1% v/v FBS (Atlanta Biologicals), 1% v/v GlutaMAX (Life Technologies, 
Grand Island, NY), and 1% v/v penicillin/streptomycin (Fisher Scientific) so as to 
synchronize cell cycle phase (267) and maximize mRNA production after 
treatment. Pharmacological agonists and antagonists to transcription factors 
were added in fresh DMEM High; with Sodium Pyruvate and without L-glutamine 
(Fisher Scientific) supplemented with 10% v/v FBS (Atlanta Biologicals), 1% v/v 
GlutaMAX (Life Technologies, Grand Island, NY), and 1% v/v 
penicillin/streptomycin (Fisher Scientific) or fresh low serum (0.1%) media for 
serum starvation experiments. 
 It was predicted that hypothesized positive effectors of elastogenesis (e.g., 
neuraminidase, IGF-1) would increase the total amount of elastin transcription, 
deposition and/or increase the rate of elastin deposition. Conversely, negative 
effectors of elastogenesis (e.g., chondroitin sulfate) would decrease the total 
amount of elastin transcription, deposition and/or decrease the rate of elastin. 
Sp1. Sp1 is a known regulator of elastic fiber formation (146; Sen, 2011 
#165) that was implicated in the PAINT analysis as having a potential binding site 
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in the elastin promoter. In order to validate the PAINT analysis and the culture 
model we administered mithramycin (Sigma, St. Louis), a Sp1 antagonist, to 
inhibit elastin.  
PPAR. PPAR was identified through PAINT analysis as a potential 
regulatory transcription factor of elastogenesis with a potential TRE located in the 
elastin promoter. PPAR has already been shown to have dual effects on elastin 
transcription: both increasing (241) and repressing elastin expression in 
fibroblasts (238, 242). PPARα has yet to be examined for its role in 
elastogenesis therefore we tested the effects of PPARα agonist and antagonist 
on elastin expression. 
 HFFs were plated at confluence and allowed to attach overnight before 
treatment with 1 – 100 µM PPARα agonist (C7081, Sigma), 3.33 – 30 µM 
PPARα antagonist (GW6471, Sigma), and/or 10 – 30 µM PPARγ antagonist 
(GW9662, Sigma). RNA was extracted at 24 h using Qiagen’s RNeasy RNA 
extraction kit according to the manufacturer’s instructions. RNA integrity was 
tested by Bioanalyzer 2100  (Agilent Technologies, Palo Alto, CA) and cDNA was 
prepared using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) with 1 µg 
RNA according to the manufacturer’s instructions. cDNA preparations were 
diluted 1:10, and 3 µL was used in 10-µl reactions for qRT-PCR as described 
previously in 6.2.3. 
 WT1/EGR-1. WT1 was identified as an enriched transcription factor by 
PAINT in the analysis of the subset of genes whose expression pattern is similar 
to elastin. A similar transcription factor that binds the same consensus sequence 
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on a TRE was identified in the other subset of the candidate elastogenic gene 
set. EGR-1 was enriched to bind the subset of genes with an expression pattern 
different from elastin. EGR-1 has a similar conformational structure as WT1 and 
often regulates the same genes in an opposing direction. The identification of 
these pair of opposing transcription factors in the different subsets suggest WT1 
and EGR-1 act to coordinate regulation of the elastin gene.  
 The one available pharmacological agent to regulate transcription factors 
WT1 or EGR-1 was the WT1 antagonist Ganetespib (Sta-9090), an 
investigational anticancer drug developed by Synta Pharmaceuticals (Lexington, 
MA). Ganetespib is a small molecule inhibitor of heat shock protein 90 (HSP90), 
a molecular chaperone required for the proper maturation and activation of 
numerous client proteins and often overexpressed in cancer (268-271). Hsp90 
 
Figure 6.1. Egr-1 is hypothesized to signal through the MAPK pathway and suppress 
elastin transcription. Conversely, displacement of Egr-1 by transcription factor WT1 will 
shift the signaling cascade of events toward increase elastin transcription. 
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also associates with WT1 protein and stabilizes its expression (272). 
Pharmacological inhibition of Hsp90 with Ganetespib resulted in ubiquitination 
and subsequent proteasome-dependent degradation of WT1 in the human CML 
cell line K562 and AML cell line KG-1. Downstream targets of WT1, c-Myc and 
Bcl-2 were also subsequently downregulated (272). 
 EGR-1 was experimentally determined to be a downstream target of 
extracellular signal-regulated kinase 1 and 2 (ERK1/2) in a mononuclear 
phagocyte (RAW) cell culture model. Carbon monoxide mediated suppression of 
ERK activation resulted in Egr-1 inhibition. ERK 1/2-driven Egr-1 expression and 
regulation of its downstream target genes was cGMP-dependent (273). 
Modification of the signaling cascade of factors regulating elastin transcription by 
insertion of Egr-1 leads to the hypothesis that Egr-1 is a negative regulator of 
elastin transcription via the MAPK pathway. Conversely, displacement of Egr-1 
by transcription factor WT1 will shift the signaling cascade of events toward 
increase elastin transcription. Treatment of HFFs with 12 nM – 1 µM Ganetespib 
is expected to antagonize WT1 and thus decrease elastin transcription compared 
to MeOH controls. If elastin regulation is mediated via the MAPK pathway, co-
culture of 37 nM Ganetespib with 50 nM Mek inhibitor PD98059 may reverse the 
effects by decreasing downstream Egr-1 and upregulating elastin transcription. 
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6.2.5 Transfection of Plasmid Expression Vectors 
6.2.5.1 Plasmid Stock Culture Preparation 
 In the absences of pharmacological agents to augment expression of WT1 
and EGR-1, transfection of plasmid expression vectors containing the sequence 
for WT1 and EGR-1 were performed on HFFs. Sequence-Verified human WT1 
and EGR1 were generated from the Mammalian Gen Collection (MGC), a trans-
NIH initiative, that provides sequence-validated full-length protein-coding (FL-
CDS) cDNA clones (Thermo Fisher Scientific, Pittsburgh, PA). Plasmids were 
obtained as live bacterial cultures containing the plasmid of interest. Stock 
cultures for each plasmid were prepared by isolation of a single colony from a 
streak plate on LB agar containing 100 µg/mL ampicillin. Bacterial cultures of 
stock cultures for WT1 and EGR-1, in addition to empty vector control were 
proliferated in 100 mL Luria Broth (LB) medium containing 100 µg/mL Ampicillin 
overnight and plasmid purification performed with a Plasmid Midi Kit (Qiagen, 
Valencia, CA) according to manufacturer’s instructions. Plasmids were extracted 
and concentration determined by spectrophotometry. Concentrations were 
adjusted to be equal for each type of plasmid. 
 
6.2.5.2 Transfection with Amaxa Nucleofector Kit 
 Transfection of human foreskin fibroblasts (HFFs) with plasmid vectors 
with performed with a Lonza Amaxa Nucleofector Kit (Lonza) according to 
manufacturer’s protocol. For each transfection reaction 82 µL of Nucleofector 
Solution plus 18 µL of supplement was combined to make 100 µL of total 
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reaction volume. Passage 7 HFFs were detached from the plate with TrypLE. 3 x 
106 cells/transfection were centrifuged at 10,000 rpm x 5 min and the cell pellet 
resuspended in 100 µL Nucleofector Solution. 2.5 µg plasmid DNA was added to 
each reaction. Cell/DNA suspension was transferred to a certified cuvette and 
placed in the Nucleofector device for administration of the program U-023 for 
normal adult human dermal fibroblasts. Media is immediately added to the 
cell/DNA suspension and aliquotted into 4 replicate wells of a 6-well plate. 3 
individual transfections were performed for each of 3 plasmid expression vectors. 
RNA was extracted at 24 h post transfection and converted to cDNA for qRT-
PCR quantification of elastin expression. 
 
6.2.5.3 Transfection with Lipofectamine 
Human foreskin fibroblasts (ATCC no. SCRC-1041) (HFFs) were plated in 
6-well plates at 1.0x104 cells/cm2 overnight prior to transfection. For each well, 
2.5 µg DNA (expression vector, and 2.5µL of PLUS reagent was incubated with 
100 µL OptiMEM medium for 15 minutes at room temperature. 2.75 µL 
Lipofectamine was added to the transfection medium and incubated 30 minutes 
at room temperature. One mixture was prepared with 0.5 µg GFP plasmid 
following the same procedure; this mixture was used to transfect a separate well 
of cells. The plated cells were washed twice with sterile PBS before 2 mL 
OptiMEM medium before the DNA containing transfection mixture was added. 
Transfection efficiency was assessed at 18 hours by immunofluorescence, 
specifically determining the percentage of cells producing GFP in the GFP-
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transfected population. RNA was 
extracted, cDNA synthesized, and 
mRNA expression levels quantified with 
qRT-PCR as described above. 
 
6.2.6 Design of a quantitative Elastin 
ELISA 
 We have taken steps toward 
development of a novel in vitro assay 
that quantifies incorporation of elastin into the ECM of fibroblast monolayers. 
Human foreskin fibroblasts (ATCC no. SCRC-1041) were seeded into wells of 96 
well culture plates at 1x104 cells/cm2 in media. In order to prevent a ring effect 
whereby evaporation occurs from wells on the plate perimeter, the outer wells 
are filled with PBS and the inner 60 wells are utilized for the assay as illustrated 
in Figure #. Duplicate plates were designed for parallel culture in order to 
measure elastin in one plate and normalize to cell viability in a replicate plate. 
 Pharmacological agents were added in varying concentrations. Control 
wells received delivery vehicles. As a control, we administered bacterial 
neuraminidase (Neu1) to cultured cells since Neu1 is required for assembly of 
elastic fibers (94) and studies have shown administration of Neu1 augments 
elastin deposition by VSMCs (50). 
 
 
Figure 6.2. 96-well plate setup for 
development of a quantitative elastin 
assay. The pink circles represent the 60 
wells that contained cells while the outer  
ring of white circles represent the wells 
incubated with PBS in order to prevent 
evaporation from cell-containing wells within 
the incubator. 
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 Day 3 was chosen as a fixed timepoint because it demonstrates the 
transition period between human foreskin fibroblast (HFF) proliferation to steady 
state and the point at which the amount of elastin deposition can be assessed 
prior to steady state in HFFs (Figure 6.3). 
 Seeding densities ranging from 102 – 1011 cells/cm2 were assayed by MTS 
assay and anti-elastin ELISA. A seeding density of 1 x 104 cells/cm2 was chosen 
based on Figure 6.3 where elastogenesis is still occurring in the exponential 
A B 
  
  
Figure 6.3. Elastin ELISA quantification is optimal for elastin deposition after 3 days in 
culture. A. Proliferation of human foreskin fibroblasts (HFFS) as measured by MTS assay 
reaches a steady state around 3-5 days in culture. B. Elastin deposition by HFFs reaches a 
steady state by approximately 4 days in culture. Immunofluorescence of anti-elastin labeling 
was detected by elastin ELISA (n=3/timepoint). 
A B 
  
  
Figure 6.4. Elastin ELISA quantification is optimal for seeding density after 3 days in 
culture. A. Proliferation of human foreskin fibroblasts (HFFS) as measured by MTS assay 
reaches a steady state around 3-5 days in culture. B. Elastin deposition by HFFs reaches a 
steady state by approximately 4 days in culture. Immunofluorescence of anti-elastin labeling 
was detected by elastin ELISA (n=3/timepoint). 
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growth phase but in a large enough quantity to be assayed. 
 
6.2.6.1 Immunostaining Elastin 
 At 72 hours post treatment, cells were rinsed with PBS and fixed with ice 
cold methanol. The monolayer was rinsed 3 times in PBS before incubation in 
blocking solution of 5% goat serum in PBS for 30 minutes at room temperature 
(RT). Cells were then incubated overnight at 4ºC with 1:1000 primary anti-bovine 
elastin antibody (a generous gift from Dr. Mecham) in solution containing 1% 
goat serum in PBS. Cells were washed 3 times with PBS before secondary 
antibody labeling with 1:10000 horseradish peroxidase (HRP) labeled anti-rabbit 
IgG in 1% goat serum in PBS for 45 minutes at RT. All unbound antibody was 
washed away with 3 washes of PBS. The cell layer was then incubated with ECL 
plus detection reagents containing peroxide to generate chemifluorescence. The 
assay was incubated in the dark at RT and chemifluorescence was detected at 
15 minute time intervals by spectrophotometry at 430nm. Raw absorbance 
values were normalized to cell viability as assessed by MTS assay described 
next. 
 
6.2.6.2 MTS Assay for Normalization 
 Normalization of elastin immunofluorescence was performed using a 
colorimetric MTS assay using One Solution Reagent (Promega) to measure cell 
viability as a function of metabolic activity. Replicate 96-well plates of HFFs or 
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nRASMCs were seeded and cultured identically to conditions set for 
immunolabeling. 
 The One Solution Reagent is comprised of a tetrazolium compound MTS 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt) and an electron coupling reagent PES (phenazine 
ethosulfate). PES has enhanced chemical stability, which allows it to be 
combined with MTS to form a stable solution. The MTS tetrazolium compound is 
reduced by the mitochondria of live cells to yield a formazan product that is 
soluble in tissue culture medium. This conversion is presumably accomplished by 
NADPH or NADH produced by dehydrogenase enzymes in metabolically active 
cells. 
 At the time of fixation of 96-well plates used in elastin immunolabeling, 
One Solution Reagent was added to the parallel plates in order to compare total 
viability. 20 µL One Solution Reagent was added via multichannel pipette to each 
well of the 96-well plate containing live cells in 100 µL cell culture media and 
incubated at 37 ºC in a humidified CO2 incubator. Absorbance was quantified by 
spectroscopy at 490 nm at the same 15 minute intervals as parallel plates for 
elastin immunolabeling. Background absorbance from control wells containing no 
cells was subtracted from the sample absorbance measurements. The MTS 
assay has a sensitivity of 800 cells per 96-well plate. 
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6.2.7 Fabrication of 3D Gelatin Constructs 
6.2.7.1 Cell Culture of Microcarrier Beads 
 Macroporous gelatin-coated microcarrier beads, CultiSpher-G, (Percell 
Biolytica AB, Astorp, Sweden), with an average particle diameter of 130-380 µm, 
pore size of 20 µm, and density 1.02-1.04 g/cm3 at 25 ºC, were purchased from 
Sigma Chemical Co. (St. Louis, MO). The microcarrier beads were rehydrated, 
autoclaved, and preincubated at 37 ºC in cell culture medium according to 
manufacturer instructions. Microcarrier beads were combined with HDFs 
(passage 4) or HFFs (passage 8) at a ratio of 106 cells per 0.5 mL suspended 
microcarrier beads. The cell-microcarrier mixture was added to 50 mL cell culture 
medium in a 125 mL siliconized Techne biological stirrer flask (R&D Systems, 
Minneapolis, MN). The suspension was subjected to an intermittent stirring 
regime (30 min rest, 2 min at 50 rpm) on a Techne Biological Stirrer (model 
MCS-104S) for 48 h at 37 ºC in a humidified 5% CO2 incubator. Additional media 
(25 mL) was added after 24 h incubation. 
 
6.2.7.2 Tubular Structure Formation in Agarose Molds 
 An agarose mold for assembling 4 mm tubular structures was created with 
2% molten agarose (Low EEO, J.T. Baker Chemical Co., Phillipsburg, NJ) in 
Dulbecco’s phosphate buffered saline (PBS) and a template manufactured from 
acrylic and polyetheretherketone (PEEK). The template was designed to fit into a 
6-well tissue culture plate (Falcon; Becton-Dickinson, Franklin Lakes, NJ) 
containing agarose and removed after the agarose had solidified. The agarose 
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mold was preincubated with PBS for 1 h and then with cell culture media for 2 h 
at 37 ºC in a humidified 5% CO2 incubator. The 48h incubated cell-microcarrier 
beads described previously were seeded into the tubular molds and covered with 
cell culture media that was replaced every 24h over a culture period of 7 or 14 
days at 37 ºC in a in a humidified 5% CO2 incubator. 
 
6.2.7.3 Histological Staining and Immunohistochemistry 
 For histochemical staining, tubular constructs were dissected away from 
the agarose molds and rinsed twice with PBS and fixed in cold methanol for 10 
minutes. The structures were rinsed 3 times in PBS before incubation in blocking 
solution of 5% goat serum in PBS for 30 minutes at room temperature (RT). Cells 
were then incubated overnight at 4ºC with 1:1000 primary anti-bovine elastin 
antibody (Dr. Mecham) in solution containing 1% goat serum in PBS. Cells were 
washed 3 times with PBS before secondary antibody labeling with Alexa Fluor 
546-conjugated anti-rabbit IgG (Invitrogen, Carlsbad, CA) in 1% goat serum in 
PBS for 45 minutes at RT. All unbound antibody was washed away with 3 
washes of PBS before mounting in Vectashield mounting medium (Vector 
Laboratories, Burlingame, CA). Elastin fibers were detected by 
immunofluorescent imaging using a Leica sp5 confocal microscope with a 20X 
objective.  
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6.3 Results 
6.3.1 Elastic Fiber 
Assembly 
 Of all the 
different cell types 
cultured and 
immunolabeled with 
the combination of 
anti-elastin antibodies, only one cell type displayed extracellular elastic fiber 
staining: the human foreskin fibroblast (HFF). Intracellular tropoelastin is seen at 
day 3 and by day 5 elastic fibers first appeared in the extracellular matrix space. 
The density of fibers increased up to a certain plateau by day 7 and did not seem 
to further increase in number or thickness by day 14. 
 
6.3.2 Comparison of Elastic Fiber Assembly by Cell Type  
 Anti-tropoelastin immunolabeling of certain in vitro cultured cell types 
(Table 6.1) produced a diffuse intracellular stain of tropoelastin monomers often 
 
Figure 6.5 Anti-elastin confocal microscopic detection of elastin-containing fibers in 
human foreskin fibroblast ECM on successive days of culture. Anti-elastin stained fibers are 
green and DAPI stained nuclei are blue.  
Table 6.1. Cell associated elastin immunostaining 
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appearing punctate. After extended 
culture length the tropoelastin 
monomers did not appear to migrate 
to the extracellular matrix space to 
form elastic fibers. It is possible that 
in these cell types under these 
culture conditions elastic fiber 
assembly is impaired.  
 
6.3.3 Screening of Candidate Elastogenic Regulators  
 The in vitro culture model of HFFs was validated with predicted inhibitor of 
elastin transcription, mithramycin A. Increasing concentrations of mithramycin 
decrease elastin expression in a dose dependent manner (Figure 6.6). 
 
Figure 6.6. Mithramycin, an antagonist of 
Sp1, inhibits elastin expression in a dose 
dependent manner in human foreskin 
fibroblasts (HFFs). It is known from previous 
studies that transcription factor Sp1 enhances 
elastogenesis 
 
Figure 6.7. Serum starving HFFs treated with PPARα  antagonist decreased elastin 
transcription at high concentrations. Reduction in serum levels 24 hours before and 
during treatment with PPARα antagonist reversed the previously seen increase in elastin 
transcription. Statistical analysis was performed with Student’s T test (p<0.05) 
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 Human foreskin fibroblasts (HFFs) cultured in media containing 10% FBS 
display seemingly conflicting upregulation of elastin expression in response to 
both PPARα agonist and antagonist treatment. Experiments employing serum 
starvation with no or low levels of FBS diminished the statistically significant 
increase in elastin transcription, however increasing concentrations of PPARα a 
gonist in 0.2% FBS/DMEM 
appeared to trend toward an 
increase (Figure 6.8). 
Conversely serum starvation 
prior to treatment with PPARα 
antagonist displayed a reduction 
in elastin transcription levels in 
0% FBS/DMEM in response to 
the highest treatment of 30 µM 
PPARα antagonist (Figure 6.7) 
 
Figure 6.8. Serum starving HFFs treated with PPARα  agonist did not augment elastin 
transcription. Reduction in serum levels 24 hours before and during treatment with 
PPARα agonist reduced the previously seen increase in elastin transcription. Statistical 
analysis with Student’s T test did not validate any regulation of elastin. 
 
Figure 6.9. WT1 antagonist Ganetespib 
treatment decreased elastin transcription in a 
dose dependent manner in both human foreskin 
fibroblasts (HFFs) and rat aortic smooth muscle 
cells (RASMCs) as measured by qRT-PCR (n=3 
samples/concentration). Statistical analysis 
calculated with Student’s T test (p<0.05). 
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 WT1 
antagonist 
Ganetespib 
treatment 
decreased 
elastin 
transcription in 
a dose dependent manner in both human foreskin fibroblasts (HFFs) and rat 
aortic smooth muscle cells (RASMCs) as measured by qRT-PCR (Figure 6.9). 
Ganetespib is thus a novel regulator of elastogenesis. 
 Subsequent experimentation to elucidated the mechanism by which 
Ganetespib downregulates elastin employed co-culture of a MEK1 inhibitor 
PD98059. The MEK1 inhibitor was unable to rescue downregulation of elastin 
transcription in response to WT1 antagonist Ganetespib at the treated 
concentration and duration (Figure 6.10). 
 
 
Figure 6.10. Inhibition of Mek1 with PD98059 does not rescue 
downregulation of elastin in response to WT1 antagonist Ganetespib. 
Human foreskin fibroblasts (HFFs) and rat aortic smooth muscle cells 
were co-cultured with 37nM Ganetespib and 50nM Mek1 inhibitor for 24 h. 
Elastin expression was quantified with qRT-PCR and statistical 
significance computed with Student’s T test (p<0.05). 
A B 
  
Figure 6.11. Neuraminidase (Neu1) does not affect total elastin deposition (A) or rate of 
deposition (B) by human foreskin fibroblasts (HFFs) in the elastin assay (n=3/timepoint and 
concentration). 
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6.3.4 Development toward an ELISA to quantify elastin deposition 
 Measurement of elastin deposition in response to the Neuraminidase 
(Neu1) positive control did not elicit the expected increase in elastin total 
deposition or rate of deposition (Figure 6.11). Increasing concentrations of 
Neuraminidase did not have any effect on anti-elastin absorbance, neither did 
increased culture length. However the proposed negative control Chondroitin 
Sulfate (CS), a known inhibitor of elastogenesis, reduced elastin deposition by 
HFFs at day 3.  
 The elastin assay made use of other positive regulator of elastogenesis, 
Pro-Gly and IGF-1. Elastin expression was minimally increased with both Pro-Gly 
A B 
 
 C 
  
Figure 6.12. Known regulators of elastin were tested in the Elastin ELISA. A, IGF-1 , a 
known enhancer of elastogenesis, increased elastin deposition, along with B, pro-gly, 
another known enhancer. C, Chondroitin Sulfate (CS), a known inhibitor of elastogenesis, 
reduced elastin deposition by HFFs in an elastin ELISA. (n=3/concentration). Statistical 
analysis with Student’s T test (p<0.05). 
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and IGF-1 treatment, however not in a dose dependent manner (Figure 6.12 A 
and B). 
 A gene from the 63-gene candidate elastogenic set was screened by 
exogenous addition of 0.22 – 18 µg/mL Haptoglobin. A significant increase in 
elastin was quantified at 2 and 18 µg/mL (Figure 6.13). 
  
 
  
 
Figure 6.13. Haptoglobin increased 
elastin deposition by HFFs in an elastin 
ELISA (n=3/concentration). Statistical 
analysis with Student’s T test (p<0.04). 
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6.3.5 Elastin Expression in Transfectants 
 Expression vector efficiency was 
determined with qRT-PCR expression. 
WT1 transfected HFFs demonstrated an 
85 fold increase in WT1 as compared to 
empty vector transfected HFFs. EGR-1 
expression was increased approximately 
3 fold (Figure 
6.15). Statistical 
analysis was 
performed with a 
Students T-test 
and determined to 
be significant for 
WT1 transfected 
cells but not for 
EGR-1. 
 Figure 6.16 
illustrates a 
dramatic decrease 
in elastin 
expression by 89% 
(p=0.009) in 
 
Figure 6.15. Transfection of expression vectors validated with 
qRT-PCR.  
 
Figure 6.16. Elastin expression is decreased by EGR-1 in HFFs. 
Transfected HFFs with plasmid expression vectors was performed 
with Lonza Amaxa Nucleofector Kit and qRT-PCR performed on 
RNA extracted 24 h post transfection. Elastin expression 
significantly decreased by EGR-1 expression by 89%. Elastin 
expression is differentially regulated between the WT1 and EGR-1 
transfected  
 
Figure 6.14 . V3 induced tropoelastin 
expression in smooth muscle cells. 
PAC-1 cells were transfected with 
lipofectamine with V3-containing plasmid 
and empty vector control. RNA was 
extracted at 24h and expression levels 
determined by qRT-PCR with TaqMan 
primers for elastin. 
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response to a modest, yet not statistically significant, increase in EGR-1 
expression. It is possible that expression can be improved with increased number 
of transfections thus lowering the standard deviation. Surprisingly only a modest 
increase in EGR-1 expression was required for repeated decreases in elastin 
expression (n=3). In response to WT1 transfection elastin expression is not 
significantly regulated however its mean expression level is 82% higher than 
empty vector control. The standard deviation is too large due to large increases 
in elastin transcription in only 2 of the 4 transfections. Statistical analysis 
between the two experimental groups WT1 transfected HFFs and EGR-1 
transfected HFFs is significantly different (p<0.05). 
 Comparison of multiple transfections points toward a trend in elastin 
regulation in response to 
WT1. As WT1 
expression increases 
with more efficient 
transfections, the 
average expression level 
of elastin increases as 
measured by qRT-PCR 
(Figure 6.17). 
 
 
 
 
Figure 6.17. Elastin expression is trending toward 
significance with improved WT1 transfection efficiency. 
Comparison of elastin expression in two different transfections 
shows a 75% increase in elastin expression (1.08 vs. 1.89) with 
a 5.7 fold increase in WT1 (15 vs. 85). 
 134 
6.3.6. Elastin Expression in 3D Gelatin Constructs 
 The beginnings of construction on the proof of concept model of a 3D 
gelatin construct from macroporous gelatin-coated microcarrier beads and 
human foreskin fibroblasts (HFFs) were generated. Fusion of the beads occurred 
after 7 day of culture in the tubular shaped molds and strengthened in tension as 
noticed by handling with increasing culture duration. Cellular staining indicated 
infiltration of some cells into the pores but the majority of HFFs were attached to 
the bead surface or in the extracellular space between beads. Anti-elastin 
staining demonstrated the presence of mature elastic fibers at 7 days and 12 
days in culture  (Figure 6.19).  
 
 
 
  
Figure 6.18. Macroporous gelatin microcarrier beads populated with HFFs. Human 
foreskin fibroblasts (HFFs) adhered to gelatin microcarrier beads over 48 hours in a stirred 
suspension before seeding into tubular molds. The HFF populated beads fused forming a 
tubular structure. Brightfield images were taken at 6 days and 17 days in culture. Remodeling 
and filling of the intrabead space either by cells or extracellular matrix is apparent by 17 days.  
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6.4 Discussion 
 Increasing concentrations of mithramycin, an antagonist Sp1, a known 
augmenter of elastogenesis in HFFs decreased elastin expression, thus 
validating the tissue culture model as an appropriate assay for regulators of 
elastin transcription. 
 WT1 antagonist Ganetespib treatment decreased elastin transcription in a 
dose dependent manner in both human foreskin fibroblasts (HFFs) and rat aortic 
smooth muscle cells (RASMCs) as measured by qRT-PCR. This marks the first 
time a WT1 antagonist has been shown to downregulate elastin transcription. 
 Subsequent experimentation aimed at elucidating the mechanism by 
which Ganetespib downregulated elastin targeted the MAPK pathway. Co-culture 
of a MEK1 inhibitor PD98059 attempted to disrupt downstream signaling of Egr-
1, a hypothesized suppressor of elastogenesis. The MEK1 inhibitor was unable 
to rescue downregulation of elastin transcription in response to WT1 antagonist 
 
 
Figure 6.19. Elastin immunostaining of macroporous gelatin microcarrier beads 
populated with HFFs. Human foreskin fibroblasts (HFFs) adhered to gelatin microcarrier 
beads over 48 hours in a stirred suspension before seeding into tubular molds. The HFF 
populated beads fused forming a tubular structure and were fixed at day 7 and day 12 and 
immunostained for elastin. 
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Ganetespib at the treated concentration and duration. It is possible that the 
MEK1 inhibitor did not fully disrupt downstream signaling as it did not block 
MEK2. Future studies could aim to target MEK1/2 or the downstream target of 
ERK 1/2 to decrease Egr-1 signaling. It is also possible that the concentration of 
MEK1 inhibitor at 50 nM was too low to fully suppress all MEK1 signaling. A 
concentration increase of MEK inhibitor can be performed to possibly generate 
an increase in elastin transcription. 
 Contrary to expected results, elastin expression increased in HFFs treated 
with both PPARα agonist and PPARα antagonist. If only PPARα levels are 
changing in response to the agonist and antagonist, then it would follow that any 
effects seen would have opposing expressions. It is likely that the PPARα 
agonist or PPARα antagonist is inducing transcription via stimulation of another 
enhancer of elastin transcription. Follow-up qRT-PCR was performed on 
expression levels of PPAR∂. In smooth muscle cells, PPAR∂ agonist was shown 
to increase tropoelastin production (274). qRT-PCR confirmed that PPARα 
antagonist increased PPAR∂ expression, possibly as a compensatory response 
to decreased PPARα activity. Future experimentation should neutralize the 
increase in PPAR∂ by incorporation of the appropriate concentration of PPAR∂ 
antagonist. 
 Steps toward the development of an elastin ELISA based on anti-elastin 
labeling normalized to MTS assay of cellular proliferation were taken to quantify 
total elastin deposition and rate of deposition. An optimal timepoint of 
quantification was established at three days of culture while elastin deposition 
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and cell proliferation are still in the exponential growth phase prior to steady 
state. Optimal seeding density of A seeding density of 1 x 104 cells/cm2 was 
chosen at which point elastin is being deposited in the exponential growth phase 
at a large enough quantity to be assayed. 
 Contrary to expected results, Neu1, a positive regulator of elastogenesis 
did not increase total elastin deposition or rate of deposition as measured by 
elastin ELISA. Other positive regulators Pro-Gly and IGF-1 did show a marginal 
increase in elastin deposition with statistical significance assessed by Students T 
test, however not in a dose dependent manner as expected. Chondroitin Sulfate, 
a negative regulator of elastogenesis also passed the Student’s T test of 
significant regulation but the decrease in elastin deposition did not occur at 
intermediate timepoints. 
 The conflicting or marginal results could be due to the need for increased 
optimization of the parameters surrounding the elastin ELISA. Subsequent 
analyses could be performed to alter cellular seeding density, length of culture, 
and media concentration of FBS. If elastin expression is quantifiable in an in vitro 
system but elastin deposition is not as easily quantified, It is also possible that 
oxidative and nitrosative modification of tropoelastin within the in vitro model are 
preventing elastic fiber assembly (28). In a study by Akhtar et al. oxidation 
reduced crosslinking and interactions with other proteins required for elastic fiber 
assembly, including fibulin-4, fibulin-5, and fibrillin-2. Measurement of 
exogenously added oxidized tropoelastin showed less incorporation into the 
preexisting microfibrils of human retinal pigmented epithelial ARPE-19 cells 
 138 
compared to unoxidized tropoelastin as detected by immunofluorescence 
microscopy (28). Nitration of TE was confirmed using the rabbit anti-N-Tyr 
antibody, followed by a FITC-conjugated anti-rabbit secondary antibody (28). If 
the in vitro culture model for the elastin ELISA is undergoing any oxidative stress, 
it would follow that elastic fiber assembly may be impaired. Gene ontological 
analysis of the 63 candidate elastogenic genes shows enrichment for the 
functional group of oxidoreductase which facilitates redox reactions. It is also 
possible that oxidative and nitrosative modification of tropoelastin within the in 
vitro model are preventing elastic fiber assembly (28). In a study by Akhtar et al. 
oxidation reduced crosslinking and interactions with other proteins required for 
elastic fiber assembly, including fibulin-4, fibulin-5, and fibrillin-2. Measurement of 
exogenously added oxidized tropoelastin showed less incorporation into the 
preexisting microfibrils of human retinal pigmented epithelial ARPE-19 cells 
compared to unoxidized tropoelastin as detected by immunofluorescence 
microscopy (28). Nitration of TE was confirmed using the rabbit anti-N-Tyr 
antibody, followed by a FITC-conjugated anti-rabbit secondary antibody (28). If 
the in vitro culture model for the elastin ELISA is undergoing any oxidative stress, 
it would follow that elastic fiber assembly may be impaired. 
 An optional culture model to pursue for screening of elastogenic regulators 
is the 3D culture of macroporous gelatin microcarrier beads seeding with human 
foreskin fibroblasts (HFFs). Deposition of elastic fibers is seen at 12 days in 
culture but not at 7 with an increase in culture duration also correlating with an 
increased ease in handling. The rings remained solid after 12 days and did not 
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dissociate into fragments. The 3D model offers advantages to 2D culture models 
by mimicking the increase in cell-cell contact and cell-scaffold contact in the 
native ECM environment, thus more closely evoking native cell responses. 
 Overall 3D, ECM-based cell scaffolds are superior over 3D synthetic scaffolds or 
two dimensional (2D) monolayer cell cultures in efforts to simulate the chemical 
and physical environment of tissues (86, 88). This model can serve to screen 
potential regulatory gene and transcription factors in future studies. 
 
6.5 Conclusion 
 Increasing concentrations of mithramycin, an antagonist Sp1, a known 
augmenter of elastogenesis in HFFs decreased elastin expression, thus 
validating the tissue culture model as an appropriate assay for regulators of 
elastin transcription. While elastin transcription can be appropriately assessed, 
steps toward development of an elastin ELISA displayed conflicting or marginal 
variance of elastin deposition between experimental and control wells. Further 
optimization of the assay is required in order to clearly distinguish the effects of 
elastogenic regulators. 
 Screening of transcription factors identified as potential regulators of 
elastogenesis by PAINT with pharmacological agents discovered a novel 
regulator of elastin transcription. Ganetespib, a WT1 antagonist, repeatedly 
downregulates elastin expression in a dose dependent manner. The mechanism 
by which Ganetespib mediates elastin downregulation has yet to be determined, 
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however it wasn’t altered with co-culture of 50 nM MEK1 inhibitor aimed at 
disrupting downstream regulation of EGR-1 via the MAPK pathway. 
 Egr-1, a member of the same transcription factor family as WT1, binds the 
same transcriptional regulatory elements (TREs) and is known to regulate the 
same genes, often in opposing directions whereby EGR1 activates the 
transcription of genes that WT1 represses (257, 258). Expression of Egr-1 by 
transfection of plasmid expression vectors results in decreased elastin 
transcription. This result fits the story of opposing roles of WT1 and Egr-1 for 
regulation of elastin transcription. Experimentation to augment elastin expression 
by expression of WT1 plasmid expression vector is trending toward an increase 
in elastin expression, however it has not approached statistical significance. 
Incorporation of additional transfections to increase statistical power may 
overcome standard deviation to yield an increase in elastin. 
 Future studies can also employ the use of an elastin producing 3D culture 
model incorporating human foreskin fibroblasts (HFFs) with gelatin microcarrier 
beads. Tubular constructs were created and after 12 days of culture were 
manageable and populated with mature elastic fibers. This proof of concept 
culture system provides the advantages of more closely mimicking the native cell 
environment in a 3D environment as compared to a 2D monolayer culture. 
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CHAPTER SEVEN 
CONCLUSIONS, STUDY LIMITATIONS, AND FUTURE DIRECTIONS 
7.1 Conclusions 
Particularly important to the mechanical performance of tissues is elastin, 
an extracellular matrix (ECM) protein deposited by vascular smooth muscle cells 
(VSMCs) in the form of elastic fibers. In addition to serving as major structural 
elements of tissues, providing extensibility and elastic recoil, elastic fibers also 
influence vascular cell behaviors such as biochemical signaling pathways. 
Disruption of elastic fibers can initiate and progressively lead to the pathology of 
life threatening complications such as atherosclerosis, aneurysm and 
vasospasms (4, 5). Failure to regenerate a healthy elastin matrix in response to 
damage during disease (e.g., inflammation-mediated elastin degradation in 
atherosclerosis) can severely compromise elastic tissue homeostasis (13, 14). A 
major concern in the construction of tissue engineered elastin-rich tissue is the 
ability to regulate cell behavior and encourage the regeneration of elastin fibers. 
The overarching goal of this application was to advance an approach to 
regenerative medicine involving accelerated production of elastic fibers. Severe 
quantitative and qualitative deficiencies in the process of elastogenesis exhibited 
by cultured cells (28, 29) create an impediment to the engineering of tissues 
requiring functional elastin architecture. 
 Through convergent DNA microarray analysis of gene expression profiles 
associated with normal elastogenesis occurring during 1) mouse lung and aorta 
development, 2) elastogenesis in lung and skin in response to injury, and 3) in 
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vascular smooth muscle cells (VSMCs) stimulated to produce elastin fibers, 63 
commonly regulated genes were identified genes with known regulators of elastin 
formation (Eln, Lox, Mfap2, Mfap5) and genes that appear to represent new 
players in the process of elastogenesis.  
 Gene ontological analysis highlighted functional categories of extracellular 
matrix (ECM) and secretion, which follow the elastin gene beginning with 
secretion of a tropoelastin monomer and subsequent assimilation into mature 
elastic fibers comprising the ECM. The enrichment for the ontological group of 
oxidoreductase enzymes may prove to be a hindrance to elastogenesis as 
oxidation of tropoelastin prevents proper elastic fiber assembly. This may pertain 
primarily to the elastogenic processes of wound healing that are undergoing 
oxidative stress and ultimate assembly of inferior elastic fibers compared to 
developmental elastic fibers. Hierarchical organization of gene regulation within 
the 5 different elastogenic processes yielded a table of genes ranging from most 
similarly expressed as elastin to down to most differentially regulated compared 
to elastin (Appendix A). Group V highlights genes regulated similar to elastin 
during injury and different from elastin during development. These genes may 
provide insight into inferior elastic fiber quality in injury models. 
 Promoter Analysis and Interaction Network Generation Tool, PAINT, 
predicted the likelihood of transcription factor binding subset of the 63-gene 
candidate elastogenic set in which expression patterns were similar to elastin 
characterized 11 overrepresented TREs of which four were previously known to 
regulate elastogenesis: B-Myb Sp1, cKrox and PPAR. A closer look at the TREs 
 143 
enriched within the elastin promoter revealed five overrepresented TREs, of 
which two were known form previous studies to regulate elastin: PPAR and Sp1. 
The finding of elastogenic transcription factors validates the use of PAINT to 
identify regulators of elastogenesis. Many new candidate elastin regulating 
transcription factors were identified for which pharmacological agents exist and 
can ultimately be tested for effects on elastogenesis. 
 Specific mapping of TREs using chromatin immunoprecipitation (ChIP) 
studies and the UCSC Genome Browser illustrated binding sites for PPAR, a 
PPAR coactivator, and WT1/EGR-1 around the elastin transcription start site. 
The likelihood of TF/TRE binding in the elastin promoter indicates PPAR and 
WT1/EGR-1 as potential regulators of elastogenesis. 
 Additional gene regulation was assessed through target mRNA searches 
with microRNA.org. MicroRNA (miRNA) binding sites on the 63 genes in the 
candidate elastogenic gene set were particularly prevalent in Lox, an important 
crosslinker of elastin fibers. Additionally miR-29, a known regulator of 
elastogenesis, was significantly predominant within the 63-gene elastogenic 
gene set. It is likely that other miRNAs highlighted in the miRNA analysis play a 
likely role in the regulation of elastogenesis. 
Increasing concentrations of mithramycin, an antagonist Sp1, a known 
augmenter of elastogenesis in HFFs decreased elastin expression, thus 
validating the tissue culture model as an appropriate assay for regulators of 
elastin transcription. While elastin transcription can be appropriately assessed, 
steps toward development of an elastin ELISA displayed conflicting or marginal 
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variance of elastin deposition between experimental and control wells. Further 
optimization of the assay is required in order to clearly distinguish the effects of 
elastogenic regulators. 
 Screening of transcription factors identified as potential regulators of 
elastogenesis by PAINT with pharmacological agents discovered a novel 
regulator of elastin transcription. Ganetespib, a WT1 antagonist, repeatedly 
downregulates elastin expression in a dose dependent manner. The mechanism 
by which Ganetespib mediates elastin downregulation has yet to be determined, 
however it wasn’t altered with co-culture of 50 nM MEK1 inhibitor aimed at 
disrupting downstream regulation of EGR-1 via the MAPK pathway. 
 Egr-1, a member of the same transcription factor family as WT1, binds the 
same transcriptional regulatory elements (TREs) and is known to regulate the 
same genes, often in opposing directions whereby EGR1 activates the 
transcription of genes that WT1 represses (257, 258). Expression of Egr-1 by 
transfection of plasmid expression vectors results in decreased elastin 
transcription. This result fits the story of opposing roles of WT1 and Egr-1 for 
regulation of elastin transcription. Experimentation to augment elastin expression 
by expression of WT1 plasmid expression vector is trending toward an increase 
in elastin expression, however it has not approached statistical significance. 
Incorporation of additional transfections to increase statistical power may 
overcome standard deviation to yield an increase in elastin. 
 Future studies can also employ the use of an elastin producing 3D culture 
model incorporating human foreskin fibroblasts (HFFs) with gelatin microcarrier 
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beads. Tubular constructs were created and after 12 days of culture were 
manageable and populated with mature elastic fibers. This proof of concept 
culture system provides the advantages of more closely mimicking the native cell 
environment in a 3D environment as compared to a 2D monolayer culture. 
 
7.2 Study Limitations 
7.2.1 Microarray Limitations 
Elastin is highly expressed in utero and then strongly downregulated after 
birth (275, 276). Only low maintenance levels of tropoelastin mRNA are found in 
most elastic tissues in adults (276, 277). Repair of severe injuries, such as third-
degree burns, produces tissue that is often heavily scarred and severely limited 
in flexibility, range of motion, and tissue function (278). Similar scarring is seen 
after prolonged cancer radiation therapy, in sun-damaged skin (279), and in 
systemic sclerosis (280, 281), In the vasculature, Eln haploinsufficient 
phenotypes include narrowing (stenosis) of the ascending aorta in the perinatal 
period and hypertension later in life. Production of a collagen-rich extracellular 
matrix (ECM) that is deficient in elastic fibers occurs following these injury 
induced conditions. A major cause of the deficiency in elastic fiber production is 
the failure to upregulate tropoelastin gene expression in postnatal tissues.  It is a 
recognized risk that in models of elastogenesis not occurring during development 
in which lower quality or defective elastic fibers are produced, comparison of 
commonly regulated genes may exclude certain critical genes. It is however 
necessary to include processes in which elastogenesis occurs outside of 
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development so as to preen the convergent list of regulated genes from 
commonly regulated genes specific to development. Comparison of the genes 
common to developmental processes of elastogenesis to injury models or in vitro 
models could shed light on key genes responsible for elastic fiber defects in 
wound repair and in vitro.  
 
7.2.2 Epigenetic Regulation 
 In addition to studying gene expression, transcription factor induction of 
gene expression and microRNA inhibition of gene expression, newer findings 
suggest the importance of regulation at the epigenetic level. Epigenetic 
regulation refers to heritable changes in gene regulation that occur without a 
change in the DNA sequence and are therefore not encoded at the genomic level 
and can therefore not be assessed by microarray technology. Epigenetic 
regulation primarily concerns the chromatin structure and the possible chemical 
modification of some DNA bases. 
 DNA molecules are tightly wound around proteins known as histones to 
form a complex known as chromatin. Post-translational modification of histones 
alters their interaction with DNA and with proteins in the cell's nucleus. 
Combinations of such modifications are thought to constitute a code, the so-
called “histone code” that plays a role in genome function, including gene 
regulation and DNA repair. Additionally DNA can be modified mainly by DNA 
methylation, typically occurring at CpG sites, that is, at sites where a cytosine (C) 
is directly followed by a guanine (G) in the DNA sequence. Such sites are often 
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found at higher density near gene promoter sequences where they are 
collectively referred to as CpG islands. Both chromatin structure and CpG islands 
have become an increasing concern of computational biologists although good 
models and data are often missing to be able to conduct large-scale exploratory 
computer studies. 
 
7.2.3. 2D culture model 
In summary I have shown HFFs are very efficient producing elastin fibers 
after 3 days in culture as compared to other cell types which did not produce any 
extracellular fibers (PAC-1, HDF, HASMC, RASMC, MLF). Also relative amounts 
of elastin mRNA are higher in HFFs compared to other cells (PAC-1, HDF, 
HASMC). These findings indicate that HFFs are efficient at in vitro elastin 
formation. Because of the known opposing regulatory roles of transcription 
factors WT1 and Egr-1 along with experimental findings of a decrease in elastin 
transcription in both HFFs treated with a WT1 antagonist and also HFFs 
transfected to express EGR-1, it would follow that elastin transcription would be 
upregulated in response to WT1 expression. Because repeated experiments 
have yet to yield significantly upregulated elastin transcription it may not be 
possible in this 2D culture system of HFFs to see a substantial increase in elastin 
transcription. It is possible that HFFs are assembling elastic fibers at maximum 
capacity with no possible cellular resources for augmentation of transcription. 
 It has been shown that 3D, ECM-based cellular scaffolds offer overall 
superiority over 3D synthetic scaffolds and 2D monolayer cell cultures in in 
efforts to simulate the chemical and physical environment of tissues (86, 88). 3D 
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culture models most closely mimic native cell environment whereby cells within 
3D scaffolds come into contact with other cells and ECM in three dimensions and 
are therefore expected to more closely evoke native cell responses than 2D 
substrates. 
 
7.3 Future Directions 
7.3.1 Modulation of Differentially Expressed Genes in Development vs. Injury 
 Hierarchical organization of gene regulation within the 5 different 
elastogenic processes yielded a table of genes ranging from most similarly 
expressed as elastin to down to most differentially regulated compared to elastin 
(Appendix A). Group V highlights genes regulated similar to elastin during injury 
and different from elastin during development. These genes may provide insight 
into inferior elastic fiber quality in injury models. Inhibition of this set of genes 
may suppress inherent inhibitors or adult elastin expression, inflammation 
associated genes, or oxidative stress resulting in an upregulation of 
elastogenesis quantity and quality. 
 Wound healing models incorporating an injury such as naphthalene 
injection or skin punch biopsy and subsequent elastin regeneration as described 
in the convergent microarray analysis would provide an excellent model for 
testing this group of genes. In vitro culture models of wound healing can also be 
evaluated such as a scratch test assay. A confluent monolayer of elastin 
producing cells (e.g., HFFs, nRASMCs) is first cultured with sufficient time to 
deposit a rich extracellular matrix (~7 days). The monolayer is then disrupted and 
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a group of cells destroyed or displaced by scratching a line through the layer. 
The open gap is then slowly closed during “healing” by migrating cells to cover 
the damaged area. Addition of pharmacological antagonists to Aebp1, Cebpa, 
Cebpb, Hk2, Por, or Ptgis can be added in experimental groups. Some 
antagonists may need to be added under serum starved conditions to increase 
effectiveness. Cell layers can be fixed at 2, 3, 4, and 5 days post injury for 
immunostaining of elastin to assess elastic fiber quality. Cell monolayers can be 
rinsed twice with PBS and fixed in cold methanol for 10 minutes. The monolayers 
can be rinsed 3 times in PBS before incubation in blocking solution of 5% goat 
serum in PBS for 30 minutes at room temperature (RT). Cells can then incubate 
overnight at 4ºC with 1:1000 primary anti-bovine elastin antibody (Dr. Mecham) in 
solution containing 1% goat serum in PBS. Cells can then be washed 3 times 
with PBS before secondary antibody labeling with Alexa Fluor 546-conjugated 
anti-rabbit IgG (Invitrogen, Carlsbad, CA) in 1% goat serum in PBS for 45 
minutes at RT. All unbound antibody will be washed away with 3 washes of PBS 
before mounting in Vectashield mounting medium (Vector Laboratories, 
Burlingame, CA). Elastin fibers can be detected by immunofluorescent imaging 
using a Leica sp5 confocal microscope. 
 An alternate in vitro wound healing model could incorporate Electronic 
Cell-substrate Impedance Sensing (ECIS) plates. A monolayer of cells could be 
cultured as before and injured via high voltage shocks. This model has the 
advantage of reducing injury variability. Immunostaining can be performed as 
described previously.  
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RNA can be extracted and qRT-PCR performed as described previously. This 
model also offers the increased data collection capabilities of impedance as cells 
migrate to cover the gap during the wound healing process. Antagonism to the 
genes identified as upregulated in wound healing of elastogenesis and 
downregulated during developmental elastogenesis may lead to increased elastic 
fiber quality, larger diameter or length of continuous fibers, or increased rate to 
elastic fiber deposition. 
 
7.3.2 MicroRNA Studies 
 miRNAs inhibition may prove to enhance elastin transcription. miR-23 is 
known to restrict cardiac valve formation by inhibiting hyaluronic acid synthase 2 
(Has2) and production of extracellular hyaluronic acid (HA) (282). HA facilitates 
the synthesis and organization of microfibrils (fibrillin), a microfibrillar scaffold 
component for elastic fiber deposition (283). HA has been suggested to play an 
indirect role in elastogenesis through its intimate binding of versican (65) which in 
turn interacts with microfibrillar proteins (fibulin-1, 2) and elastin-associated 
proteins to form higher-order macromolecular structures important for elastic fiber 
assembly (65, 284-286). The highly anionic nature of HA causes soluble 
tropoelastin to assemble and facilitates LOX-mediated crosslinking into an 
insoluble matrix (287, 288), and stabilize elastin fibers against degradation by 
elastase (286, 289, 290). Inhibition of miR-23 may increases HAS2 and HA and 
subsequent elastin may be upregulated. 
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 Alternate miRNAs to target in future studies are miR-133 and miR-590. In 
a study by Shan et al. nicotine produced significant upregulation of expression of 
TGF-β1 and TGF-βRII at the protein level, and a 60–70% decrease in the levels 
of miRNAs miR-133 and miR-590 (291). TGF-β1 and TGF-βRII are targets for 
miR-133 and miR-590 repression so the downregulation of miR-133 and miR-590 
partly accounts for the upregulation of TGF-β1 and TGF-βRII. Additionally, 
transfection of miR-133 or miR-590 into cultured atrial fibroblasts decreased 
TGF-β1 and TGF-βRII levels and collagen content (291). Canonical TGFβ 
signaling has been shown to upregulate elastin in fibroblasts (118, 122) and 
aortic cells (120). Inhibition of miR-133 and miR-590 with anti-sense miRNAs 
may increase levels of TGF-β1 and TGF-βRII and stimulate tropoelastin 
expression. 
Experimentation to assess the effects of miR-23, miR-133, or miR-590 on 
elastogenesis can incorporate antisense oligonucleotides (ASOs) or anti-miRNA 
oligonucleotides (AMOs) to selectively bind target miRNAs or their mRNA 
targets. AMOs are synthetic nucleotides that can be transfected into the cell to 
inhibit miRNA activity. Human foreskin fibroblasts can be plated in 6-well plates 
at 1.0x104 cells/cm2 overnight prior to transfection. For each well, 2.5 µg DNA 
(expression vector, and 2.5µL of PLUS reagent can be incubated with 100 µL 
OptiMEM medium for 15 minutes at room temperature. 2.75 µL Lipofectamine 
can be added to the transfection medium and incubated 30 minutes at room 
temperature. One mixture can be prepared with 0.5 µg GFP plasmid following the 
same procedure; this mixture can be used to transfect a separate well of cells. 
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The plated cells will need to be washed twice with sterile PBS before 2 mL 
OptiMEM medium before the DNA containing transfection mixture was added. 
Transfection efficiency can be assessed at 18 hours by immunofluorescence, 
specifically determining the percentage of cells producing GFP in the GFP-
transfected population. 
 RNA can then be extracted at 12 h, 24 h, 48 h, and 72 h post injury and 
converted to cDNA. Elastin transcription can be assessed by qRT-PCR of elastin 
normalized to a reference gene (B2M) as described in Chapter 4.2. 
 
7.3.3 PPAR delta Regulation 
 QRT-PCR confirmed that PPARα antagonist increased PPAR∂ expression 
in HFFs, possibly as a compensatory response to decreased PPARα activity. 
The next experimentation should attempt to neutralize PPARα-mediated 
upregulation of PPAR∂ and subsequent upregulation on elastin expression. 
PPAR∂ can be eliminated from the PPARα experimentation as an independent 
variable by determining the appropriate concentration of PPAR∂ antagonist to 
add to all experimental samples and control. 
 Preliminary studies assessed the effects of varying concentrations of 
PPAR∂ antagonist on HFFS (1.11, 3.33, 10 and 30 µM) with no significant effects 
on elastin expression (Figure 7.1). The next step in experimentation should be to 
coculture PPARα antagonist with varying concentrations of PPAR∂.  
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 HFFs can be plated at confluence and allowed to attach overnight before 
treatment with 1.11 – 10 µM PPARα antagonist (GW6471, Sigma), and/or 1.11 - 
10 µM PPAR∂ antagonist. 
Different PPAR∂ antagonists 
can be tested as well. 
GSK0660 is a potent PPARβ/δ 
antagonist with a pIC50 of 6.8 
(160 nM). GSK0660 is nearly 
inactive on PPARα and PPARγ 
with IC50s greater than 10 µM. 
Another PPAR∂ antagonist, 
PT-S58, is a PPAR β/δ full antagonist, and a derivative of GSK0660. PT-S58 has 
a three-fold higher affinity for the receptor than GSK0660 and is a potent inhibitor 
of agonist-induced target gene expression. Unlike GSK0660, PT-S58 blocks the 
recruitment co-repressor molecules such as SMRT. 
 Because the antagonists inhibit PPAR∂ activity, QRT-PCR cannot be used 
to validate inhibition by PPAR∂ expression. PPAR∂ activity can be measured by 
immunoblotting. Cell lysates can be fractionated into cytosolic and nuclear 
fractions, and proteins separated by SDS-PAGE, transferred to polyvinylidene 
difluoride membranes and immunoblotted with specific antibodies as described 
by . Protein levels can then be determined by densitometry and PPAR∂ 
antagonist concentration can be optimized to reduce PPAR∂ levels to the same 
as control treated samples. 
 
Figure 7.1. HFFs treated with PPAR∂ did not effect 
elastin expression. HFFs were cultured with 1.11, 
3.33, 10, and 30 µM PPAR∂ antagonist (4 
samples/concentration). 
 154 
 Experimentation can then be performed with coculture of PPARα 
antagonist and PPAR∂ antagonist for 24 h, 48 h, and 72 h prior to RNA extraction 
using Qiagen’s RNeasy RNA extraction kit according to the manufacturer’s 
instructions. RNA integrity can be tested by Bioanalyzer 2100 (Agilent 
Technologies, Palo Alto, CA) and cDNA can be prepared using the iScript cDNA 
synthesis kit (Bio-Rad, Hercules, CA) with 1 µg RNA according to the 
manufacturer’s instructions. cDNA preparations can be diluted 1:10, and 3 µL 
used in 10-µl reactions for qRT-PCR as described previously in 6.2.3 to assess 
elastin expression levels. It is expected that PPAR∂ antagonist treatment will 
reduce PPAR∂ levels back to baseline levels when cocultured with PPARα 
antagonist and elastin expression levels will be decreased. 
 
7.3.4 Elucidation of the Mechanism by which Ganetespib Decreases Elastin 
Expression 
 Future studies could aim to target MEK1/2 or the downstream target of 
ERK 1/2 to decrease Egr-1 signaling. It is also possible that the concentration of 
MEK 1 inhibitor at 50 nM was too low to fully suppress all MEK 1 signaling. A 
concentration increase of MEK inhibitor PD98059 can be performed in a 3-fold 
dose dependent manner at 50 nM, 150 nM, 450 nM, and 1.35 µM PD98059. 
Increased concentration is expected to fully inhibit Mek1 and generate an 
increase in elastin transcription. An alternate inhibitor, U0126, displayed a higher 
affinity for MEK 1 and also inhibits MEK 2. Treatment of HFFs with variable 
concentrations of U0126 may be a more potent inhibitor of the MAPK pathway 
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and potential downstream EGR-1 signaling. Experiments can aim to reverse the 
downregulatory effects of Ganetespib on elastin expression through coculture of 
Ganetespib and U0126. RNA can be extracted at 12 h, 24 h, and 36 h post 
treatment and elastin expression can be quantified by qRT-PCR for elastin. 
 Alternately these experiments can be conducted under serum-free 
conditions along with serum starvation pre-treatment with antagonists in order to 
increase potency of antagonists. 
 
 
7.3.5 Candidate Regulator Screening in 3D HFF-Gelatin Microcarriers Culture 
Model 
 The proof of concept of construction of a 3D tubular structure offers 
advantages to 2D culture models by mimicking the increase in cell-cell contact 
and cell-scaffold contact in the native ECM environment, thus more closely 
evoking native cell responses. An optional culture model to pursue for screening 
of elastogenic regulators is the 3D culture of macroporous gelatin microcarrier 
beads seeding with human foreskin fibroblasts (HFFs). Deposition of elastic 
fibers is seen at 12 days in culture but not at 7 with an increase in culture 
duration also correlating with an increased ease in handling. The rings remained 
solid after 12 days and did not dissociate into fragments.  
 Experimentation aimed to test candidate regulatory genes, transcription 
factors, and miRNAs can utilize the 3D culture model to hopefully obtain more 
substantial effects on elastin deposition and/or rate to elastin deposition. 
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Following the same protocol for HFF seeding of gelatin microcarrier beads as 
described in 6.2.7. Experimental agonists, antagonists, or antisense-miRNAs can 
be added exogenously in the media after plating the HFF-bead complexes into a 
tubular structure. After 5 d, 7 d, and 9 d of treatment, the tubular structures can 
be fixed in ice cold methanol and labeled with anti-elastin antibodies as 
described in 6.2.7. 
It is expected that potential enhancers of elastogenesis may increase the 
rate of elastin deposition, therefore those tubular structures can be fixed for anti-
elastin immunohistochemistry earlier than control rings are expected to display 
intact elastic fibers. Potential inhibitors can be fixed at later timepoints to address 
whether an inhibitor may act to decrease overall elastin deposition or decrease 
rate to elastic fiber formation. Total elastin deposition can be semi-quantitated 
with densitometry of immunoflurorescent images. Additional measurements of 
elastic fiber diameter and length can be used to address overall elastic fiber 
quality. A truly quantitative measurement of total elastin deposition can be 
determined with immunoblotting. Elastin protein can be isolated and purified as 
described by Dr. Mecham (265)wt1. 
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APPENDICES 
Appendix A 
A. Hierarchical Table of 63 Regulated Genes in Convergent Microarray Analysis 
of Processes in which Elastogenesis is a Key Component  
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Table A: Convergent microarray analysis of processes in which elastogenesis is 
a key component identified 63 genes as potential regulators of elastogenesis 
which are depicted in a hierarchal Table A-2 from genes whose expression 
pattern is most similar to elastin descending to genes whose expression pattern 
is most different from elastin across all 5 processes. An “X” in the table is 
representative of having met the criteria in Table A-1. 
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Appendix B 
Figure B: Heatmaps of Significantly Regulated Genes in Response to Versican 
V3 Expression in Vascular Smooth Muscle Cells (VSMCs) 
 
Figure B-1: The 3 sample pair analysis of yielded 521 genes significantly 
regulated in response to V3 with a fold change > 1.5 and a paired Student’s T-
test p<0.05. The false discovery rate (FDR) is 1.7%. Increasing the fold change 
to 2.0 decreases the number of significant genes to 247 with an FDR of 0.0%. 
A B 
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Appendix C 
Figure C: Versican effects on TGFβ Signaling 
 
Figure C: The 3 sample pair analysis yielded 8 significantly regulated genes in 
the TGFβ pathway. Increases of expression are seen in ROCK1 and TGFβ3 
while decreases in the expression of Decorin, Comp, Bmp6, TGFβ1, Fst, and 
InhbB. 
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Appendix D 
 
Figure D. Human Elastin Splice Variants 
 
 
Figure D. The human elastin gene mRNA is alternately spliced into 5 different 
variants. Elastogenic cells produce multiple forms of tropoelastin mRNA within 
the same tissue, suggesting there may not be a functional or architectural 
difference between isoforms (292). The isoforms vary in size from 692 – 724 
translated amino acid residues. The exons code for either hydrophobic (Variable) 
segments or lysine-rich crosslinkable (conserved) segments of elastin. 
 
  
 162 
 
References 
 
1. B. Chailley-Heu, O. Boucherat, A. M. Barlier-Mur, J. R. Bourbon, FGF-18 
is upregulated in the postnatal rat lung and enhances elastogenesis in 
myofibroblasts. American journal of physiology. Lung cellular and 
molecular physiology 288, L43 (Jan, 2005). 
2. A. a. L. R. Robert, Ed., Biology and Pathology of Elastic Tissues,  (1980). 
3. E. D. Hay, The cell biology of the extracellular matrix.  (Platinum Press, 
Ney York, 1991). 
4. S. S. Ahanchi, N. D. Tsihlis, M. R. Kibbe, The role of nitric oxide in the 
pathophysiology of intimal hyperplasia. Journal of vascular surgery 45 
Suppl A, A64 (Jun, 2007). 
5. W. H. Pearce, V. P. Shively, Abdominal aortic aneurysm as a complex 
multifactorial disease: interactions of polymorphisms of inflammatory 
genes, features of autoimmunity, and current status of MMPs. Ann N Y 
Acad Sci 1085, 117 (Nov, 2006). 
6. F. Sato et al., Distinct steps of cross-linking, self-association, and 
maturation of tropoelastin are necessary for elastic fiber formation. Journal 
of molecular biology 369, 841 (Jun 8, 2007). 
7. M. J. Rock et al., Molecular basis of elastic fiber formation. Critical 
interactions and a tropoelastin-fibrillin-1 cross-link. The Journal of 
biological chemistry 279, 23748 (May 28, 2004). 
8. T. Nakamura et al., Fibulin-5/DANCE is essential for elastogenesis in vivo. 
Nature 415, 171 (Jan 10, 2002). 
9. H. Yanagisawa et al., Fibulin-5 is an elastin-binding protein essential for 
elastic fibre development in vivo. Nature 415, 168 (Jan 10, 2002). 
10. P. R. Parks WC, Lee KA, Mecham R. Elastin, Elastin. Advances in Cell 
Molecular Biology 6,  (1993). 
11. A. J. Bank et al., Contribution of collagen, elastin, and smooth muscle to in 
vivo human brachial artery wall stress and elastic modulus. Circulation 94, 
3263 (Dec 15, 1996). 
12. E. W. Raines, The extracellular matrix can regulate vascular cell 
migration, proliferation, and survival: relationships to vascular disease. 
International journal of experimental pathology 81, 173 (Jun, 2000). 
 163 
13. Y. Kimura, H. Okuda, Inhibitory effects of soluble elastin on intraplatelet 
free calcium concentration. Thrombosis research 52, 61 (Oct 1, 1988). 
14. Z. Urban et al., Connection between elastin haploinsufficiency and 
increased cell proliferation in patients with supravalvular aortic stenosis 
and Williams-Beuren syndrome. Am J Hum Genet 71, 30 (Jul, 2002). 
15. Z. Urban et al., Isolated supravalvular aortic stenosis: functional 
haploinsufficiency of the elastin gene as a result of nonsense-mediated 
decay. Hum Genet 106, 577 (Jun, 2000). 
16. C. A. Morris, C. B. Mervis, Williams syndrome and related disorders. 
Annual review of genomics and human genetics 1, 461 (2000). 
17. F. Ringpfeil, Selected disorders of connective tissue: pseudoxanthoma 
elasticum, cutis laxa, and lipoid proteinosis. Clin Dermatol 23, 41 (Jan-
Feb, 2005). 
18. B. Loeys et al., Homozygosity for a missense mutation in fibulin-5 (FBLN5) 
results in a severe form of cutis laxa. Human molecular genetics 11, 2113 
(Sep 1, 2002). 
19. P. N. Robinson et al., The molecular genetics of Marfan syndrome and 
related disorders. J Med Genet 43, 769 (Oct, 2006). 
20. H. C. Dietz, B. Loeys, L. Carta, F. Ramirez, Recent progress towards a 
molecular understanding of Marfan syndrome. Am J Med Genet C Semin 
Med Genet 139C, 4 (Nov 15, 2005). 
21. R. Mecham, E. Davis, Elastic fiber structure and assembly. P. D. 
Yurchenco, Birk, D.E. and Mecham, R.P., eds., Ed., In Extracellular Matrix 
Assembly and Structure (Academic Press, New York, USA, 1994). 
22. C. M. Kielty, M. J. Sherratt, A. Marson, C. Baldock, Fibrillin microfibrils. 
Adv Protein Chem 70, 405 (2005). 
23. S. M. Mithieux, A. S. Weiss, Elastin. Adv Protein Chem 70, 437 (2005). 
24. C. M. Kielty, M. J. Sherratt, C. A. Shuttleworth, Elastic fibres. Journal of 
cell science 115, 2817 (Jul 15, 2002). 
25. J. Rosenbloom, W. R. Abrams, R. Mecham, Extracellular matrix 4: the 
elastic fiber. FASEB J 7, 1208 (Oct, 1993). 
26. L. Debelle, A. J. Alix, The structures of elastins and their function. 
Biochimie 81, 981 (Oct, 1999). 
 164 
27. E. H. Sonnenblick, The structural basis and importance of restoring forces 
and elastic recoil for the filling of the heart. European heart journal Suppl 
A, 107 (1980). 
28. K. Akhtar et al., Oxidative and nitrosative modifications of tropoelastin 
prevent elastic fiber assembly in vitro. The Journal of biological chemistry 
285, 37396 (Nov 26, 2010). 
29. F. Opitz et al., Tissue engineering of ovine aortic blood vessel substitutes 
using applied shear stress and enzymatically derived vascular smooth 
muscle cells. Ann Biomed Eng 32, 212 (Feb, 2004). 
30. L. Chen et al., Positional differences in the wound transcriptome of skin 
and oral mucosa. BMC genomics 11, 471. 
31. J. C. Snyder, A. C. Zemke, B. R. Stripp, Reparative capacity of airway 
epithelium impacts deposition and remodeling of extracellular matrix. Am J 
Respir Cell Mol Biol 40, 633 (Jun, 2009). 
32. C. Kuhn, S. Y. Yu, M. Chraplyvy, H. E. Linder, R. M. Senior, The induction 
of emphysema with elastase. II. Changes in connective tissue. Lab Invest 
34, 372 (Apr, 1976). 
33. Y. Fukuda, Y. Masuda, M. Ishizaki, Y. Masugi, V. J. Ferrans, 
Morphogenesis of abnormal elastic fibers in lungs of patients with 
panacinar and centriacinar emphysema. Human pathology 20, 652 (Jul, 
1989). 
34. C. R. Hoff, D. R. Perkins, J. M. Davidson, Elastin gene expression is 
upregulated during pulmonary fibrosis. Connect Tissue Res 40, 145 
(1999). 
35. J. M. Maki et al., Lysyl oxidase is essential for normal development and 
function of the respiratory system and for the integrity of elastic and 
collagen fibers in various tissues. The American journal of pathology 167, 
927 (Oct, 2005). 
36. I. K. Hornstra et al., Lysyl oxidase is required for vascular and 
diaphragmatic development in mice. The Journal of biological chemistry 
278, 14387 (Apr 18, 2003). 
37. P. J. McLaughlin et al., Targeted disruption of fibulin-4 abolishes 
elastogenesis and causes perinatal lethality in mice. Molecular and 
cellular biology 26, 1700 (Mar, 2006). 
38. M. J. Fazio et al., Human elastin gene: new evidence for localization to the 
long arm of chromosome 7. Am J Hum Genet 48, 696 (Apr, 1991). 
 165 
39. J. M. Davidson, Smad about elastin regulation. Am J Respir Cell Mol Biol 
26, 164 (Feb, 2002). 
40. Z. Indik et al., Alternative splicing of human elastin mRNA indicated by 
sequence analysis of cloned genomic and complementary DNA. 
Proceedings of the National Academy of Sciences of the United States of 
America 84, 5680 (Aug, 1987). 
41. L. Debelle, A. M. Tamburro, Elastin: molecular description and function. Int 
J Biochem Cell Biol 31, 261 (Feb, 1999). 
42. B. Vrhovski, A. S. Weiss, Biochemistry of tropoelastin. Eur J Biochem 258, 
1 (Nov 15, 1998). 
43. J. Rosenbloom, Elastin: relation of protein and gene structure to disease. 
Lab Invest 51, 605 (Dec, 1984). 
44. D. D. Carson, Extracellular matrix: forum introduction. Reproductive 
biology and endocrinology : RB&E 2, 1 (Jan 7, 2004). 
45. J. D. Hood, D. A. Cheresh, Role of integrins in cell invasion and migration. 
Nature reviews. Cancer 2, 91 (Feb, 2002). 
46. C. C. Lynch, L. M. Matrisian, Matrix metalloproteinases in tumor-host cell 
communication. Differentiation; research in biological diversity 70, 561 
(Dec, 2002). 
47. M. Larsen, V. V. Artym, J. A. Green, K. M. Yamada, The matrix 
reorganized: extracellular matrix remodeling and integrin signaling. 
Current opinion in cell biology 18, 463 (Oct, 2006). 
48. L. Alberts J, Raff, Roberts, Walter, Molecular Biology of The Cell. 4th ed.  
(Garland Science, 2002). 
49. R. L. Robert AM, in Frontiers of Matrix Biology, S. Karger, Ed. (1980), vol. 
9. 
50. A. Hinek, A. V. Pshezhetsky, M. von Itzstein, B. Starcher, Lysosomal 
sialidase (neuraminidase-1) is targeted to the cell surface in a multiprotein 
complex that facilitates elastic fiber assembly. The Journal of biological 
chemistry 281, 3698 (Feb 10, 2006). 
51. F. Antonicelli, G. Bellon, S. Lorimier, W. Hornebeck, Role of the elastin 
receptor complex (S-Gal/Cath-A/Neu-1) in skin repair and regeneration. 
Wound repair and regeneration : official publication of the Wound Healing 
Society [and] the European Tissue Repair Society 17, 631 (Sep-Oct, 
2009). 
 166 
52. Y. Tatano et al., Elastogenesis in cultured dermal fibroblasts from patients 
with lysosomal beta-galactosidase, protective protein/cathepsin A and 
neuraminidase-1 deficiencies. J Med Invest 53, 103 (Feb, 2006). 
53. A. Hinek, R. P. Mecham, F. Keeley, M. Rabinovitch, Impaired elastin fiber 
assembly related to reduced 67-kD elastin-binding protein in fetal lamb 
ductus arteriosus and in cultured aortic smooth muscle cells treated with 
chondroitin sulfate. J Clin Invest 88, 2083 (Dec, 1991). 
54. R. P. Mecham, Overview of extracellular matrix. Current protocols in cell 
biology / editorial board, Juan S. Bonifacino ... [et al.] Chapter 10, Unit 10 
1 (May, 2001). 
55. L. Robert, Aging of connective tissue. Mechanisms of ageing and 
development 14, 273 (Nov-Dec, 1980). 
56. A. Tsamis, J. T. Krawiec, D. A. Vorp, Elastin and collagen fibre 
microstructure of the human aorta in ageing and disease: a review. 
Journal of the Royal Society, Interface / the Royal Society 10, 20121004 
(Jun 6, 2013). 
57. N. Gundiah, B. R. M, A. P. L, Determination of strain energy function for 
arterial elastin: Experiments using histology and mechanical tests. Journal 
of biomechanics 40, 586 (2007). 
58. C. G. Cho et al., A study of the solar effect on actinic keratoses by 
quantification of elastic fibres using an image analysis system. Acta 
dermato-venereologica 79, 278 (Jul, 1999). 
59. S. L. Chapman et al., Fibulin-2 and fibulin-5 cooperatively function to form 
the internal elastic lamina and protect from vascular injury. 
Arteriosclerosis, thrombosis, and vascular biology 30, 68 (Jan, 2010). 
60. R. Huang et al., Inhibition of versican synthesis by antisense alters smooth 
muscle cell phenotype and induces elastic fiber formation in vitro and in 
neointima after vessel injury. Circulation research 98, 370 (Feb 17, 2006). 
61. J. Y. Hwang et al., Retrovirally mediated overexpression of 
glycosaminoglycan-deficient biglycan in arterial smooth muscle cells 
induces tropoelastin synthesis and elastic fiber formation in vitro and in 
neointimae after vascular injury. Am J Pathol 173, 1919 (Dec, 2008). 
62. M. J. Merrilees et al., Changes in elastin, elastin binding protein and 
versican in alveoli in chronic obstructive pulmonary disease. Respir Res 9, 
41 (2008). 
63. S. Privitera, C. A. Prody, J. W. Callahan, A. Hinek, The 67-kDa 
enzymatically inactive alternatively spliced variant of beta-galactosidase is 
 167 
identical to the elastin/laminin-binding protein. J Biol Chem 273, 6319 (Mar 
13, 1998). 
64. A. Hinek, S. E. Wilson, Impaired elastogenesis in Hurler disease: 
dermatan sulfate accumulation linked to deficiency in elastin-binding 
protein and elastic fiber assembly. Am J Pathol 156, 925 (Mar, 2000). 
65. T. N. Wight, Versican: a versatile extracellular matrix proteoglycan in cell 
biology. Current opinion in cell biology 14, 617 (Oct, 2002). 
66. M. Ikeda et al., Elastic fiber assembly is disrupted by excessive 
accumulation of chondroitin sulfate in the human dermal fibrotic disease, 
keloid. Biochem Biophys Res Commun 390, 1221 (Dec 25, 2009). 
67. A. Hinek, K. R. Braun, K. Liu, Y. Wang, T. N. Wight, Retrovirally mediated 
overexpression of versican v3 reverses impaired elastogenesis and 
heightened proliferation exhibited by fibroblasts from Costello syndrome 
and Hurler disease patients. The American journal of pathology 164, 119 
(Jan, 2004). 
68. M. J. Merrilees et al., Retrovirally mediated overexpression of versican v3 
by arterial smooth muscle cells induces tropoelastin synthesis and elastic 
fiber formation in vitro and in neointima after vascular injury. Circulation 
research 90, 481 (Mar 8, 2002). 
69. P. A. Keire et al., Expression of versican isoform V3 in the absence of 
ascorbate improves elastogenesis in engineered vascular constructs. 
Tissue Eng Part A 16, 501 (Feb, 2010). 
70. R. L. Robert AM, S. Karger, Ed. (1980). 
71. W. B. Keeling, P. A. Armstrong, P. A. Stone, D. F. Bandyk, M. L. Shames, 
An overview of matrix metalloproteinases in the pathogenesis and 
treatment of abdominal aortic aneurysms. Vascular and endovascular 
surgery 39, 457 (Nov-Dec, 2005). 
72. B. S. Brooke, A. Bayes-Genis, D. Y. Li, New insights into elastin and 
vascular disease. Trends in cardiovascular medicine 13, 176 (Jul, 2003). 
73. U. R. Rodgers, A. S. Weiss, Cellular interactions with elastin. Pathol Biol 
(Paris) 53, 390 (Sep, 2005). 
74. T. M. Seasholtz, M. Majumdar, J. H. Brown, Rho as a mediator of G 
protein-coupled receptor signaling. Mol Pharmacol 55, 949 (Jun, 1999). 
75. S. K. Karnik et al., Elastin induces myofibrillogenesis via a specific 
domain, VGVAPG. Matrix Biol 22, 409 (Sep, 2003). 
 168 
76. E. A. Thomas, J. R. Matli, J. L. Hu, M. J. Carson, J. G. Sutcliffe, Pertussis 
toxin treatment prevents 5-HT(5a) receptor-mediated inhibition of cyclic 
AMP accumulation in rat C6 glioma cells. Journal of neuroscience 
research 61, 75 (Jul 1, 2000). 
77. R. Amar, [Breast morphology, or the breast as part of the general 
morphology of the trunk. Method for the localization of the nipples]. 
Annales de chirurgie plastique 25, 249 (1980). 
78. P. R. Parks WC, Lee KA, Mecham R., Elastin. Advances in Cell Molecular 
Biology 6, 133 (1993). 
79. A. Krettek, G. K. Sukhova, P. Libby, Elastogenesis in human arterial 
disease: a role for macrophages in disordered elastin synthesis. 
Arteriosclerosis, thrombosis, and vascular biology 23, 582 (Apr 1, 2003). 
80. H. Wolinsky, S. Glagov, A lamellar unit of aortic medial structure and 
function in mammals. Circulation research 20, 99 (Jan, 1967). 
81. U. Hedin, J. Roy, P. K. Tran, K. Lundmark, A. Rahman, Control of smooth 
muscle cell proliferation--the role of the basement membrane. Thrombosis 
and haemostasis 82 Suppl 1, 23 (Sep, 1999). 
82. C. M. Spofford, W. M. Chilian, The elastin-laminin receptor functions as a 
mechanotransducer in vascular smooth muscle. American journal of 
physiology. Heart and circulatory physiology 280, H1354 (Mar, 2001). 
83. C. M. Spofford, W. M. Chilian, Mechanotransduction via the elastin-laminin 
receptor (ELR) in resistance arteries. Journal of biomechanics 36, 645 
(May, 2003). 
84. A. Patel, B. Fine, M. Sandig, K. Mequanint, Elastin biosynthesis: The 
missing link in tissue-engineered blood vessels. Cardiovasc Res 71, 40 
(Jul 1, 2006). 
85. U. A. Stock et al., Dynamics of extracellular matrix production and 
turnover in tissue engineered cardiovascular structures. Journal of cellular 
biochemistry 81, 220 (Mar 26, 2001). 
86. J. L. Long, R. T. Tranquillo, Elastic fiber production in cardiovascular 
tissue-equivalents. Matrix Biol 22, 339 (Jun, 2003). 
87. M. H. Swee, W. C. Parks, R. A. Pierce, Developmental regulation of 
elastin production. Expression of tropoelastin pre-mRNA persists after 
down-regulation of steady-state mRNA levels. The Journal of biological 
chemistry 270, 14899 (Jun 23, 1995). 
 169 
88. J. Stitzel et al., Controlled fabrication of a biological vascular substitute. 
Biomaterials 27, 1088 (Mar, 2006). 
89. S. H. Lee et al., Elastic biodegradable poly(glycolide-co-caprolactone) 
scaffold for tissue engineering. Journal of biomedical materials research. 
Part A 66, 29 (Jul 1, 2003). 
90. P. Chen, E. Marsilio, R. H. Goldstein, I. V. Yannas, M. Spector, Formation 
of lung alveolar-like structures in collagen-glycosaminoglycan scaffolds in 
vitro. Tissue Eng 11, 1436 (Sep-Oct, 2005). 
91. R. A. Pierce, T. J. Mariani, R. M. Senior, Elastin in lung development and 
disease. Ciba Found Symp 192, 199 (1995). 
92. M. C. Bruce, C. E. Honaker, Transcriptional regulation of tropoelastin 
expression in rat lung fibroblasts: changes with age and hyperoxia. The 
American journal of physiology 274, L940 (Jun, 1998). 
93. B. A. Kozel et al., Genetic modifiers of cardiovascular phenotype caused 
by elastin haploinsufficiency act by extrinsic noncomplementation. The 
Journal of biological chemistry 286, 44926 (Dec 30, 2011). 
94. B. Starcher et al., Neuraminidase-1 is required for the normal assembly of 
elastic fibers. American journal of physiology. Lung cellular and molecular 
physiology 295, L637 (Oct, 2008). 
95. W. C. Parks, H. Secrist, L. C. Wu, R. P. Mecham, Developmental 
regulation of tropoelastin isoforms. The Journal of biological chemistry 
263, 4416 (Mar 25, 1988). 
96. K. A. Holbrook, P. H. Byers, Structural abnormalities in the dermal 
collagen and elastic matrix from the skin of patients with inherited 
connective tissue disorders. The Journal of investigative dermatology 79 
Suppl 1, 7s (Jul, 1982). 
97. G. C. Sephel, A. Sturrock, M. G. Giro, J. M. Davidson, Increased elastin 
production by progeria skin fibroblasts is controlled by the steady-state 
levels of elastin mRNA. The Journal of investigative dermatology 90, 643 
(May, 1988). 
98. M. D. Botney et al., Extracellular matrix protein gene expression in 
atherosclerotic hypertensive pulmonary arteries. The American journal of 
pathology 140, 357 (Feb, 1992). 
99. E. F. Bernstein et al., Enhanced elastin and fibrillin gene expression in 
chronically photodamaged skin. The Journal of investigative dermatology 
103, 182 (Aug, 1994). 
 170 
100. K. R. Stenmark, A. G. Durmowicz, J. D. Roby, R. P. Mecham, W. C. 
Parks, Persistence of the fetal pattern of tropoelastin gene expression in 
severe neonatal bovine pulmonary hypertension. J Clin Invest 93, 1234 
(Mar, 1994). 
101. M. Yamamoto et al., Increase in elastin gene expression and protein 
synthesis in arterial smooth muscle cells derived from patients with 
Moyamoya disease. Stroke; a journal of cerebral circulation 28, 1733 
(Sep, 1997). 
102. G. Deslee et al., Elastin expression in very severe human COPD. The 
European respiratory journal 34, 324 (Aug, 2009). 
103. T. Rangasamy et al., Cigarette smoke-induced emphysema in A/J mice is 
associated with pulmonary oxidative stress, apoptosis of lung cells, and 
global alterations in gene expression. American journal of physiology. 
Lung cellular and molecular physiology 296, L888 (Jun, 2009). 
104. J. Vila Torres, M. Pineda Marfa, M. A. Gonzalez Ensenat, J. Lloreta Trull, 
Pathology of the elastic tissue of the skin in Costello syndrome. An image 
analysis study using mathematical morphology. Analytical and quantitative 
cytology and histology / the International Academy of Cytology [and] 
American Society of Cytology 16, 421 (Dec, 1994). 
105. E. Morava, M. Guillard, D. J. Lefeber, R. A. Wevers, Autosomal recessive 
cutis laxa syndrome revisited. Eur J Hum Genet 17, 1099 (Sep, 2009). 
106. M. C. Zweers et al., Deficiency of tenascin-X causes abnormalities in 
dermal elastic fiber morphology. The Journal of investigative dermatology 
122, 885 (Apr, 2004). 
107. H. C. Dietz, R. P. Mecham, Mouse models of genetic diseases resulting 
from mutations in elastic fiber proteins. Matrix Biol 19, 481 (Nov, 2000). 
108. J. E. Wagenseil, R. P. Mecham, New insights into elastic fiber assembly. 
Birth Defects Res C Embryo Today 81, 229 (Dec, 2007). 
109. H. Yanagisawa, E. C. Davis, Unraveling the mechanism of elastic fiber 
assembly: The roles of short fibulins. Int J Biochem Cell Biol 42, 1084 (Jul, 
2010). 
110. J. P. Annes, J. S. Munger, D. B. Rifkin, Making sense of latent TGFbeta 
activation. Journal of cell science 116, 217 (Jan 15, 2003). 
111. P. J. Sime, Z. Xing, F. L. Graham, K. G. Csaky, J. Gauldie, Adenovector-
mediated gene transfer of active transforming growth factor-beta1 induces 
prolonged severe fibrosis in rat lung. J Clin Invest 100, 768 (Aug 15, 
1997). 
 171 
112. J. Dai et al., Overexpression of transforming growth factor-beta1 stabilizes 
already-formed aortic aneurysms: a first approach to induction of 
functional healing by endovascular gene therapy. Circulation 112, 1008 
(Aug 16, 2005). 
113. V. M. Kahari, Y. Q. Chen, M. M. Bashir, J. Rosenbloom, J. Uitto, Tumor 
necrosis factor-alpha down-regulates human elastin gene expression. 
Evidence for the role of AP-1 in the suppression of promoter activity. The 
Journal of biological chemistry 267, 26134 (Dec 25, 1992). 
114. J. M. Liu, J. M. Davidson, The elastogenic effect of recombinant 
transforming growth factor-beta on porcine aortic smooth muscle cells. 
Biochem Biophys Res Commun 154, 895 (Aug 15, 1988). 
115. S. E. McGowan, R. McNamer, Transforming growth factor-beta increases 
elastin production by neonatal rat lung fibroblasts. Am J Respir Cell Mol 
Biol 3, 369 (Oct, 1990). 
116. M. C. Zhang, M. Giro, D. Quaglino, Jr., J. M. Davidson, Transforming 
growth factor-beta reverses a posttranscriptional defect in elastin 
synthesis in a cutis laxa skin fibroblast strain. J Clin Invest 95, 986 (Mar, 
1995). 
117. Y. Katsuta et al., Fibulin-5 accelerates elastic fibre assembly in human 
skin fibroblasts. Exp Dermatol 17, 837 (Oct, 2008). 
118. P. P. Kuang et al., Activation of elastin transcription by transforming 
growth factor-beta in human lung fibroblasts. American journal of 
physiology. Lung cellular and molecular physiology 292, L944 (Apr, 2007). 
119. S. D. Katchman, S. Hsu-Wong, I. Ledo, M. Wu, J. Uitto, Transforming 
growth factor-beta up-regulates human elastin promoter activity in 
transgenic mice. Biochem Biophys Res Commun 203, 485 (Aug 30, 
1994). 
120. V. Marigo, D. Volpin, G. M. Bressan, Regulation of the human elastin 
promoter in chick embryo cells. Tissue-specific effect of TGF-beta. 
Biochimica et biophysica acta 1172, 31 (Feb 20, 1993). 
121. V. M. Kahari et al., Transforming growth factor-beta up-regulates elastin 
gene expression in human skin fibroblasts. Evidence for post-
transcriptional modulation. Lab Invest 66, 580 (May, 1992). 
122. S. E. McGowan, Influences of endogenous and exogenous TGF-beta on 
elastin in rat lung fibroblasts and aortic smooth muscle cells. The 
American journal of physiology 263, L257 (Aug, 1992). 
 172 
123. V. Marigo, D. Volpin, G. Vitale, G. M. Bressan, Identification of a TGF-beta 
responsive element in the human elastin promoter. Biochem Biophys Res 
Commun 199, 1049 (Mar 15, 1994). 
124. U. Kucich, J. C. Rosenbloom, W. R. Abrams, M. M. Bashir, J. 
Rosenbloom, Stabilization of elastin mRNA by TGF-beta: initial 
characterization of signaling pathway. Am J Respir Cell Mol Biol 17, 10 
(Jul, 1997). 
125. M. Zhang, R. A. Pierce, H. Wachi, R. P. Mecham, W. C. Parks, An open 
reading frame element mediates posttranscriptional regulation of 
tropoelastin and responsiveness to transforming growth factor beta1. 
Molecular and cellular biology 19, 7314 (Nov, 1999). 
126. Y. Hew, C. Lau, Z. Grzelczak, F. W. Keeley, Identification of a GA-rich 
sequence as a protein-binding site in the 3'-untranslated region of chicken 
elastin mRNA with a potential role in the developmental regulation of 
elastin mRNA stability. The Journal of biological chemistry 275, 24857 
(Aug 11, 2000). 
127. J. E. Lee, J. Y. Lee, J. Wilusz, B. Tian, C. J. Wilusz, Systematic analysis 
of cis-elements in unstable mRNAs demonstrates that CUGBP1 is a key 
regulator of mRNA decay in muscle cells. PLoS One 5, e11201 (2010). 
128. U. Kucich, J. C. Rosenbloom, W. R. Abrams, J. Rosenbloom, 
Transforming growth factor-beta stabilizes elastin mRNA by a pathway 
requiring active Smads, protein kinase C-delta, and p38. Am J Respir Cell 
Mol Biol 26, 183 (Feb, 2002). 
129. E. van Rooij et al., Dysregulation of microRNAs after myocardial infarction 
reveals a role of miR-29 in cardiac fibrosis. Proceedings of the National 
Academy of Sciences of the United States of America 105, 13027 (Sep 2, 
2008). 
130. R. A. Boon et al., MicroRNA-29 in aortic dilation: implications for aneurysm 
formation. Circulation research 109, 1115 (Oct 28, 2011). 
131. C. E. Ott et al., MicroRNAs differentially expressed in postnatal aortic 
development downregulate elastin via 3' UTR and coding-sequence 
binding sites. PLoS One 6, e16250 (2011). 
132. P. Zhang et al., Inhibition of microRNA-29 enhances elastin levels in cells 
haploinsufficient for elastin and in bioengineered vessels--brief report. 
Arteriosclerosis, thrombosis, and vascular biology 32, 756 (Mar, 2012). 
133. B. Joddar, A. Ramamurthi, Elastogenic effects of exogenous hyaluronan 
oligosaccharides on vascular smooth muscle cells. Biomaterials 27, 5698 
(Nov, 2006). 
 173 
134. C. R. Kothapalli, C. E. Gacchina, A. Ramamurthi, Utility of hyaluronan 
oligomers and transforming growth factor-beta1 factors for elastic matrix 
regeneration by aneurysmal rat aortic smooth muscle cells. Tissue Eng 
Part A 15, 3247 (Nov, 2009). 
135. B. P. Toole, Hyaluronan-CD44 Interactions in Cancer: Paradoxes and 
Possibilities. Clinical cancer research : an official journal of the American 
Association for Cancer Research 15, 7462 (Dec 15, 2009). 
136. S. J. DiCamillo et al., Neutrophil elastase-initiated EGFR/MEK/ERK 
signaling counteracts stabilizing effect of autocrine TGF-beta on 
tropoelastin mRNA in lung fibroblasts. American journal of physiology. 
Lung cellular and molecular physiology 291, L232 (Aug, 2006). 
137. C. M. Alvira et al., Inhibition of transforming growth factor beta worsens 
elastin degradation in a murine model of Kawasaki disease. The American 
journal of pathology 178, 1210 (Mar, 2011). 
138. S. Akool el et al., Nitric oxide induces TIMP-1 expression by activating the 
transforming growth factor beta-Smad signaling pathway. The Journal of 
biological chemistry 280, 39403 (Nov 25, 2005). 
139. S. M. Kutz et al., TGF-beta 1-induced PAI-1 expression is E box/USF-
dependent and requires EGFR signaling. Experimental cell research 312, 
1093 (Apr 15, 2006). 
140. J. A. Foster, M. L. Miller, M. R. Benedict, R. A. Richmann, C. B. Rich, 
Evidence for insulin-like growth factor-I regulation of chick aortic 
elastogenesis. Matrix 9, 328 (Aug, 1989). 
141. C. B. Rich, H. D. Goud, M. Bashir, J. Rosenbloom, J. A. Foster, 
Developmental regulation of aortic elastin gene expression involves 
disruption of an IGF-I sensitive repressor complex. Biochem Biophys Res 
Commun 196, 1316 (Nov 15, 1993). 
142. K. J. Conn et al., Insulin-like growth factor-I regulates transcription of the 
elastin gene through a putative retinoblastoma control element. A role for 
Sp3 acting as a repressor of elastin gene transcription. The Journal of 
biological chemistry 271, 28853 (Nov 15, 1996). 
143. D. B. Badesch, P. D. Lee, W. C. Parks, K. R. Stenmark, Insulin-like growth 
factor I stimulates elastin synthesis by bovine pulmonary arterial smooth 
muscle cells. Biochem Biophys Res Commun 160, 382 (Apr 14, 1989). 
144. C. B. Rich et al., IGF-I regulation of elastogenesis: comparison of aortic 
and lung cells. The American journal of physiology 263, L276 (Aug, 1992). 
 174 
145. B. L. Wolfe et al., Insulin-like growth factor-I regulates transcription of the 
elastin gene. The Journal of biological chemistry 268, 12418 (Jun 15, 
1993). 
146. D. E. Jensen, C. B. Rich, A. J. Terpstra, S. R. Farmer, J. A. Foster, 
Transcriptional regulation of the elastin gene by insulin-like growth factor-I 
involves disruption of Sp1 binding. Evidence for the role of Rb in mediating 
Sp1 binding in aortic smooth muscle cells. The Journal of biological 
chemistry 270, 6555 (Mar 24, 1995). 
147. S. Sen et al., Retinoblastoma protein modulates the inverse relationship 
between cellular proliferation and elastogenesis. The Journal of biological 
chemistry 286, 36580 (Oct 21, 2011). 
148. I. Carreras, C. B. Rich, M. P. Panchenko, J. A. Foster, Basic fibroblast 
growth factor decreases elastin gene transcription in aortic smooth muscle 
cells. Journal of cellular biochemistry 85, 592 (2002). 
149. C. B. Rich, M. A. Nugent, P. Stone, J. A. Foster, Elastase release of basic 
fibroblast growth factor in pulmonary fibroblast cultures results in down-
regulation of elastin gene transcription. A role for basic fibroblast growth 
factor in regulating lung repair. The Journal of biological chemistry 271, 
23043 (Sep 20, 1996). 
150. M. Weinstein, X. Xu, K. Ohyama, C. X. Deng, FGFR-3 and FGFR-4 
function cooperatively to direct alveogenesis in the murine lung. 
Development 125, 3615 (Sep, 1998). 
151. J. Gao, T. W. Jordan, T. W. Cutress, Immunolocalization of basic 
fibroblast growth factor (bFGF) in human periodontal ligament (PDL) 
tissue. J Periodontal Res 31, 260 (May, 1996). 
152. A. Palmon et al., Basic fibroblast growth factor suppresses tropoelastin 
gene expression in cultured human periodontal fibroblasts. J Periodontal 
Res 36, 65 (Apr, 2001). 
153. C. B. Rich, M. R. Fontanilla, M. Nugent, J. A. Foster, Basic fibroblast 
growth factor decreases elastin gene transcription through an AP1/cAMP-
response element hybrid site in the distal promoter. The Journal of 
biological chemistry 274, 33433 (Nov 19, 1999). 
154. I. Carreras et al., Functional components of basic fibroblast growth factor 
signaling that inhibit lung elastin gene expression. American journal of 
physiology. Lung cellular and molecular physiology 281, L766 (Oct, 2001). 
155. M. Takamiya, K. Saigusa, N. Nakayashiki, Y. Aoki, Studies on mRNA 
expression of basic fibroblast growth factor in wound healing for wound 
 175 
age determination. International journal of legal medicine 117, 46 (Feb, 
2003). 
156. J. M. Davidson, O. Zoia, J. M. Liu, Modulation of transforming growth 
factor-beta 1 stimulated elastin and collagen production and proliferation 
in porcine vascular smooth muscle cells and skin fibroblasts by basic 
fibroblast growth factor, transforming growth factor-alpha, and insulin-like 
growth factor-I. J Cell Physiol 155, 149 (Apr, 1993). 
157. H. H. Hong, P. C. Trackman, Cytokine regulation of gingival fibroblast lysyl 
oxidase, collagen, and elastin. Journal of periodontology 73, 145 (Feb, 
2002). 
158. W. Li et al., Lysyl oxidase oxidizes basic fibroblast growth factor and 
inactivates its mitogenic potential. Journal of cellular biochemistry 88, 152 
(Jan 1, 2003). 
159. K. Thompson, M. Rabinovitch, Exogenous leukocyte and endogenous 
elastases can mediate mitogenic activity in pulmonary artery smooth 
muscle cells by release of extracellular-matrix bound basic fibroblast 
growth factor. J Cell Physiol 166, 495 (Mar, 1996). 
160. N. S. Gibran, F. F. Isik, D. M. Heimbach, D. Gordon, Basic fibroblast 
growth factor in the early human burn wound. The Journal of surgical 
research 56, 226 (Mar, 1994). 
161. C. Bertram, R. Hass, Cellular senescence of human mammary epithelial 
cells (HMEC) is associated with an altered MMP-7/HB-EGF signaling and 
increased formation of elastin-like structures. Mechanisms of ageing and 
development 130, 657 (Oct, 2009). 
162. J. Liu et al., Heparin-binding EGF-like growth factor regulates elastin and 
FGF-2 expression in pulmonary fibroblasts. American journal of 
physiology. Lung cellular and molecular physiology 285, L1106 (Nov, 
2003). 
163. V. Moulin, Growth factors in skin wound healing. European journal of cell 
biology 68, 1 (Sep, 1995). 
164. L. S. Van Winkle, J. M. Isaac, C. G. Plopper, Distribution of epidermal 
growth factor receptor and ligands during bronchiolar epithelial repair from 
naphthalene-induced Clara cell injury in the mouse. The American journal 
of pathology 151, 443 (Aug, 1997). 
165. S. J. DiCamillo et al., Elastase-released epidermal growth factor recruits 
epidermal growth factor receptor and extracellular signal-regulated 
kinases to down-regulate tropoelastin mRNA in lung fibroblasts. The 
Journal of biological chemistry 277, 18938 (May 24, 2002). 
 176 
166. T. Ichiro, S. Tajima, T. Nishikawa, Preferential inhibition of elastin 
synthesis by epidermal growth factor in chick aortic smooth muscle cells. 
Biochem Biophys Res Commun 168, 850 (Apr 30, 1990). 
167. D. K. Madtes, H. K. Busby, T. P. Strandjord, J. G. Clark, Expression of 
transforming growth factor-alpha and epidermal growth factor receptor is 
increased following bleomycin-induced lung injury in rats. Am J Respir Cell 
Mol Biol 11, 540 (Nov, 1994). 
168. T. P. Strandjord, J. G. Clark, D. E. Guralnick, D. K. Madtes, 
Immunolocalization of transforming growth factor-alpha, epidermal growth 
factor (EGF), and EGF-receptor in normal and injured developing human 
lung. Pediatr Res 38, 851 (Dec, 1995). 
169. W. D. Hardie et al., Immunolocalization of transforming growth factor 
alpha and epidermal growth factor receptor in lungs of patients with cystic 
fibrosis. Pediatric and developmental pathology : the official journal of the 
Society for Pediatric Pathology and the Paediatric Pathology Society 2, 
415 (Sep-Oct, 1999). 
170. T. D. Le Cras et al., Transient induction of TGF-alpha disrupts lung 
morphogenesis, causing pulmonary disease in adulthood. American 
journal of physiology. Lung cellular and molecular physiology 287, L718 
(Oct, 2004). 
171. K. Kohri, I. F. Ueki, J. A. Nadel, Neutrophil elastase induces mucin 
production by ligand-dependent epidermal growth factor receptor 
activation. American journal of physiology. Lung cellular and molecular 
physiology 283, L531 (Sep, 2002). 
172. F. S. Carneiro et al., TNF-alpha knockout mice have increased corpora 
cavernosa relaxation. The journal of sexual medicine 6, 115 (Jan, 2009). 
173. W. Xiong et al., Blocking TNF-alpha attenuates aneurysm formation in a 
murine model. J Immunol 183, 2741 (Aug 15, 2009). 
174. M. Fujita et al., Overexpression of tumor necrosis factor-alpha produces 
an increase in lung volumes and pulmonary hypertension. American 
journal of physiology. Lung cellular and molecular physiology 280, L39 
(Jan, 2001). 
175. A. C. Lau, T. T. Duong, S. Ito, R. S. Yeung, Matrix metalloproteinase 9 
activity leads to elastin breakdown in an animal model of Kawasaki 
disease. Arthritis and rheumatism 58, 854 (Mar, 2008). 
176. Z. W. She, M. D. Wewers, D. J. Herzyk, W. B. Davis, Tumor necrosis 
factor increases the elastolytic potential of adherent neutrophils: a role for 
hypochlorous acid. Am J Respir Cell Mol Biol 9, 386 (Oct, 1993). 
 177 
177. C. R. Kothapalli, A. Ramamurthi, Induced elastin regeneration by 
chronically activated smooth muscle cells for targeted aneurysm repair. 
Acta biomaterialia 6, 170 (Jan, 2010). 
178. A. Churg, J. Dai, H. Tai, C. Xie, J. L. Wright, Tumor necrosis factor-alpha 
is central to acute cigarette smoke-induced inflammation and connective 
tissue breakdown. American journal of respiratory and critical care 
medicine 166, 849 (Sep 15, 2002). 
179. J. S. Hui-Yuen, T. T. Duong, R. S. Yeung, TNF-alpha is necessary for 
induction of coronary artery inflammation and aneurysm formation in an 
animal model of Kawasaki disease. J Immunol 176, 6294 (May 15, 2006). 
180. A. C. Lau, T. T. Duong, S. Ito, G. J. Wilson, R. S. Yeung, Inhibition of 
matrix metalloproteinase-9 activity improves coronary outcome in an 
animal model of Kawasaki disease. Clinical and experimental immunology 
157, 300 (Aug, 2009). 
181. K. F. Chung, Cytokines as targets in chronic obstructive pulmonary 
disease. Current drug targets 7, 675 (Jun, 2006). 
182. F. Croute et al., Interleukin-1 beta stimulates fibroblast elastase activity. Br 
J Dermatol 124, 538 (Jun, 1991). 
183. A. Ito, P. C. Leppert, Y. Mori, Human recombinant interleukin-1 alpha 
increases elastase-like enzyme in human uterine cervical fibroblasts. 
Gynecologic and obstetric investigation 30, 239 (1990). 
184. K. Bry, J. A. Whitsett, U. Lappalainen, IL-1beta disrupts postnatal lung 
morphogenesis in the mouse. Am J Respir Cell Mol Biol 36, 32 (Jan, 
2007). 
185. U. Lappalainen, J. A. Whitsett, S. E. Wert, J. W. Tichelaar, K. Bry, 
Interleukin-1beta causes pulmonary inflammation, emphysema, and 
airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol 32, 
311 (Apr, 2005). 
186. K. Isoda et al., Deficiency of interleukin-1 receptor antagonist promotes 
spontaneous femoral artery aneurysm formation in mice. The American 
journal of pathology 180, 1254 (Mar, 2012). 
187. J. L. Berk, C. Franzblau, R. H. Goldstein, Recombinant interleukin-1 beta 
inhibits elastin formation by a neonatal rat lung fibroblast subtype. The 
Journal of biological chemistry 266, 3192 (Feb 15, 1991). 
188. P. P. Kuang et al., NF-kappaB induced by IL-1beta inhibits elastin 
transcription and myofibroblast phenotype. American journal of 
physiology. Cell physiology 283, C58 (Jul, 2002). 
 178 
189. P. P. Kuang, R. H. Goldstein, Regulation of elastin gene transcription by 
interleukin-1 beta-induced C/EBP beta isoforms. American journal of 
physiology. Cell physiology 285, C1349 (Dec, 2003). 
190. R. A. Rippe, L. W. Schrum, B. Stefanovic, J. A. Solis-Herruzo, D. A. 
Brenner, NF-kappaB inhibits expression of the alpha1(I) collagen gene. 
DNA and cell biology 18, 751 (Oct, 1999). 
191. N. Miglino et al., Cigarette smoke inhibits lung fibroblast proliferation by 
translational mechanisms. The European respiratory journal 39, 705 (Mar, 
2012). 
192. P. P. Kuang, R. H. Goldstein, Regulation of elastin gene transcription by 
proteasome dysfunction. American journal of physiology. Cell physiology 
289, C766 (Sep, 2005). 
193. A. Charles, X. Tang, E. Crouch, J. S. Brody, Z. X. Xiao, Retinoblastoma 
protein complexes with C/EBP proteins and activates C/EBP-mediated 
transcription. Journal of cellular biochemistry 83, 414 (Aug 21-Sep 5, 
2001). 
194. A. Mauviel et al., Human recombinant interleukin-1 beta up-regulates 
elastin gene expression in dermal fibroblasts. Evidence for transcriptional 
regulation in vitro and in vivo. The Journal of biological chemistry 268, 
6520 (Mar 25, 1993). 
195. J. Song, Lee, K., Kong, S., Choi, D., The effects of interleukin-1B and 
interleukin-10 in the expression of elastin gene in cultured human 
fibrolasts. Korean J. Dermatol. 37, 846 (1999). 
196. J. Uitto, S. Hsu-Wong, S. D. Katchman, M. M. Bashir, J. Rosenbloom, 
Skin elastic fibres: regulation of human elastin promoter activity in 
transgenic mice. Ciba Found Symp 192, 237 (1995). 
197. E. R. Neptune et al., Dysregulation of TGF-beta activation contributes to 
pathogenesis in Marfan syndrome. Nature genetics 33, 407 (Mar, 2003). 
198. Z. Yao et al., A Marfan syndrome gene expression phenotype in cultured 
skin fibroblasts. BMC genomics 8, 319 (2007). 
199. T. M. Holm et al., Noncanonical TGFbeta signaling contributes to aortic 
aneurysm progression in Marfan syndrome mice. Science 332, 358 (Apr 
15, 2011). 
200. M. Kretzschmar, J. Doody, I. Timokhina, J. Massague, A mechanism of 
repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes & 
development 13, 804 (Apr 1, 1999). 
 179 
201. R. B. Rucker, M. A. Dubick, Elastin metabolism and chemistry: potential 
roles in lung development and structure. Environ Health Perspect 55, 179 
(Apr, 1984). 
202. S. D. Shapiro, S. K. Endicott, M. A. Province, J. A. Pierce, E. J. Campbell, 
Marked longevity of human lung parenchymal elastic fibers deduced from 
prevalence of D-aspartate and nuclear weapons-related radiocarbon. J 
Clin Invest 87, 1828 (May, 1991). 
203. G. L. Argraves, S. Jani, J. L. Barth, W. S. Argraves, ArrayQuest: a web 
resource for the analysis of DNA microarray data. BMC bioinformatics 6, 
287 (2005). 
204. C. Li, W. Hung Wong, Model-based analysis of oligonucleotide arrays: 
model validation, design issues and standard error application. Genome 
biology 2, RESEARCH0032 (2001). 
205. C. M. Kelleher, S. E. McLean, R. P. Mecham, Vascular extracellular matrix 
and aortic development. Curr Top Dev Biol 62, 153 (2004). 
206. S. McLean, B. Mecham, C. Kelleher, T. Mariani, R. Mecham, Extracellular 
matrix gene expression in the developing mouse aorta. Miner, Ed., 
Advances in Developmental Biology (Elsevier, 2005), vol. 15. 
207. E. L. Rawlins, B. L. Hogan, Epithelial stem cells of the lung: privileged few 
or opportunities for many? Development 133, 2455 (Jul, 2006). 
208. A. Alibes, P. Yankilevich, A. Canada, R. Diaz-Uriarte, IDconverter and 
IDClight: conversion and annotation of gene and protein IDs. BMC 
bioinformatics 8, 9 (2007). 
209. L. Chen et al., Positional differences in the wound transcriptome of skin 
and oral mucosa. BMC genomics 11, 471 (2010). 
210. J. M. Lemire, M. J. Merrilees, K. R. Braun, T. N. Wight, Overexpression of 
the V3 variant of versican alters arterial smooth muscle cell adhesion, 
migration, and proliferation in vitro. J Cell Physiol 190, 38 (Jan, 2002). 
211. M. Lin et al., dChipSNP: significance curve and clustering of SNP-array-
based loss-of-heterozygosity data. Bioinformatics 20, 1233 (May 22, 
2004). 
212. C. Li, W. H. Wong, Model-based analysis of oligonucleotide arrays: 
expression index computation and outlier detection. Proceedings of the 
National Academy of Sciences of the United States of America 98, 31 (Jan 
2, 2001). 
 180 
213. S. D. Jani, G. L. Argraves, J. L. Barth, W. S. Argraves, GeneMesh: a web-
based microarray analysis tool for relating differentially expressed genes 
to MeSH terms. BMC bioinformatics 11, 166 (2010). 
214. R. C. Gentleman et al., Bioconductor: open software development for 
computational biology and bioinformatics. Genome biology 5, R80 (2004). 
215. M. B. Eisen, P. T. Spellman, P. O. Brown, D. Botstein, Cluster analysis 
and display of genome-wide expression patterns. Proceedings of the 
National Academy of Sciences of the United States of America 95, 14863 
(Dec 8, 1998). 
216. C. M. RR Sokal, Univ Kans Sci Bull, 1409 (1958). 
217. R. K. Curtis, M. Oresic, A. Vidal-Puig, Pathways to the analysis of 
microarray data. Trends in biotechnology 23, 429 (Aug, 2005). 
218. G. E. Gonye, P. Chakravarthula, J. S. Schwaber, R. Vadigepalli, From 
promoter analysis to transcriptional regulatory network prediction using 
PAINT. Methods Mol Biol 408, 49 (2007). 
219. R. Sharan. (Scribe: Shaul Karni and Yifat Felder, Tel-Aviv University, 
2007). 
220. R. Vadigepalli, P. Chakravarthula, D. E. Zak, J. S. Schwaber, G. E. 
Gonye, PAINT: a promoter analysis and interaction network generation 
tool for gene regulatory network identification. Omics : a journal of 
integrative biology 7, 235 (Fall, 2003). 
221. M. Madan Babu, S. A. Teichmann, Evolution of transcription factors and 
the gene regulatory network in Escherichia coli. Nucleic acids research 31, 
1234 (Feb 15, 2003). 
222. P. J. Farnham, In vivo assays to examine transcription factor localization 
and target gene specificity. Methods 26, 1 (Jan, 2002). 
223. S. H. Kang, K. Vieira, J. Bungert, Combining chromatin 
immunoprecipitation and DNA footprinting: a novel method to analyze 
protein-DNA interactions in vivo. Nucleic acids research 30, e44 (May 15, 
2002). 
224. M. S. Ricci, W. S. El-Deiry, DNA footprinting. Methods Mol Biol 223, 117 
(2003). 
225. J. D. Hughes, P. W. Estep, S. Tavazoie, G. M. Church, Computational 
identification of cis-regulatory elements associated with groups of 
functionally related genes in Saccharomyces cerevisiae. Journal of 
molecular biology 296, 1205 (Mar 10, 2000). 
 181 
226. A. J. Hartemink, D. K. Gifford, T. S. Jaakkola, R. A. Young, Combining 
location and expression data for principled discovery of genetic regulatory 
network models. Pacific Symposium on Biocomputing. Pacific Symposium 
on Biocomputing, 437 (2002). 
227. T. Ideker, O. Ozier, B. Schwikowski, A. F. Siegel, Discovering regulatory 
and signalling circuits in molecular interaction networks. Bioinformatics 18 
Suppl 1, S233 (2002). 
228. B. P. Berman et al., Exploiting transcription factor binding site clustering to 
identify cis-regulatory modules involved in pattern formation in the 
Drosophila genome. Proceedings of the National Academy of Sciences of 
the United States of America 99, 757 (Jan 22, 2002). 
229. E. H. Davidson et al., A genomic regulatory network for development. 
Science 295, 1669 (Mar 1, 2002). 
230. R. Elkon, C. Linhart, R. Sharan, R. Shamir, Y. Shiloh, Genome-wide in 
silico identification of transcriptional regulators controlling the cell cycle in 
human cells. Genome research 13, 773 (May, 2003). 
231. K. Bury. (Cambridge University Press, Cambridge, UK, 1999). 
232. L. M. Jakt, L. Cao, K. S. Cheah, D. K. Smith, Assessing clusters and 
motifs from gene expression data. Genome research 11, 112 (Jan, 2001). 
233. C. Xu et al., The muscle-specific microRNAs miR-1 and miR-133 produce 
opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 
in cardiomyocytes. Journal of cell science 120, 3045 (Sep 1, 2007). 
234. J. Kim et al., A MicroRNA feedback circuit in midbrain dopamine neurons. 
Science 317, 1220 (Aug 31, 2007). 
235. B. John et al., Human MicroRNA targets. PLoS biology 2, e363 (Nov, 
2004). 
236. P. Landgraf et al., A mammalian microRNA expression atlas based on 
small RNA library sequencing. Cell 129, 1401 (Jun 29, 2007). 
237. C. S. Hofmann et al., B-Myb represses elastin gene expression in aortic 
smooth muscle cells. The Journal of biological chemistry 280, 7694 (Mar 
4, 2005). 
238. R. L. Widom, J. Y. Lee, C. Joseph, I. Gordon-Froome, J. H. Korn, The 
hcKrox gene family regulates multiple extracellular matrix genes. Matrix 
Biol 20, 451 (Nov, 2001). 
 182 
239. P. Takacs, Y. Zhang, K. Candiotti, S. Jaramillo, C. A. Medina, Effects of 
PPAR-delta agonist and zinc on vaginal smooth muscle cells collagen and 
tropoelastin production. Int Urogynecol J,  (May 11). 
240. C. Reynaud, C. Gleyzal, C. Jourdan-Le Saux, P. Sommer, Comparative 
functional study of the lysyl oxidase promoter in fibroblasts, Ras-
transformed fibroblasts, myofibroblasts and smooth muscle cells. Cell Mol 
Biol (Noisy-le-grand) 45, 1237 (Dec, 1999). 
241. H. J. Kim et al., Peroxisome proliferator-activated receptor {delta} 
regulates extracellular matrix and apoptosis of vascular smooth muscle 
cells through the activation of transforming growth factor-{beta}1/Smad3. 
Circulation research 105, 16 (Jul 2, 2009). 
242. S. E. McGowan, S. K. Jackson, M. M. Doro, P. J. Olson, Peroxisome 
proliferators alter lipid acquisition and elastin gene expression in neonatal 
rat lung fibroblasts. Am J Physiol 273, L1249 (Dec, 1997). 
243. P. Dowell et al., p300 functions as a coactivator for the peroxisome 
proliferator-activated receptor alpha. The Journal of biological chemistry 
272, 33435 (Dec 26, 1997). 
244. M. F. Ritchie, C. Yue, Y. Zhou, P. J. Houghton, J. Soboloff, Wilms tumor 
suppressor 1 (WT1) and early growth response 1 (EGR1) are regulators of 
STIM1 expression. The Journal of biological chemistry 285, 10591 (Apr 2, 
2010). 
245. M. A. Harrington et al., Inhibition of colony-stimulating factor-1 promoter 
activity by the product of the Wilms' tumor locus. The Journal of biological 
chemistry 268, 21271 (Oct 5, 1993). 
246. Z. Y. Wang, S. L. Madden, T. F. Deuel, F. J. Rauscher, 3rd, The Wilms' 
tumor gene product, WT1, represses transcription of the platelet-derived 
growth factor A-chain gene. The Journal of biological chemistry 267, 
21999 (Nov 5, 1992). 
247. R. Sarfstein, H. Werner, The WT1 Wilms' tumor suppressor gene is a 
downstream target for insulin-like growth factor-I (IGF-I) action in PC12 
cells. Journal of neurochemistry 99, 818 (Nov, 2006). 
248. M. Little, C. Wells, A clinical overview of WT1 gene mutations. Human 
mutation 9, 209 (1997). 
249. Y. Oji et al., Overexpression of the Wilms' tumor gene W T1 in primary 
astrocytic tumors. Cancer science 95, 822 (Oct, 2004). 
 183 
250. D. M. Loeb et al., Wilms' tumor suppressor gene (WT1) is expressed in 
primary breast tumors despite tumor-specific promoter methylation. 
Cancer Res 61, 921 (Feb 1, 2001). 
251. H. Miwa, M. Beran, G. F. Saunders, Expression of the Wilms' tumor gene 
(WT1) in human leukemias. Leukemia 6, 405 (May, 1992). 
252. G. R. Grubb, K. Yun, B. R. Williams, M. R. Eccles, A. E. Reeve, 
Expression of WT1 protein in fetal kidneys and Wilms tumors. Lab Invest 
71, 472 (Oct, 1994). 
253. M. A. Ghanem et al., Expression and prognostic value of Wilms' tumor 1 
and early growth response 1 proteins in nephroblastoma. Clinical cancer 
research : an official journal of the American Association for Cancer 
Research 6, 4265 (Nov, 2000). 
254. N. P. Pavletich, C. O. Pabo, Zinc finger-DNA recognition: crystal structure 
of a Zif268-DNA complex at 2.1 A. Science 252, 809 (May 10, 1991). 
255. B. Christy, D. Nathans, DNA binding site of the growth factor-inducible 
protein Zif268. Proceedings of the National Academy of Sciences of the 
United States of America 86, 8737 (Nov, 1989). 
256. A. H. Swirnoff, J. Milbrandt, DNA-binding specificity of NGFI-A and related 
zinc finger transcription factors. Molecular and cellular biology 15, 2275 
(Apr, 1995). 
257. V. P. Sukhatme et al., A zinc finger-encoding gene coregulated with c-fos 
during growth and differentiation, and after cellular depolarization. Cell 53, 
37 (Apr 8, 1988). 
258. B. R. Dey et al., Repression of the transforming growth factor-beta 1 gene 
by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol 8, 595 
(May, 1994). 
259. V. Baron et al., Inhibition of Egr-1 expression reverses transformation of 
prostate cancer cells in vitro and in vivo. Oncogene 22, 4194 (Jul 3, 2003). 
260. B. H. Ahn, M. H. Park, Y. H. Lee, S. Min do, Phorbol myristate acetate-
induced Egr-1 expression is suppressed by phospholipase D isozymes in 
human glioma cells. FEBS letters 581, 5940 (Dec 22, 2007). 
261. A. Krones-Herzig et al., Early growth response 1 acts as a tumor 
suppressor in vivo and in vitro via regulation of p53. Cancer Res 65, 5133 
(Jun 15, 2005). 
 184 
262. S. Kuhn, C. Skerka, P. F. Zipfel, Mapping of the complement regulatory 
domains in the human factor H-like protein 1 and in factor H1. J Immunol 
155, 5663 (Dec 15, 1995). 
263. C. Skerka, E. L. Decker, P. F. Zipfel, A regulatory element in the human 
interleukin 2 gene promoter is a binding site for the zinc finger proteins 
Sp1 and EGR-1. The Journal of biological chemistry 270, 22500 (Sep 22, 
1995). 
264. B. Kramer, A. Meichle, G. Hensel, P. Charnay, M. Kronke, 
Characterization of an Krox-24/Egr-1-responsive element in the human 
tumor necrosis factor promoter. Biochimica et biophysica acta 1219, 413 
(Oct 18, 1994). 
265. R. P. Mecham, Methods in elastic tissue biology: elastin isolation and 
purification. Methods 45, 32 (May, 2008). 
266. P. C. Dartsch, H. Hammerle, E. Betz, Orientation of cultured arterial 
smooth muscle cells growing on cyclically stretched substrates. Acta 
anatomica 125, 108 (1986). 
267. T. J. Langan, R. C. Chou, Synchronization of mammalian cell cultures by 
serum deprivation. Methods Mol Biol 761, 75 (2011). 
268. H. Kubota et al., Increased expression of co-chaperone HOP with HSP90 
and HSC70 and complex formation in human colonic carcinoma. Cell 
stress & chaperones 15, 1003 (Nov, 2010). 
269. L. Neckers, Hsp90 inhibitors as novel cancer chemotherapeutic agents. 
Trends in molecular medicine 8, S55 (2002). 
270. E. Pick et al., High HSP90 expression is associated with decreased 
survival in breast cancer. Cancer Res 67, 2932 (Apr 1, 2007). 
271. L. Whitesell, S. L. Lindquist, HSP90 and the chaperoning of cancer. 
Nature reviews. Cancer 5, 761 (Oct, 2005). 
272. H. Bansal et al., Heat shock protein 90 regulates the expression of Wilms 
tumor 1 protein in myeloid leukemias. Blood 116, 4591 (Nov 25, 2010). 
273. S. Mishra et al., Carbon monoxide rescues ischemic lungs by interrupting 
MAPK-driven expression of early growth response 1 gene and its 
downstream target genes. Proceedings of the National Academy of 
Sciences of the United States of America 103, 5191 (Mar 28, 2006). 
274. P. Takacs, Y. Zhang, K. Candiotti, S. Jaramillo, C. A. Medina, Effects of 
PPAR-delta agonist and zinc on vaginal smooth muscle cells collagen and 
tropoelastin production. Int Urogynecol J 23, 1775 (Dec, 2012). 
 185 
275. M. M. Bashir et al., Characterization of the complete human elastin gene. 
Delineation of unusual features in the 5'-flanking region. The Journal of 
biological chemistry 264, 8887 (May 25, 1989). 
276. E. C. Davis, Stability of elastin in the developing mouse aorta: a 
quantitative radioautographic study. Histochemistry 100, 17 (Jul, 1993). 
277. M. J. Sherratt, Tissue elasticity and the ageing elastic fibre. Age (Dordr) 
31, 305 (Dec, 2009). 
278. J. Rnjak, S. G. Wise, S. M. Mithieux, A. S. Weiss, Severe burn injuries and 
the role of elastin in the design of dermal substitutes. Tissue engineering. 
Part B, Reviews 17, 81 (Apr, 2011). 
279. H. Suwabe, A. Serizawa, H. Kajiwara, M. Ohkido, Y. Tsutsumi, 
Degenerative processes of elastic fibers in sun-protected and sun-
exposed skin: immunoelectron microscopic observation of elastin, fibrillin-
1, amyloid P component, lysozyme and alpha1-antitrypsin. Pathology 
international 49, 391 (May, 1999). 
280. E. C. Davis, S. A. Blattel, R. P. Mecham, Remodeling of elastic fiber 
components in scleroderma skin. Connect Tissue Res 40, 113 (1999). 
281. B. L. Loeys et al., Mutations in fibrillin-1 cause congenital scleroderma: 
stiff skin syndrome. Science translational medicine 2, 23ra20 (Mar 17, 
2010). 
282. A. K. Lagendijk, M. J. Goumans, S. B. Burkhard, J. Bakkers, MicroRNA-23 
restricts cardiac valve formation by inhibiting Has2 and extracellular 
hyaluronic acid production. Circulation research 109, 649 (Sep 2, 2011). 
283. B. J. Reinboth, M. L. Finnis, M. A. Gibson, L. B. Sandberg, E. G. Cleary, 
Developmental expression of dermatan sulfate proteoglycans in the elastic 
bovine nuchal ligament. Matrix Biol 19, 149 (May, 2000). 
284. A. I. Olin et al., The proteoglycans aggrecan and Versican form networks 
with fibulin-2 through their lectin domain binding. The Journal of biological 
chemistry 276, 1253 (Jan 12, 2001). 
285. Z. Isogai et al., Versican interacts with fibrillin-1 and links extracellular 
microfibrils to other connective tissue networks. The Journal of biological 
chemistry 277, 4565 (Feb 8, 2002). 
286. D. R. Zimmermann, M. T. Dours-Zimmermann, M. Schubert, L. Bruckner-
Tuderman, Versican is expressed in the proliferating zone in the epidermis 
and in association with the elastic network of the dermis. The Journal of 
cell biology 124, 817 (Mar, 1994). 
 186 
287. W. Volker et al., Mapping of proteoglycans in atherosclerotic lesions. 
European heart journal 11 Suppl E, 29 (Aug, 1990). 
288. C. Fornieri, M. Baccarani-Contri, D. Quaglino, Jr., I. Pasquali-Ronchetti, 
Lysyl oxidase activity and elastin/glycosaminoglycan interactions in 
growing chick and rat aortas. The Journal of cell biology 105, 1463 (Sep, 
1987). 
289. J. O. Cantor et al., The effect of hyaluronan on elastic fiber injury in vitro 
and elastase-induced airspace enlargement in vivo. Proc Soc Exp Biol 
Med 225, 65 (Oct, 2000). 
290. J. O. Cantor, G. M. Turino, Can exogenously administered hyaluronan 
improve respiratory function in patients with pulmonary emphysema? 
Chest 125, 288 (Jan, 2004). 
291. H. Shan et al., Downregulation of miR-133 and miR-590 contributes to 
nicotine-induced atrial remodelling in canines. Cardiovasc Res 83, 465 
(Aug 1, 2009). 
292. W. C. Parks, M. E. Kolodziej, R. A. Pierce, Phorbol ester-mediated 
downregulation of tropoelastin expression is controlled by a 
posttranscriptional mechanism. Biochemistry 31, 6639 (Jul 28, 1992). 
 
 
